Agents and methods for targeted delivery to cells
By using the combination of hydrophobic particles and targeted compounds, efficient targeted delivery of target cells is achieved, and the problem of selective delivery of traditional Chinese medicines to target cells is solved, and the accuracy of treatment and diagnosis is improved.
Patent Information
- Application Number
- CN202380031803.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-01
- Filing Date
- 2023-02-02
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art has difficulty in effectively targeting the challenge of delivering nucleic acids containing antigen receptors to specific cells, especially selective delivery of agents to target cells during treatment or diagnosis.
Using particles containing hydrophobic moieties, the payload is delivered to the target cell by binding to the binding moiety covalently linked to it, using the docking compound, for example through specific binding of antibodies or antibody fragments to the cell surface antigen, to achieve targeting. deliver.
Efficient targeted delivery of target cells is achieved, the impact on non-target cells is reduced, the therapeutic effect and diagnostic accuracy is improved, and it is especially suitable for the generation of genetically modified immune effector cells to treat diseased cells expressing specific antigens.
Smart Images

Figure BDA0005066769670000051 
Figure BDA0005066769670000131 
Figure BDA0005066769670000151
Abstract
Description
Technical Field
[0001] The present invention relates to agents and methods for delivering payload targeted to cells.Payload includes various molecules, such as therapeutic agents or diagnostic agents, particularly nucleic acids, such as DNA or RNA.In some embodiments, payload includes nucleic acids encoding antigen receptors (such as T cell receptors (TCR) or chimeric antigen receptors (CAR)).Delivering the payload of nucleic acids encoding antigen receptors (such as TCR or CAR) to cells can contribute to the generation of genetically modified immune effector cells expressing antigen receptors.In some embodiments, the present invention relates to administration particles and compounds, the particles include hydrophobic moieties, the hydrophobic moieties have a binding moiety (connection compound) covalently attached thereto, and the particles carry payload, such as nucleic acids encoding antigen receptors, the compound is bound to the binding moiety of the connection compound and the cell surface antigen (docking compound) on the target cell (such as immune effector cell).In some embodiments, docking compound includes peptide or polypeptide.In some embodiments, docking compound includes a binding moiety (primary targeting moiety) bound to target cells and another binding moiety bound to the binding moiety of the connection compound. The binding portion of the linking compound can bind to the binding portion of the docking compound on the docking compound, and the primary targeting portion can then bind to the target antigen on the target cell (such as an antigen on an immune effector cell), thereby precisely delivering the payload to the target cell (such as an immune effector cell).
[0002] In many areas of medical therapy and diagnostics, there is a need to selectively deliver agents, such as nucleic acids, therapeutic agents (drugs), or diagnostic agents (e.g., imaging agents), to specific cells in a subject, such as a patient.
[0003] Active targeting of cells can be achieved by conjugating the desired payload directly or indirectly to a targeting moiety that binds to a cell surface antigen on the target cell of interest. The targeting moiety is typically a construct that has affinity for a cell surface target (e.g., a membrane protein), including an antibody or antibody fragment.
[0004] The present invention relates to a method in which a docking compound that is bound to a target cell (e.g., by being bound to a cell surface antigen) is used. The docking compound also comprises a portion that is targeted by a particle, and the particle comprises a payload and is equipped with a binding portion that targets the portion on the docking compound. In some embodiments, administration is carried out by connecting a compound to a docking compound that is bound to a particle comprising a payload (e.g., a nucleic acid encoding an antigen receptor). The docking compound can be bound to the target cell, e.g., by being bound to a cell surface antigen, thereby causing the cell to take up the payload. A common example of a pair of interacting moieties on a connecting compound and a docking compound is an antibody / antigen system. The concept described herein allows for targeting a wide range of target cells using a single type of particle, i.e., by using a single type of particle in combination with different docking compounds targeting different primary targets. The concept described herein has further advantages because the primary targeting using a single docking compound can be carried out in combination with different particles comprising different payloads. Summary of the Invention
[0005] The present invention relates to the medicament and method for delivering payload to cell by targeting.In some embodiments, payload includes nucleic acid encoding antigen receptor, such as T cell receptor (TCR) or chimeric antigen receptor (CAR).The medicament and method for the nucleic acid encoding antigen receptor for targeted delivery described herein can be used for in vitro / ex vivo or in vivo generation of genetically modified immune effector cells expressing antigen receptor.Genetic modification is achieved using granule and docking compound described herein, the granule includes nucleic acid encoding antigen receptor for genetic modification, the docking compound is bound to granule by connecting compound, and the docking compound includes targeting molecules for targeting immune effector cells.Granule can deliver nucleic acid to cell in vitro / ex vivo and in vivo.Genetically modified immune effector cells expressing antigen receptor described herein can be used for treating disease, wherein target cell (such as diseased cell expressing antigen (such as tumor antigen)) is beneficial.Target cell can express antigen on cell surface for CAR recognition or for TCR recognition in the case of MHC.Treatment described herein can provide selective elimination of such cells expressing antigen, thereby minimizing the adverse effects on normal cells that do not express antigen. Provide to the subject genetically modified to express by binding to the antigen (or its processed product) and target cell antigen receptor (such as CAR or TCR) immune effector cell, such as by administering genetically modified immune effector cell to the subject or producing genetically modified immune effector cell in the subject. In some embodiments, immune effector cell is CD3+T cell. In some embodiments, docking compound described herein is bound to the CD3 receptor on T cell. In some embodiments, immune effector cell is CD8+T cell. In some embodiments, docking compound described herein is bound to the CD8 receptor on T cell. In some embodiments, immune effector cell is CD4+T cell. In some embodiments, docking compound described herein is bound to the CD4 receptor binding on T cell.
[0006] Methods and medicaments described herein and immune effector cells genetically modified to express antigen receptors are particularly useful for treating diseases, wherein the disease is characterized by the diseased cells expressing the antigens targeted by immune effector cells. In some embodiments, immune effector cells have binding specificity to disease-associated antigens (when present on diseased cells) by CAR. In some embodiments, immune effector cells have binding specificity to the processed products of disease-associated antigens (when present on diseased cells) by TCR. In some embodiments, cells are genetically modified to stably express antigen receptors on their surface. In some embodiments, cells are genetically modified to transiently express antigen receptors on their surface.
[0007] In one aspect, the present invention relates to a method of preparing a composition for delivering a payload to a cell expressing a cell surface antigen, the method comprising:
[0008] (a) providing a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and
[0009] (b) binding the particle from (a) to a compound comprising (i) a moiety that binds to said binding moiety covalently linked to a hydrophobic moiety, and (ii) a moiety that targets said cell surface antigen.
[0010] In some embodiments, the method further comprises: (c) loading the particle with a payload.
[0011] In one aspect, the invention relates to a method of delivering a payload to a cell expressing a cell surface antigen, comprising adding to the cell a composition comprising:
[0012] (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and carrying the payload, and
[0013] (b) A compound comprising (i) a moiety that binds to a binding moiety covalently linked to a hydrophobic moiety, and (ii) a moiety that targets said cell surface antigen.
[0014] In some embodiments, the payload comprises a nucleic acid.
[0015] In some embodiments, the cell comprises a diseased cell. In some embodiments, the payload comprises a compound effective for treating a disease. In some embodiments, the cell surface antigen comprises a tumor antigen. In some embodiments, the cell comprises a tumor or cancer cell.
[0016] In some embodiments, the cell comprises an immune effector cell. In some embodiments, the payload comprises a nucleic acid encoding an antigen receptor. In some embodiments, the cell surface antigen comprises a cell surface antigen on an immune effector cell.
[0017] In one aspect, the invention relates to a method of preparing an immune effector cell genetically modified to express an antigen receptor, comprising adding to the immune effector cell a composition comprising:
[0018] (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and carrying a nucleic acid encoding an antigen receptor, and
[0019] (b) A compound comprising (i) a moiety that binds to a binding moiety covalently linked to a hydrophobic moiety, and (ii) a moiety that targets a cell surface antigen on said immune effector cell.
[0020] In some embodiments, the cells described herein exist ex vivo.
[0021] In some embodiments, the cells described herein are present in a subject, and the methods described herein comprise administering to the subject a composition described herein.
[0022] In one aspect, the invention relates to a method of treating a subject, comprising:
[0023] (I) preparing ex vivo immune effector cells genetically modified to express an antigen receptor using a method comprising adding to the immune effector cells a composition comprising:
[0024] (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and carrying a nucleic acid encoding the antigen receptor, and
[0025] (b) a compound comprising (i) a moiety that binds to a binding moiety covalently linked to a hydrophobic moiety, and (ii) a moiety that targets a cell surface antigen on said immune effector cell, and (II) administering to a subject the immune effector cell genetically modified to express the antigen receptor.
[0026] In one aspect, the invention relates to a method of treating a subject, comprising administering to the subject:
[0027] (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and carrying a nucleic acid encoding an antigen receptor, and
[0028] (b) A compound comprising (i) a moiety that binds to a binding moiety covalently linked to a hydrophobic moiety, and (ii) a moiety that targets a cell surface antigen on said immune effector cell.
[0029] In some embodiments, nucleic acids encoding antigen receptors are delivered to immune effector cells.
[0030] In some embodiments, a nucleic acid encoding an antigen receptor is delivered to an immune effector cell, resulting in an immune effector cell genetically modified to express the antigen receptor.
[0031] In some embodiments, the cell surface antigen is characteristic of an immune effector cell.
[0032] In some embodiments, the immune effector cells comprise T cells.
[0033] In some embodiments, the immune effector cells comprise CD8+ and / or CD4+ T cells.
[0034] In some embodiments, the cell surface antigen comprises CD4 and / or CD8.
[0035] In some embodiments, the cell surface antigen comprises CD3.
[0036] In some embodiments, the antigen receptor targets an antigen associated with a disease, disorder, or condition, or a cell expressing an antigen associated with a disease, disorder, or condition.
[0037] In some embodiments, the subject has a disease, disorder, or condition associated with the antigen.
[0038] In some embodiments, the antigen associated with the disease, disorder, or condition comprises a tumor antigen.
[0039] In some embodiments, the cell expressing an antigen associated with a disease, disorder, or condition is a tumor or cancer cell.
[0040] In some embodiments, the disease, disorder, or condition associated with the antigen comprises a tumor or cancer.
[0041] In some embodiments, the methods described herein are methods of treating or preventing cancer in a subject.
[0042] In some embodiments, the antigen associated with the disease, disorder, or condition comprises an antigen of an infectious agent.
[0043] In some embodiments, the infectious material comprises a virus.
[0044] In some embodiments, the disease, disorder, or condition associated with the antigen is an infection.
[0045] In some embodiments, the methods described herein are methods of treating or preventing an infection in a subject.
[0046] In some embodiments, the methods described herein further comprise administering to the subject an antigen targeted by an antigen receptor, a polynucleotide encoding the antigen, or a host cell genetically modified to express the antigen.
[0047] In some embodiments, the polynucleotide is RNA.
[0048] In some embodiments, the antigen receptor comprises a chimeric antigen receptor (CAR) or a T cell receptor (TCR).
[0049] In some embodiments, the genetic modification is transient or stable.
[0050] In some embodiments, genetic modification is performed by viral-based methods, transposon-based methods, or gene editing-based methods.
[0051] In some embodiments, the particle is a lipid particle, a polymer particle, or a mixture thereof.
[0052] In some embodiments, the particle is a viromer.
[0053] In some embodiments, the particle is a non-viral particle.
[0054] In some embodiments, the particles are nanoparticles.
[0055] In some embodiments, the nucleic acid comprises DNA and / or RNA.
[0056] In some embodiments, the hydrophobic moiety having the binding moiety covalently linked thereto and the particle are non-covalently associated with each other.
[0057] In some embodiments, the hydrophobic moiety having the binding moiety covalently attached thereto is an integral part of the particle.
[0058] In some embodiments, the hydrophobic moiety having the binding moiety covalently attached thereto comprises a polymer.
[0059] In some embodiments, the hydrophobic moiety having the binding moiety covalently attached thereto comprises a compound of Formula I:
[0060] L-X1-P-X2-B(I)
[0061] in
[0062] P contains polymers;
[0063] L comprises a hydrophobic moiety attached to a first terminus of the polymer;
[0064] B comprises a binding moiety attached to the second terminus of the polymer;
[0065] X1 is absent or is the first linking moiety; and
[0066] X2 does not exist or is a second connecting portion.
[0067] In some embodiments, X1 comprises a carbonyl group.
[0068] In some embodiments, X2 comprises the reaction product of a maleimide group and a sulfhydryl or cysteine group of a compound comprising a binding moiety.
[0069] In some embodiments, the hydrophobic portion comprises two C8-C24 hydrocarbon chains.
[0070] In some embodiments, the hydrophobic portion comprises two C10-C18 hydrocarbon chains.
[0071] In some embodiments, the hydrophobic moiety is or is contained within a lipid.
[0072] In some embodiments, the lipid comprises a phospholipid, such as a glycerophospholipid.
[0073] In some embodiments, the lipid comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE).
[0074] In some embodiments, the polymer provides stealth properties, increases circulation half-life, and / or reduces nonspecific protein binding or cell adhesion.
[0075] In some embodiments, the polymer comprises polyethylene glycol (PEG).
[0076] In some embodiments, the hydrophobic moiety having a binding moiety covalently attached thereto comprises a distearoyl-glycero-phosphoethanolamine-polyethylene glycol conjugate (DSPE-PEG).
[0077] In some embodiments, a hydrophobic moiety having a binding moiety covalently linked thereto can be obtained by reacting a sulfhydryl or cysteine reactive group of a heterobifunctional PEGylation reagent comprising the hydrophobic moiety with a sulfhydryl or cysteine group of a compound comprising the binding moiety.
[0078] In some embodiments, the heterobifunctional PEGylation reagent comprises a linear heterobifunctional PEGylation reagent.
[0079] In some embodiments, the sulfhydryl or cysteine reactive group comprises a maleimide group.
[0080] In some embodiments, the heterobifunctional PEGylation reagent comprises DSPE-PEG-maleimide.
[0081] In some embodiments, the hydrophobic portion having a binding moiety covalently attached thereto comprises the reaction product of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)] and a compound comprising the formula SH(CH2)nC(O)-B, wherein n ranges from 1-5 and B comprises the binding moiety.
[0082] In some embodiments, n is 2.
[0083] In some embodiments, the hydrophobic moiety having the binding moiety covalently linked thereto comprises a compound of Formula II
[0084]
[0085] wherein B comprises the binding moiety.
[0086] In some embodiments, a moiety comprising the structure: -N-peptide-C(O)-NH2 is included.
[0087] In some embodiments, the polyethylene glycol (PEG) comprises 20-200 ethylene oxide units, such as about 45 ethylene oxide units.
[0088] In some embodiments, the polyethylene glycol (PEG) comprises polyethylene glycol-2000.
[0089] In some embodiments, the binding moiety covalently linked to the hydrophobic moiety and the moiety bound to the binding moiety covalently linked to the hydrophobic moiety are non-covalently bound to each other.
[0090] In some embodiments, the binding moiety covalently linked to the hydrophobic moiety comprises an antibody or antibody derivative.
[0091] In some embodiments, antibody derivatives comprise antibody fragments.
[0092] In some embodiments, the moiety that binds to the binding moiety that is covalently linked to the hydrophobic moiety comprises a peptide.
[0093] In some embodiments, the binding moiety covalently linked to the hydrophobic moiety comprises a peptide.
[0094] In some embodiments, the moiety that binds to the binding moiety covalently linked to the hydrophobic moiety comprises an antibody or antibody derivative.
[0095] In some embodiments, antibody derivatives comprise antibody fragments.
[0096] In some embodiments, the peptide comprises an ALFA-tag.
[0097] In some embodiments, the antibody or antibody derivative comprises a VHH domain comprising the CDR1 sequence VTISALNAMAMG, the CDR2 sequence AVSERGNAM, and the CDR3 sequence LEDRVDSFHDY.
[0098] In some embodiments, the binding moiety covalently linked to the hydrophobic moiety comprises a peptide comprising an ALFA-tag; and the moiety that binds to the binding moiety covalently linked to the hydrophobic moiety comprises an antibody or antibody derivative comprising a VHH domain comprising the CDR1 sequence VTISALNAMAMG, the CDR2 sequence AVSERGNAM, and the CDR3 sequence LEDRVDSFHDY.
[0099] In some embodiments, (i) the moiety that binds to the binding moiety covalently linked to the hydrophobic moiety and (ii) the moiety that targets the cell surface antigen are attached to each other.
[0100] In some embodiments, (i) the moiety that binds to the binding moiety that is covalently linked to the hydrophobic moiety and (ii) the moiety that targets the cell surface antigen are covalently linked to each other.
[0101] In some embodiments, the compound of (b) comprises a peptide or polypeptide.
[0102] In some embodiments, the moiety that targets a cell surface antigen comprises an antibody or an antibody derivative.
[0103] In some embodiments, antibody derivatives comprise antibody fragments.
[0104] In some embodiments, the compound of (b) comprises a bispecific antibody.
[0105] In some embodiments, the bispecific antibody comprises a bispecific single chain antibody.
[0106] In some embodiments, the moiety that targets a cell surface antigen comprises an ankyrin repeat protein.
[0107] In some embodiments, the component of (a) is bound to the compound of (b).
[0108] In one aspect, the present invention relates to a composite comprising:
[0109] (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and
[0110] (b) A compound comprising (i) a moiety that binds to a binding moiety covalently linked to a hydrophobic moiety, and (ii) a moiety that targets a cell surface antigen.
[0111] In some embodiments, the particles carry a payload.
[0112] In some embodiments, the binding moiety covalently linked to the hydrophobic moiety comprises a peptide comprising an ALFA-tag; and the moiety that binds to the binding moiety covalently linked to the hydrophobic moiety comprises an antibody or antibody derivative comprising a VHH domain comprising the CDR1 sequence VTISALNAMAMG, the CDR2 sequence AVSERGNAM, and the CDR3 sequence LEDRVDSFHDY.
[0113] In one aspect, the invention relates to a particle comprising a hydrophobic portion having a peptide covalently attached thereto, wherein the peptide comprises an ALFA-tag.
[0114] In one aspect, the invention relates to a compound comprising a hydrophobic moiety having a peptide covalently attached thereto, wherein the peptide comprises an ALFA-tag.
[0115] In one aspect, the invention relates to a bispecific binding molecule comprising (i) a portion that binds to a peptide comprising an ALFA-tag, and (ii) a portion that targets a cell surface antigen.
[0116] In one aspect, the invention relates to a bispecific binding molecule comprising (i) an antibody or antibody derivative comprising a VHH domain comprising the CDR1 sequence VTISALNAMAMG, the CDR2 sequence AVSERGNAM, and the CDR3 sequence LEDRVDSFHDY, and (ii) a portion that targets a cell surface antigen. BRIEF DESCRIPTION OF THE DRAWINGS
[0117] Figure 1 :Formulation and characterization of functionalized lipid nanoparticles (LNPs) containing RNA
[0118] LNPs were formulated with varying mole % of Alfa-tagged lipids (lipid mixture: DODMA / cholesterol (Chol) / DOPE / C16-PEG-ceramide / DSPE-PEG2k-Alfa 40 / 48 / 10 / 2 - x / x = 0, 0.2, 0.5, 1; N / P ratio: 4; cargo: Thy1.1 / Luc RNA 1:1 w / w; RNA concentration: 0.1 μg / μl). aCD8-DARPin X NbAlfa was added via post-functionalization [w / w* = ligand to cargo ratio 0.55]. Successful RNA incorporation was confirmed by agarose gel electrophoresis. The size and PDI of LNPs with and without ligand were measured by dynamic light scattering at an RNA concentration of 0.005 g / L. **No measurable PDI.
[0119] Figure 2 : T cell targeting using aCD3 ligand-modified LNPs
[0120] LNPs were formulated with or without ligand (cargo: Thy1.1 / Luc RNA 1:1 w / w; N / P ratio: 4; lipid mixture: DODMA / cholesterol / DOPE / C16 PEG2k Ceramide / DSPE-PEG2k-Alfa [40 / 48 / 10 / 1.8 / 0.2]; aCD3-VHH x NbAlfa post-functionalization [w / w* = ligand to cargo ratio 1.15]; RNA concentration: 0.1 μg / μl). Successful RNA incorporation was confirmed by agarose gel electrophoresis. For transfection studies, 15 μl of the respective formulations were pre-diluted in 50 μl of X-Vivo 15 in ultra-low adhesion 96-well plates. 1e6 thawed human PBMCs were diluted in 50 μl of X-Vivo 15 (with 10% PHS) and added to the nanoparticle dilution (1500 ng RNA). After incubation for 30 min (37 ° C, 5% CO 2 ), 200 μl of X-Vivo 15 + 5% PHS was added to each well, and the cells were cultured for an additional 18 h (37 ° C, 5% CO 2 ). Next, cell type-specific transfection (Thy1.1) and T cell activation (CD69) were analyzed by flow cytometry. (A) LNP characteristics. Diameter and PDI were determined by DLS measurement. (B) Cell type-specific Thy1.1 (transfection, y-axis) signals within viable CD14+ monocytes, CD56+ NK cells, CD19+ B cells, CD3+ T cells, CD4+ T cells, or CD8+ T cells were shown. (C) Histograms show the expression of CD69 activation markers on T cell populations in treated PBMCs.
[0121] Figure 3 T cell targeting of LPLX using aCD8 DARPin-modified
[0122] LPLX was functionalized with two different ligands, aCD8 DARPin X Spycatcher or aCD8 DARPin X NbAlfa. LPLX contains a cationic Viromer L3 polymer and functionalized lipids for RNA encapsulation (cargo: Thy1.1 / LucRNA 1:1 w / w; RNA concentration: 0.1 μg / μL; N / P ratio: 7.5; ligand to cargo w / w ratio of 0.25 for aCD8 DARPin X Spycatcher; 0.1 for aCD8 DARPin X NbAlfa; ligand to functionalized lipid molar ratio of 1.5:1 for aCD8 DARPin X Spycatcher / Spy-tagged PEG2k-DSPE; and 3.5:1 for aCD8 DARPin X NbAlfa / Alfa-tagged PEG2k-DSPE). Diameter and PDI were determined by DLS measurements. RNA was successfully incorporated by agarose gel electrophoresis. For transfection studies, 0.5 or 0.1 μl of the corresponding preparation was pre-diluted in 50 μl X-Vivo 15 in a 96-well plate. 1e6 thawed human T cells were diluted in 50 μl X-Vivo 15 and added to nanoparticle diluent (50 or 100 ng RNA). After incubation for 30 min (37 ° C, 5% CO ), 200 μl X-Vivo15+5% PHS was added to each well, and the cells were cultured for an additional 18 h (37 ° C, 5% CO ). Next, CD4 and CD8 specific transfection (Thy1.1) were analyzed by flow cytometry. Thy1.1 (transfection, y axis) signals in viable CD4+T cells or CD8+T cells are shown.
[0123] Figure 4 T cell targeting of LPLX using different ligand-modified LPLX
[0124] LPLX was functionalized with a fusion protein containing a CD8-targeting ligand fused to a CD8-targeting ligand (aCD8 VHH) nanobody. The CD8-targeting domain was either a DARPin or a VHH nanobody. One DARPin and four different nanobodies were tested. LPLX contained Viromer L3 for RNA encapsulation and a DSPE-PEG2k Alfa tag for ligand conjugation (cargo: Thy1.1 / Luc RNA 1:1 w / w; RNA concentration: 0.1 μg / μL; N / P ratio: 7.5; ligand to cargo w / w ratios of 0.05, 0.1, and 0.2 for aCD8 VHH x NbAlfa; ligand to cargo w / w ratio of 0.2 for aCD8 DARPin x NbAlfa; and a ligand to functionalized lipid molar ratio of 3.5:1). Diameter and PDI were determined by DLS measurements. Successful RNA incorporation was confirmed by agarose gel electrophoresis. For transfection research, 0.1 μ l of the corresponding preparation was pre-diluted in 50 μ l X-Vivo 15 in 96-well plates. 2e5 thawed human T cells were diluted in 50 μ l X-Vivo 15 and added to nanoparticle diluent (100 ng RNA). After incubation for 30 min (37 ° C, 5% CO ), 200 μ l X-Vivo15+5% PHS was added to each well, and the cells were cultured for an additional 18 h (37 ° C, 5% CO ). Next, CD4 and CD8 specific transfection (Thy1.1) were analyzed by flow cytometry. The middle graph shows the specific CD8+T cell transfection efficiency of particle conditions (see table below), which is calculated by multiplying the CD8+T cell (Thy1.1+) percentage of transfected cells by the MFI of Thy1.1+CD8+ cell mass. The dot plot corresponding to the conditions marked with boxes in the graph is shown in the upper part of the figure. These dot plots show Thy1.1 signals in viable CD8+ T cells (upper dot plot) or viable CD4+ T cells (lower dot plot).
[0125] Figure 5 T cell targeting of LPLX using different ligand-modified LPLX
[0126] LPLX was functionalized with fusion proteins containing CD8, CD4, or CD3 targeting ligands fused to aCD4 VHH X NbAlfa. The targeting domain was a DARPin, a VHH nanobody, or a scFv. One DARPin, nine different nanobodies, and two different scFvs were tested. LPLX contained Viromer L3 for RNA encapsulation and a DSPE-PEG2k Alfa tag for ligand conjugation (cargo: Thy1.1 / Luc RNA 1:1 w / w; RNA concentration: 0.1 μg / μL; N / P ratio: 7.5; ligand to cargo w / w ratios of 0.05, 0.1, and 0.2 for aCD4 VHH X NbAlfa and aCD3 scFv X NbAlfa; ligand to cargo w / w ratio of 0.2 for aCD8 DARPin X NbAlfa and aCD3 VHH X NbAlfa; and a ligand to functionalized lipid molar ratio of 3.5:1). Diameter and PDI were determined by DLS measurement. RNA was successfully incorporated by agarose gel electrophoresis. For transfection studies, 0.1 μl of the corresponding preparation was pre-diluted in 50 μl X-Vivo 15 in a 96-well plate. 2e5 thawed human T cells were diluted in 50 μl X-Vivo 15 and added to nanoparticle diluent (100 ng RNA). After incubation for 30 min (37 ° C, 5% CO ), 200 μl X-Vivo15+5% PHS was added to each well, and the cells were cultured for an additional 18 h (37 ° C, 5% CO ). Next, CD4 and CD8 specific transfection (Thy1.1) were analyzed by flow cytometry. The middle graph shows the specific CD8+ (left y axis; dark gray column) and CD4+ (right y axis; light gray column) T cell transfection efficiency of the particle conditions (see table below). By multiplying the percentage of transfected (Thy1.1+) CD8 or CD4+T cells by the MFI of the corresponding Thy1.1+ cell population, numerical values are calculated. The upper portion of the figure shows a dot plot corresponding to the conditions marked with boxes in the chart. These dot plots show viable CD8+T cells (top dot plots) or viable CD4+T cells (bottom dot plots) Thy1.1 signals in the cells.
[0127] Figure 6 : T cell targeting using LNPs with different lipid compositions
[0128] LNPs were formulated with different lipid compositions and loaded with the aCD3 VHH x NbAlfa ligand (cargo: Thy1.1 / LucRNA 1:1 w / w; N / P ratio: 4; lipid mixture: ionizable lipid / cholesterol / DOPE / C16 PEG2k ceramide / DSPE-PEG2k-Alfa [40 / 48 / 10 / 1.8 / 0.2], with DODMA (C12), HY-501 (H12), or EA-405 (E12) as the ionizable lipid; aCD3-VHH x NbAlfa post-functionalization [w / w* = ligand to cargo ratio 1.15; ligand to functionalized lipid molar ratio 1.5:1]; RNA concentration: 0.1 μg / μl). All LNPs had diameters below 120 nm and PDIs below 0.2, as determined by DLS measurements. Successful RNA incorporation was confirmed by agarose gel electrophoresis. For transfection studies, 5 or 15 μl (500 ng or 1500 ng dose) of the corresponding formulation were pre-diluted in 50 μl X-Vivo 15 in ultra-low adhesion 96-well plates. 1e6 thawed human PBMCs were diluted in 50 μl X-Vivo 15 (with 10% PHS) and added to the nanoparticle dilution solution. After incubation for 30 min (37 ° C, 5% CO ), 200 μl X-Vivo15+5% PHS was added to each well, and the cells were cultured for an additional 18 h (37 ° C, 5% CO ). Cell type-specific transfection (Thy1.1) was then analyzed by flow cytometry. The percentage of transfected cells (CD14+ monocytes, CD56+ NK cells, CD19+ B cells, CD3+ T cells, CD4+ T cells, or CD8+ T cells) in all transfected PBMCs (transfection, y axis) under each test formulation is shown (see table below).
[0129] Figure 7 T cell targeting using LPLX with different lipids and linkers
[0130] LPLX were functionalized with aCD8 DARPinXNbAlfa using three different Alfa-tagged lipids and a control lipid without an Alfa tag (DSPE-PEG2kAlfa, DOPE-(G2SG2)2Alfa, DOPE-(G2SG2)4Alfa, and DOPE-(G2SG2)2). All LPLX contained Viromer L3 for RNA encapsulation (cargo: Thy1.1 / Luc RNA 1:1 w / w; RNA concentration: 0.1 μg / μL; N / P ratio: 15; ligand to cargo w / w ratio of 0, 1.5, or 2; ligand to functionalized lipid molar ratio of 1.5:1). Diameter and PDI were determined by DLS measurements. Successful RNA incorporation was confirmed by agarose gel electrophoresis. For transfection studies, 1e6 CD8+ Jurkat cells were seeded in 100 μl RMPI + 10% FBS per well (96-deep-well plate). 3 μl of the corresponding preparation (300 ng RNA) was applied to each well, and the NP cell solution was resuspended and incubated at 37°C for 10 min. Afterwards, 900 μl of RPMI + 10% FBS was added to each well to a cell concentration of 1e6 cells / ml. On day 1, 0.1e6 cells in 100 μl were plated for luciferase expression readings. On day 1, 0.3e6 cells in 300 μl were plated for FACs-based Thy1.1 expression detection.
[0131] Figure 8 T cell targeting using LNPs with different stealth lipids and alpha-lipids
[0132] LNPs were formulated with different lipid compositions (cargo: Thy1.1 / Luc RNA 1:1 w / w; N / P ratio: 4; lipid mixture: HY501 / cholesterol / DSPC / stealth lipid / Alfa lipid [47.5 / 38 / 10 / 1.8 / 0.2], with C16 PEG2k ceramide or C14 Sar20 as stealth lipids, and DSPE PEG2k Alfa, DOPE PSar20 Alfa, or DOPE PSar10 Alfa. LNPs were post-functionalized with aCD3 VHH x NbAlfa ligand [w / w* = ligand to cargo ratio 0.48; ligand to functionalized lipid molar ratio 3.5:1]; RNA concentration: 0.1 μg / μl). All LNPs had diameters between 90 and 120 nm and a PDI below 0.3, as determined by DLS measurements. Successful RNA incorporation was confirmed by agarose gel electrophoresis. For transfection studies, 10 μl (1000 ng dose) of the corresponding formulation was pre-diluted in 50 μl X-Vivo 15 in an ultra-low adhesion 96-well plate. 1e6 thawed human PBMCs were diluted in 100% PHS and added to the nanoparticle dilution solution. The plate was incubated overnight (37° C., 5% CO 2 ). Cell type-specific transfection (Thy1.1) was then analyzed by flow cytometry. The percentage of transfected cells (CD14+ monocytes, CD56+ NK cells, CD19+ B cells, CD3+ T cells, CD4+ T cells, or CD8+ T cells) in all transfected PBMCs (transfection, y axis) under each test formulation is shown (see table below).
[0133] Figure 9 T cell targeting using LNPs in a transgenic mouse model
[0134] LNPs were formulated with different lipid compositions and loaded with aCD3 VHH x NbAlfa ligand (cargo: Thy1.1 / LucRNA 1:1 w / w; N / P ratio: 4; lipid mixture: DODMA / cholesterol / DOPE / C16 PEG2k Ceramide / DSPE-PEG2k-Alfa [40 / 48 / 10 / 1.8 / 0.2]. aCD3-VHH x NbAlfa was added by post-functionalization [w / w* = ligand to cargo ratio 1.15; ligand to functionalized lipid molar ratio 1.5:1]; RNA concentration: 0.1 μg / μl). All LNPs had diameters between 90 and 120 nm and a PDI below 0.3, as determined by DLS measurements. Successful RNA incorporation was confirmed by agarose gel electrophoresis. 20 μg of the corresponding formulations were injected intravenously into the tail vein of B6-hCD3EDG transgenic mice. Before injection, transgenic human CD3 expression on mouse T cells and specific binding of the anti-hCD3 VHH x NbAlfa ligand to the transgenic receptor were confirmed in vitro on B6-hCD3EDG splenocytes. Eighteen hours after LNP injection, animals were sacrificed, and splenocytes were analyzed by flow cytometry for cell-type-specific Thy1.1 expression. Thy1.1 (transfected, y-axis) signal is plotted against CD69 activation marker expression on non-T / B cells, mCD19+ B cells, and mCD4+ or mCD8+ T cells.
[0135] Figure 10 B cell targeting using LNPs harboring algM
[0136] LNPs were formulated with or without ligand (cargo: Thy1.1 / Luc RNA 1:1 w / w; N / P ratio: 4; lipid mixture: DODMA / cholesterol / DOPE / C16-PEG-ceramide / DSPE-PEG2k-Alfa [40 / 48 / 10 / 2 - x / x = 0, 0.2]; aIgM-VHH x NbAlfa post-functionalization [w / w* = ligand to cargo ratio 0, 0.12, 0.25, 0.4; final RNA concentration: 0.1 μg / μl). All formulation conditions produced colloidally stable particles with diameters between 100-150 nm and a PDI below 0.5. Diameter and PDI were determined by DLS measurements. Successful RNA incorporation was confirmed by agarose gel electrophoresis. For transfection studies, 10 μl of the respective formulation was pre-diluted in 50 μl of X-Vivo 15 in a 96-deep-well plate. 1e6 thawed human PBMCs were diluted in IMDM culture medium without FCS and added to nanoparticle diluent (1000ng RNA). After incubation for 30min (37°C, 5% CO2), 900μl IMDM+HI FCS+IL4 and IL21 were added to each well, and the cells were cultured for an additional 18h (37°C, 5% CO2). Next, cell type-specific transfection (Thy1.1) was analyzed by flow cytometry. Cell type-specific Thy1.1 (transfection % multiplied by MFI, y-axis divided by 100) signals in viable CD14+ monocytes, CD19+ B cells, and CD3+ T cells are shown.
[0137] Figure 11 :Freeze-Thaw Studies
[0138] Particle size analysis of functionalized lipoplexes after two freeze-thaw cycles: (A) from -20°C to room temperature and (B) from -80°C to room temperature.
[0139] Figure 12 T cell targeting using LNPs with different stealth lipids and alpha lipids
[0140] LNPs were formulated with different lipid compositions (cargo: Thy1.1 RNA / Luc RNA / Np proxy Venus 1:1:2 w / w; N / P ratio: 6; lipid mixture: HY501 / cholesterol / DSPC / stealth lipid / Alfa lipid. For the following combinations of stealth lipids and Alfa lipids, the lipid ratios were selected as [47.5 / 40.5 / 10 / 1.8 / 0.2]: C16 PEG2k Ceramide / DSPEPEG2kAlfa, DSPE PEG2k / DSPE PEG2k Alfa, DSPE pAEEA14 / DSPE pAEEA14 Alfa, or VitEpAEEA8 / DSPE pAEEA14 Alfa. For the following combinations of stealth lipids and Alfa lipids, the lipid ratios were selected as [47.5 / 38.5 / 10 / 3.8 / 0.2]: VitE PEG1k / DSPE PEG2k Alfa or VitE pAEEA8 / DSPE pAEEA14Alfa LNPs were post-functionalized with aCD3 VHH × NbAlfa ligand [w / w* = ligand to cargo ratio 0.48]; RNA concentration: 0.1 μg / μl). As determined by DLS measurements, all LNPs had diameters between 100 and 170 nm and a PDI below 0.4.
[0141] For transfection studies, 10 μl (1000 ng dose) of the corresponding formulation was pre-diluted in 50 μl X-Vivo 15 in an ultra-low adhesion 96-well plate. 1e6 thawed human PBMCs were diluted in 50 μl 100% solidified PHS and added to the nanoparticle dilution. After incubation for 30 min (37 ° C, 5% CO ), 30 μl of each transfection reaction was transferred to a second ultra-low adhesion 96-well plate, and 170 μl of X-Vivo 15 culture medium + 100 U / ml IL2 was added to each well. The cell dilutions were cultured for an additional 18 h (37 ° C, 5% CO ). Cell type-specific transfection (Thy1.1) was then analyzed by flow cytometry. The percentage of transfected cells (CD2 negative cells, CD19+B cells, CD4+T cells, and CD8+T cells) in all transfected PBMCs (transfection, y axis) under each test formulation is shown (see table below).
[0142] Figure 13 :Ligand-mediated T cell transfection in vivo
[0143] B6-hCD3EDG transgenic mice were injected intramuscularly with a mixture of RNA encoding luciferase and Thy1.1 (1:1 weight ratio mixture) either naked or formulated with LNPs (1 μg RNA dose per flank; 2 μg total RNA dose per mouse). Analysis was performed 18 hours after injection. (A) Drainage of the popliteal, inguinal, axillary, and brachial lymph nodes, as well as the spleen, was analyzed by ex vivo bioluminescence imaging. (B) Cell type-specific transfection was analyzed by flow cytometry by detecting expression of delivered Thy1.1 RNA in immune cell subsets in the popliteal and inguinal lymph nodes and spleen. (C) T cell activation status was analyzed by mean fluorescence intensity of CD69 surface expression within the illustrated organs (after staining with anti-CD69-APC antibody). LN, lymph node; LNP, lipid nanoparticle; NK, natural killer cell; PMN, polymorphonuclear cell. DETAILED DESCRIPTION
[0144] Although the present disclosure is further described in more detail below, it should be understood that the present disclosure is not limited to the specific methods, protocols and reagents described herein, as these may vary. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to limit the scope of the present disclosure, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art.
[0145] Hereinafter, the elements of the present disclosure will be described in more detail. These elements are listed together with specific embodiments, but it should be understood that they can be combined in any way and in any quantity to create other embodiments. The various described embodiments and preferred embodiments should not be interpreted as limiting the present disclosure to only the embodiments clearly described. This description should be understood to support and encompass embodiments that combine the embodiments clearly described with any number of disclosures and / or preferred elements. In addition, unless the context indicates otherwise, any arrangement and combination of all described elements in this application should be considered as disclosed by the description of the application.
[0146] The practice of the present disclosure will employ, unless otherwise indicated, conventional chemistry, biochemistry, pharmacology, cell biology, immunology, and recombinant DNA techniques, which are explained in the art.
[0147] Throughout this specification and the appended claims, unless the context requires otherwise, the word “comprise” and variations thereof (such as “comprises” and “comprising”) should be understood to imply the inclusion of the stated features, elements, members, integers or steps or groups of features, elements, members, integers or steps, but not the exclusion of any other features, elements, members, integers or steps or groups of features, elements, members, integers or steps. The term “consisting essentially of limits the scope of a claim or disclosure to the specified features, elements, members, integers or steps and those that do not materially affect the basic and novel characteristics of the claim or disclosure. The term “consisting of limits the scope of a claim or disclosure to the specified features, elements, members, integers or steps. The term “comprising” encompasses the term “consisting essentially of,” and the term “consisting essentially of encompasses the term “consisting of.” Therefore, the term “consisting essentially of or “consisting of” may be substituted for the term “comprising” at each occurrence in this application. Likewise, the term “consisting essentially of may be replaced with the term “consisting of” at each occurrence in this application.
[0148] The terms "a," "an," and "the" and similar referents used in the context of describing the disclosure (especially in the context of the claims) should be construed to cover both the singular and the plural unless otherwise indicated herein or clearly contradicted by context.
[0149] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
[0150] The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended solely to better illustrate the present disclosure and does not limit the scope of the present disclosure as claimed. No language in the specification should be construed as indicating any non-claimed element is essential to the practice of the present disclosure.
[0151] As used herein, the terms "optional" or "optionally" mean that the subsequently described event, circumstance or condition may or may not occur, and that the description includes instances where said event, circumstance or condition occurs and instances where it does not.
[0152] As used herein, "and / or" should be taken as specifically disclosing each of the two specified features or components, whether or not with the other. For example, "X and / or Y" should be taken as specifically disclosing each of (i) X, (ii) Y, and (iii) X and Y, just as if each were individually listed herein.
[0153] In the context of this disclosure, the term "about" means an interval of precision that a person of ordinary skill in the art would understand to still ensure the technical effect of the feature in question. The term generally means a deviation from the indicated value of ±10%, ±5%, ±4%, ±3%, ±2%, ±1%, ±0.9%, ±0.8%, ±0.7%, ±0.6%, ±0.5%, ±0.4%, ±0.3%, ±0.2%, ±0.1%, ±0.05%, and for example, ±0.01%. In some embodiments, "about" means a deviation from the indicated value of ±10%. In some embodiments, "about" means a deviation from the indicated value of ±5%. In some embodiments, "about" means a deviation from the indicated value of ±4%. In some embodiments, "about" means a deviation from the indicated value of ±3%. In some embodiments, "about" means a deviation from the indicated value of ±2%. In some embodiments, "about" means a deviation from the indicated value of ±1%. In some embodiments, "about" means that the deviation from the numerical value is ±0.9%. In some embodiments, "about" means that the deviation from the numerical value is ±0.8%. In some embodiments, "about" means that the deviation from the numerical value is ±0.7%. In some embodiments, "about" means that the deviation from the numerical value is ±0.6%. In some embodiments, "about" means that the deviation from the numerical value is ±0.5%. In some embodiments, "about" means that the deviation from the numerical value is ±0.4%. In some embodiments, "about" means that the deviation from the numerical value is ±0.3%. In some embodiments, "about" means that the deviation from the numerical value is ±0.2%. In some embodiments, "about" means that the deviation from the numerical value is ±0.1%. In some embodiments, "about" means that the deviation from the numerical value is ±0.05%. In some embodiments, "about" means that the deviation from the numerical value is ±0.01%. As will be understood by those of ordinary skill, the specific deviation of such values for a given technical effect will depend on the nature of the technical effect. For example, natural or biotechnological effects may generally have greater such deviations than artificial or engineered technical effects.
[0154] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated into the specification as if it were individually recited herein.
[0155] This specification refers to several documents throughout. Each document cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions for use, etc.), whether supra or infra, is hereby incorporated by reference in its entirety. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such disclosure by virtue of prior invention.
[0156] In the following, definitions and embodiments applicable to all aspects of the present disclosure are provided. Unless otherwise indicated, the terms defined below have the meanings defined. Any undefined terms have their art-recognized meanings.
[0157] As used herein, terms such as "reduce" or "inhibit" mean the ability to cause an overall decrease, for example, a decrease of about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, or about 75% or more in levels. The term "inhibit" or similar phrases include complete or substantially complete inhibition, i.e., a decrease to zero or substantially to zero.
[0158] As used herein, terms such as "enhance" mean the ability to cause an overall increase or enhancement, for example, an increase or enhancement of at least about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, about 75% or more, or about 100% or more in levels.
[0159] As used herein, "physiological pH" refers to a pH of about 7.4. In some embodiments, the physiological pH is 7.3-7.5. In some embodiments, the physiological pH is 7.35-7.45. In some embodiments, the physiological pH is 7.3, 7.35, 7.4, 7.45, or 7.5.
[0160] As used in this disclosure, "% w / v" means weight percent by volume, which is a unit of concentration that measures the amount of solute in grams (g) expressed as a percentage of the total volume of a solution in milliliters (mL).
[0161] As used in this disclosure, "wt%" refers to weight percent, which is a concentration unit that measures the amount of a substance in grams (g) expressed as a percentage of the total weight of the total composition in grams (g).
[0162] As used in this disclosure, "mole (mol) %" is defined as the ratio of the number of moles of one component to the total number of moles of all components, multiplied by 100.
[0163] As used in this disclosure, "mol % of total lipids" is defined as the ratio of the moles of one lipid component to the total moles of all lipids, multiplied by 100. In this context, in some embodiments, the term "total lipids" includes lipids and lipid-like substances.
[0164] The term "ionic strength" refers to the mathematical relationship between the amounts of different ionic species in a particular solution and their respective charges. Therefore, the ionic strength, I, is mathematically represented by the following formula:
[0165]
[0166] where c is the molar concentration of a particular ion species and z is the absolute value of its charge. The sum Σ is taken over all the different ions (i) in the solution.
[0167] According to the present disclosure, in some embodiments, the term "ionic strength" refers to the presence of monovalent ions. About the presence of divalent ions, particularly divalent cations, in some embodiments, their concentration or effective concentration (the presence of free ions) is low enough to prevent the degradation of nucleic acids due to the presence of chelating agents. In some embodiments, the concentration or effective concentration of divalent ions is below the catalytic level for hydrolyzing phosphodiester bonds between nucleotides (such as RNA nucleotides). In some embodiments, the concentration of free divalent ions is 20 μM or less. In some embodiments, there are no or substantially no free divalent ions.
[0168] "Osmolality" refers to the concentration of a specific solute expressed as osmoles of solute per kilogram of solvent.
[0169] The term "lyophilizing" or "lyophilization" refers to the freeze-drying of a substance by freezing it and then reducing the surrounding pressure (e.g., to below 15 Pa, such as below 10 Pa, below 5 Pa or 1 Pa or less) to allow the freezing medium in the substance to sublime directly from the solid phase to the gas phase. Thus, the terms "lyophilizing" and "freeze-drying" are used interchangeably herein.
[0170] The term "spray drying" refers to spray drying of a substance by mixing a (heated) gas with a fluid that is atomized (sprayed) within a vessel (spray dryer), where the solvent from the formed droplets evaporates, resulting in a dry powder.
[0171] The term "reconstitution" involves adding a solvent, such as water, to the dried product to return it to a liquid state, such as its original liquid state.
[0172] The term "recombinant" in the context of this disclosure means "produced by genetic engineering." In some embodiments, a "recombinant object" in the context of this disclosure does not occur in nature.
[0173] As used herein, the term "naturally occurring" refers to the fact that an object can be found in nature. For example, a peptide or nucleic acid that exists in an organism (including a virus) and can be isolated from a natural source and has not been intentionally modified by humans in a laboratory is naturally occurring. The term "found in nature" means "existing in nature" and includes known objects as well as objects that have not yet been discovered and / or isolated from nature but may be discovered and / or isolated from natural sources in the future.
[0174] As used herein, the terms "room temperature" and "ambient temperature" are used interchangeably herein and refer to a temperature of at least about 15° C., such as from about 15° C. to about 35° C., from about 15° C. to about 30° C., from about 15° C. to about 25° C., or from about 17° C. to about 22° C. Such temperatures include 15° C., 16° C., 17° C., 18° C., 19° C., 20° C., 21° C., and 22° C.
[0175] The term "EDTA" refers to ethylenediaminetetraacetic acid disodium salt. All concentrations are given relative to EDTA disodium salt.
[0176] The term "cryoprotectant" relates to substances added to a formulation to protect the active ingredient during the freezing stage.
[0177] The term "lyoprotectant" relates to substances added to a formulation to protect the active ingredient during the drying phase.
[0178] According to the present disclosure, the term "peptide" refers to a substance comprising about 2 or more, about 3 or more, about 4 or more, about 6 or more, about 8 or more, about 10 or more, about 13 or more, about 16 or more, about 20 or more, and up to about 50, about 100 or about 150 consecutive amino acids connected to each other by peptide bonds. The term "polypeptide" refers to large peptides, particularly peptides with at least about 151 amino acids. "Peptide" and "polypeptide" are both protein molecules. Therefore, the terms "peptide," "protein," and "polypeptide" are generally used as synonyms herein.
[0179] The peptides and polypeptides disclosed herein may comprise linear or cyclized peptide sequences.
[0180] In some embodiments, the peptides disclosed herein comprise at least one cyclic portion, i.e., a polypeptide chain containing a cyclic bond sequence, referred to herein as a "cyclic peptide." The cyclic sequence can occur by a linkage between the amino and carboxyl termini of the peptide, a linkage between the amino terminus and a side chain, a linkage between the carboxyl terminus and a side chain, or a linkage between two side chains (including the sulfur groups of two cysteine amino acids through the formation of a disulfide bond), or more complex arrangements.
[0181] In some embodiments, the peptides and polypeptides disclosed herein are composed of naturally occurring amino acids, non-naturally occurring amino acids, amino acid derivatives, and non-amino acid components, or mixtures thereof. In some embodiments, the peptides and polypeptides disclosed herein comprise amino acid mimetics and amino acid analogs. In some embodiments, the peptides and polypeptides disclosed herein comprise non-naturally occurring amino acid sequences that are resistant to enzymatic cleavage.
[0182] In some embodiments, one or more positions of the peptides or polypeptides disclosed herein are substituted with non-naturally occurring amino acids. In some embodiments, the substituted amino acids are chemically related (e.g., aliphatic, charged, basic, acidic, aromatic, hydrophilic) to the original residue or are isosteres of the original residue.
[0183] In the broadest sense herein, the term "amino acid" refers to a compound and / or substance that can, is, or has been incorporated into a peptide, for example, by forming one or more peptide bonds. In some embodiments, an amino acid has the general structure H2N–C(H)(R)–COOH. In some embodiments, the amino acid is a naturally occurring amino acid. In some embodiments, the amino acid is a non-natural amino acid. In some embodiments, the amino acid is a D-amino acid. In some embodiments, the amino acid is an L-amino acid. "Standard amino acid" refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides and polypeptides. "Non-standard amino acid" refers to any amino acid other than a standard amino acid, whether synthetically prepared or obtained from a natural source. In some embodiments, the amino acids (including the carboxyl and / or amino terminal amino acids) in a peptide or polypeptide may contain structural modifications compared to the general structure described above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and / or substitution (e.g., substitution of an amino group, a carboxylic acid group, one or more protons, and / or hydroxyl groups) compared to the general structure. In some embodiments, for example, such modifications may alter the circulatory half-life of a peptide or polypeptide containing the modified amino acid compared to an otherwise identical peptide or polypeptide containing the unmodified amino acid. In some embodiments, such modifications do not significantly alter the associated activity of a peptide or polypeptide containing the modified amino acid compared to an otherwise identical peptide or polypeptide containing the unmodified amino acid. As will be clear from the context, in some embodiments, the term "amino acid" may be used to refer to a free amino acid. In some embodiments, it may be used to refer to an amino acid residue of a peptide or polypeptide.
[0184] The following table lists the 20 naturally occurring amino acids and their abbreviations:
[0185]
[0186] Typically, amino acids are L-amino acids, while D-amino acids are indicated by the prefix "D." The prefix "homo" or "h" indicates an α-amino acid, which is similar to one of the common amino acids except for having an additional methylene group in the carbon chain.
[0187] As used herein, "Orn" means ornithine or 2,5-diaminopentanoic acid, "Dab" means 2,4-diaminobutyric acid, "Dap" means 2,3-diaminopropionic acid, "hLys" means 2,7-diaminoheptanoic acid, "hCys" means 2-amino-4-mercaptobutyric acid, and "Pen" means penicillamine or 2-amino-3-methyl-3-sulfanylbutyric acid.
[0188] Non-peptide bonds and other chemical modifications can also be included. For example, part or all of a peptide or polypeptide can be synthesized as a peptide mimetic, such as a peptidomimetic (see, for example, Simon et al. (1992) Proc. Natl. Acad. Sci. USA 89:9367-71 and Horwell (1995) Trends Biotechnol. 13:132-4). A peptide or polypeptide can include one or more (for example, all) non-hydrolyzable bonds. Many non-hydrolyzable peptide bonds and the synthesis procedures of peptides containing such bonds are known in the art. Exemplary non-hydrolyzable bonds include -[CH NH]-reduced amide peptide bonds, -[COCH ]-ketomethylene peptide bonds, -[CH (CN) NH]-(cyanomethylene) amino peptide bonds, -[CH CH (OH)]-hydroxyethylidene peptide bonds, -[CH O]-oxymethylene peptide bonds and -[CH S]-sulfomethylene peptide bonds (see, for example, U.S. Patent number 6,172,043).
[0189] As used herein, the term "amide" refers to a group of formula "-NHC(O)-".
[0190] The term "thioamide" refers to a group of formula "-NHC(S)-".
[0191] As used herein, the term "disulfide bond," "disulfide bridge," or "disulfide" includes a covalent bond formed between two sulfur atoms. The amino acid cysteine contains a sulfhydryl group that can form a disulfide bond or bridge with a second sulfhydryl group.
[0192] The term "ether" refers to a group or compound having an oxygen between two carbon atoms.
[0193] The term "thioether" refers to a group or compound having sulfur between two carbon atoms.
[0194] The term "ester" refers to a compound derived from a carboxylic acid and an alcohol, linked through the hydroxyl group of the -C(=O)OH group of the former and the formal loss of water of the hydroxyl group of the latter. Thus, the term refers to a -C(O)O- group.
[0195] The term "thioester" refers to a -C(O)S- group.
[0196] The term "triazole" refers to a chemical compound that incorporates in its structure any five-membered heterocyclic ring structure having two carbon atoms and three nitrogen atoms (eg, 1,2,3-triazole).
[0197] The term "portion" refers to a part. With respect to a specific structure such as an amino acid sequence or a protein, the term "portion" thereof may refer to a continuous or discontinuous portion of said structure.
[0198] The terms "part" and "fragment" are used interchangeably herein to refer to a continuous element. For example, a portion of a structure, such as an amino acid sequence or a protein, refers to a continuous element of the structure. When used in the context of a composition, the term "part" refers to a portion of the composition. For example, a portion of a composition can be any portion from 0.1% to 99.9% (e.g., 0.1%, 0.5%, 1%, 5%, 10%, 50%, 90%, or 99%) of the composition.
[0199] With respect to an amino acid sequence (peptide or polypeptide), a "fragment" refers to a portion of an amino acid sequence, i.e., a sequence representing an amino acid sequence that is shortened at the N-terminus and / or C-terminus. A fragment shortened at the C-terminus (N-terminal fragment) can be obtained, for example, by translation of a truncated open reading frame lacking the 3' end of the open reading frame. A fragment shortened at the N-terminus (C-terminal fragment) can be obtained, for example, by translation of a truncated open reading frame lacking the 5' end of the open reading frame, as long as the truncated open reading frame contains a start codon for initiating translation. A fragment of an amino acid sequence comprises, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the amino acid residues from the amino acid sequence. A fragment of an amino acid sequence comprises, for example, at least 6, in particular at least 8, at least 10, at least 12, at least 15, at least 20, at least 30, at least 50, or at least 100 consecutive amino acids from the amino acid sequence. Fragments of an amino acid sequence comprise sequences of, for example, up to 8, in particular up to 10, up to 12, up to 15, up to 20, up to 30 or up to 55 consecutive amino acids of an amino acid sequence.
[0200] As used herein, with respect to amino acid sequences (peptides or polypeptides), "variant" refers to an amino acid sequence that differs from a parent amino acid sequence by at least one amino acid (e.g., a different amino acid, or a modification of the same amino acid). The parent amino acid sequence can be a naturally occurring or wild-type (WT) amino acid sequence, or can be a modified form of a wild-type amino acid sequence. In some embodiments, the variant amino acid sequence has at least one amino acid difference compared to the parent amino acid sequence, e.g., 1 to about 20 amino acid differences, such as 1 to about 10 or 1 to about 5 amino acid differences, compared to the parent.
[0201] As used herein, with respect to an amino acid sequence (peptide or polypeptide), "wild type" or "WT" or "native" refers to an amino acid sequence found in nature, including allelic variations. A wild type amino acid sequence, peptide or polypeptide has an amino acid sequence that has not been intentionally modified.
[0202] For the purposes of this disclosure, a "variant" of an amino acid sequence (peptide or polypeptide) may comprise an amino acid insertion variant, an amino acid addition variant, an amino acid deletion variant, and / or an amino acid substitution variant. The term "variant" includes all mutants, splice variants, post-translational modification variants, conformations, isoforms, allelic variants, species variants, and species homologs, particularly those occurring in nature. In particular, the term "variant" includes fragments of an amino acid sequence.
[0203] Amino acid insertion variants include insertions of single or two or more amino acids in a specific amino acid sequence. In the case of amino acid sequence variants with insertion, one or more amino acid residues are inserted into a specific site in the amino acid sequence, but random insertion with appropriate screening of the resulting product is also possible. Amino acid addition variants include amino- and / or carboxyl-terminal fusions of one or more amino acids, such as 1, 2, 3, 5, 10, 20, 30, 50 or more amino acids. Amino acid deletion variants are characterized by removing one or more amino acids from the sequence, such as removing 1, 2, 3, 5, 10, 20, 30, 50 or more amino acids. The deletion can be at any position in the protein. Amino acid deletion variants comprising a deletion at the N-terminal and / or C-terminal end of the protein are also referred to as N-terminal and / or C-terminal truncated variants. Amino acid substitution variants are characterized by removing at least one residue in the sequence and inserting another residue in its place. Modifications in amino acid sequence positions that are not conserved between homologous peptides or polypeptides and / or replacing amino acids with other amino acids having similar properties are preferred. In some embodiments, the amino acid changes in the peptide and polypeptide variants are conservative amino acid changes, that is, replacements of similar charged or uncharged amino acids. Conservative amino acid changes include replacements of one of the amino acid families related in their side chains. Naturally occurring amino acids are generally divided into 4 families: acidic (aspartic acid, glutamic acid), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan and tyrosine are sometimes collectively classified as aromatic amino acids. In some embodiments, conservative amino acid substitutions include substitutions within the following groups:
[0204] Glycine, alanine;
[0205] valine, isoleucine, leucine;
[0206] Aspartic acid, glutamic acid;
[0207] Asparagine, glutamine;
[0208] Serine, threonine;
[0209] lysine, arginine; and
[0210] Phenylalanine, tyrosine.
[0211] In some embodiments, the degree of similarity (e.g., identity) between a given amino acid sequence and the amino acid sequence of a given amino acid sequence variant is at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, the degree of similarity or identity is given for an amino acid region of at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the entire length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is given for, for example, at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 amino acids (in some embodiments, contiguous amino acids). In some embodiments, the degree of similarity or identity is given for the entire length of the reference amino acid sequence. Sequence similarity can be determined using tools known in the art, such as alignment of sequence identities, such as using optimal sequence alignment, for example, using Align, using standard settings, preferably EMBOSS::needle, Matrix:Blosum62, Gap Open 10.0, Gap Extend 0.5.
[0212] "Sequence similarity" refers to the percentage of amino acids that are identical or represent conservative amino acid substitutions. "Sequence identity" between two amino acid sequences refers to the percentage of amino acids that are identical between the sequences. "Sequence identity" between two nucleic acid sequences refers to the percentage of nucleotides that are identical between the sequences.
[0213] In particular, the terms "% identical" and "% identity" or similar terms refer to the percentage of identical nucleotides or amino acids in an optimal alignment between the sequences being compared. The percentages are purely statistical, and the differences between the two sequences may, but need not, be randomly distributed over the entire length of the sequences being compared. Comparison of the two sequences is typically performed by comparing the sequences after optimal alignment of a segment or "comparison window" in order to identify local regions of corresponding sequences. Optimal alignment for comparison can be performed manually or with the aid of an algorithm, for example, the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, the local homology algorithm of Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443, the search similarity algorithm of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88, 2444, or with the aid of computer programs that use such algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In some embodiments, the percent identity of two sequences is determined using the BLASTN or BLASTP algorithm, which can be found on the National Center for Biotechnology Information (NCBI) website (e.g., at blast.ncbi.nlm.nih.gov / Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&LIN K_LOC=align2seq). In some embodiments, the algorithm parameters for the BLASTN algorithm on the NCBI website include: (i) an expectation threshold of 10; (ii) a word length of 28; (iii) a maximum match in the query range of 0; (iv) a match / mismatch score of 1, -2; (v) a gap penalty of linear; and (vi) a filter for low complexity regions. In some embodiments, the algorithm parameters for the BLASTP algorithm on the NCBI website include: (i) expectation threshold set to 10; (ii) word length set to 3; (iii) maximum match in query range set to 0; (iv) matrix set to BLOSUM62; (v) gap penalty set to existence: 11 extension: 1; and (vi) condition combination score matrix adjustment.
[0214] Percent identity is obtained by determining the number of identical positions in the sequences being compared, dividing this number by the number of positions being compared (eg, the number of positions in the reference sequence), and multiplying this result by 100.
[0215] In some embodiments, a degree of similarity or identity is given for a region of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the entire length of a reference sequence. For example, if the reference nucleic acid sequence consists of 200 nucleotides, a degree of identity is given for at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 nucleotides (in some embodiments, contiguous nucleotides). In some embodiments, a degree of similarity or identity is given for the entire length of a reference sequence.
[0216] According to the present disclosure, homologous amino acid sequences exhibit at least 40%, in particular at least 50%, at least 60%, at least 70%, at least 80%, at least 90% and for example at least 95%, at least 98 or at least 99% identity of amino acid residues.
[0217] The skilled artisan can readily prepare amino acid sequence variants described herein, for example, by recombinant DNA procedures. For example, procedures for preparing DNA sequences of peptides or polypeptides having substitutions, additions, insertions, or deletions are described in detail in Molecular Cloning: A Laboratory Manual, 4th Edition, MR Green and J. Sambrook et al. (1989), eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 2012. In addition, the peptides, polypeptides, and amino acid variants described herein can be readily prepared by known peptide synthesis techniques, for example, by solid phase synthesis and similar methods.
[0218] In some embodiments, a fragment or variant of an amino acid sequence (peptide or polypeptide) is a "functional fragment" or "functional variant". The term "functional fragment" or "functional variant" of an amino acid sequence refers to any fragment or variant that exhibits one or more functional properties that are the same or similar to the functional properties of the amino acid sequence from which it is derived, that is, it is functionally equivalent. With respect to the sequence of a binding agent (such as an antibody), a specific function is one or more binding activities exhibited by the amino acid sequence from which the fragment or variant is derived. As used herein, the term "functional fragment" or "functional variant" refers in particular to a variant molecule or sequence that comprises an amino acid sequence in which one or more amino acids are changed compared to the amino acid sequence of the parent molecule or sequence, and is still able to perform one or more functions of the parent molecule or sequence, for example, binding to a target molecule. In some embodiments, the modification in the amino acid sequence of the parent molecule or sequence does not significantly affect or change the characteristics of the molecule or sequence. In different embodiments, the function of the functional fragment or functional variant may be reduced but still significantly present, for example, the function of the functional fragment or functional variant may be at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of that of the parent molecule or sequence. However, in other embodiments, the function of a functional fragment or functional variant may be enhanced compared to the parent molecule or sequence.
[0219] An amino acid sequence (peptide or polypeptide) "derived from" a specified amino acid sequence (peptide or polypeptide) refers to the source of the first amino acid sequence. In some embodiments, an amino acid sequence derived from a specific amino acid sequence has an amino acid sequence that is identical, substantially identical, or homologous to the specific amino acid sequence or a fragment thereof. An amino acid sequence derived from a specific amino acid sequence may be a variant of the specific sequence or a fragment thereof. For example, one of ordinary skill in the art will appreciate that sequences suitable for use herein may be altered so that their sequence differs from the naturally occurring sequence or the original sequence from which they are derived, while retaining the desirable activity of the original sequence.
[0220] In some embodiments, "isolated" means removed (e.g., purified) from its natural state or from an artificial composition (e.g., a composition resulting from a production process). For example, a nucleic acid, peptide, or polypeptide naturally present in a living animal is not "isolated," but the same nucleic acid, peptide, or polypeptide partially or completely separated from coexisting materials in its natural state is "isolated." An isolated nucleic acid, peptide, or polypeptide can exist in a substantially pure form or can exist in a non-native environment, e.g., a host cell.
[0221] The term "bind" or "binding" refers to a non-covalent interaction with a target. In some embodiments, the term "bind" or "binding" refers to specific binding. As used herein, the term "specific binding" or "specifically binds" means a molecule (such as an antibody or antigen receptor) that recognizes a specific target molecule but does not substantially recognize or bind to other molecules in a sample or subject. For example, an antibody that specifically binds to an antigen from one species may also bind to that antigen from one or more other species. However, this type of cross-species reactivity itself does not change the classification of antibody specificity. In another example, an antibody that specifically binds to an antigen may also bind to different allelic forms of the antigen. However, this type of cross-reactivity itself does not change the classification of antibody specificity.
[0222] In some cases, the term "specific binding" or "specifically binds" can be used to refer to the interaction of an antibody, protein or peptide with a second chemical species, meaning that the interaction depends on the presence of a specific structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, an antibody recognizes and binds to a specific protein structure rather than generally recognizing and binding to proteins. If the antibody is specific for epitope "A," then in a reaction containing labeled "A" and the antibody, the presence of a molecule containing epitope A (or free, unlabeled A) will reduce the amount of labeled A bound to the antibody.
[0223] As used herein, the term "binds" or "capable of binding" generally refers to binding to a protein with a specific binding affinity corresponding to about 10 -7 M or lower, such as about 10 -8 M or lower, such as about 10 -9 M or lower, about 10 -10 M or lower, or about 10 -11 M or even lower K D In some embodiments, the binding moiety or binding agent binds with an affinity corresponding to an affinity at least ten-fold lower (such as at least 100-fold lower, such as at least 1,000-fold lower, such as at least 10,000-fold lower, such as at least 100,000-fold lower) than that with which it binds to a non-specific target (e.g., BSA, casein). D binds with a high affinity to the intended target.
[0224] As used herein, the term "k d ”(sec -1 ) refers to the dissociation rate constant for a specific interaction (e.g., an antibody-antigen interaction). This value is also referred to as k off value.
[0225] As used herein, the term "K D "(M)" refers to the dissociation equilibrium constant for a particular interaction (e.g., an antibody-antigen interaction).
[0226] Generally, the terms "binding" and "targeting" are used interchangeably herein.
[0227] The term "genetic modification" or simply "modification" includes transfecting cells with nucleic acids. The term "transfection" refers to the introduction of nucleic acids, such as DNA and / or RNA, into cells. For the purposes of this disclosure, the term "transfection" also includes the introduction of nucleic acids into cells or the uptake of nucleic acids by such cells, wherein the cells can be present in a subject, such as a patient, or the cells can be in vitro, such as outside the patient's body. Thus, according to the present disclosure, cells transfected with the nucleic acids described herein can be present in vitro or in vivo, for example, the cells can form an organ, tissue, and / or part of a patient's body. According to the present disclosure, transfection can be transient or stable. For some applications of transfection, only transient expression of the transfected genetic material is sufficient. RNA can be transfected into cells to transiently express the protein it encodes. Because the nucleic acids introduced during transfection are generally not integrated into the nuclear genome, the exogenous nucleic acids are diluted or degraded by mitosis. Cells that allow for free amplification of nucleic acids greatly reduce the dilution rate. If it is desired that the transfected nucleic acids are actually retained in the genome of the cell and its daughter cells, stable transfection is necessary. For example, such stable transfection can be achieved by transfection using viral-based or transposon-based systems. Typically, cells genetically modified to express an antigen receptor are stably transfected with nucleic acid encoding the antigen receptor. RNA can be transfected into cells to transiently express the protein it encodes.
[0228] As used herein, the terms "linked," "fused," or "fusion" are used interchangeably. These terms refer to the joining together of two or more elements, components, or domains.
[0229] As used herein, the term "fusion protein" refers to a polypeptide or protein comprising two or more subunits. Preferably, the fusion protein is a translational fusion between two or more subunits. Translational fusions can be produced by genetically engineering the coding nucleotide sequence of one subunit with the coding nucleotide sequence of another subunit in frame. The subunits can be interspersed by linkers.
[0230] As used herein, "endogenous" refers to any material that originates from or is produced within an organism, cell, tissue, or system.
[0231] As used herein, the term "exogenous" refers to any material introduced from outside of or generated outside of an organism, cell, tissue, or system.
[0232] As used herein, the term "autologous" is used to describe anything derived from the same subject. For example, "autologous transplantation" refers to the transplantation of tissue or organs from the same subject. The advantage of such methods is that they overcome the immune barriers that lead to rejection.
[0233] As used herein, the term "allogeneic" is used to describe anything derived from different individuals of the same species. Two or more individuals are said to be allogeneic when they are not identical in genes at one or more loci.
[0234] The term "isogenic" is used to describe anything derived from individuals or tissues with the same genotype, i.e., identical twins or animals of the same inbred strain, or their tissues.
[0235] The term "heterologous" is used to describe something that is made up of multiple different elements. For example, transplanting bone marrow from one individual into a different individual constitutes a heterologous transplant. Heterologous genes are genes derived from a source other than the subject.
[0236] According to various embodiments of the present disclosure, the nucleic acid encoding the peptide or polypeptide is taken up or introduced by the cell, i.e., transfected or transduced into the cell, and the cell can be present in vitro or in a subject, thereby causing the expression of the peptide or polypeptide. The cell can, for example, express the encoded peptide or polypeptide intracellularly (e.g., in the cytoplasm and / or nucleus), can secrete the encoded peptide or polypeptide, and / or can express it on the surface. In some embodiments, if the encoded peptide or polypeptide is an antigen receptor, the cell expresses the antigen receptor on the cell surface.
[0237] According to the present disclosure, terms such as "nucleic acid that expresses..." and "nucleic acid that encodes..." or similar terms are used interchangeably herein and, with respect to a particular peptide or polypeptide, mean that if the nucleic acid is present in an appropriate environment, such as within a cell, it can be expressed to produce the peptide or polypeptide.
[0238] As used herein, the term "expression" includes the transcription and / or translation of a specific nucleotide sequence.
[0239] In the context of this disclosure, the term "transcription" refers to a process in which the genetic code in a DNA sequence is transcribed into RNA (particularly mRNA). Subsequently, the RNA can be translated into a peptide or polypeptide.
[0240] With respect to RNA, the terms "expression" or "translation" refer to the process in the cell's ribosomes by which an mRNA chain directs the assembly of an amino acid sequence to produce a peptide or polypeptide.
[0241] Pharmaceutical products described herein, particularly kits, can include explanatory materials or instructions. As used herein, "explanatory materials" or "instructions" include publications, records, icons, or any other media of expression that can be used to convey the usability of the compositions and methods of the present disclosure. The explanatory materials of a kit of the present disclosure can, for example, be affixed to a container containing the compositions / preparations of the present disclosure, or can be transported together with a container containing the compositions / preparations. Alternatively, the explanatory materials can be transported separately from the container in order for the explanatory materials and compositions to be used in conjunction with the recipient.
[0242] The term "mean diameter" refers to the average hydrodynamic diameter of the particles measured by dynamic light scattering (DLS) and using the so-called cumulant algorithm for data analysis, which provides the so-called Z having a length dimension. 平均 , and the dimensionless polydispersity index (PDI) as a result (Koppel, D., J. Chem. Phys. 57, 1972, pp 4814-4820, ISO 13321). Here, the "average diameter", "diameter" or "size" of the particles is the same as Z 平均 This value is used synonymously with .
[0243] In some embodiments, the "polydispersity index" is calculated based on dynamic light scattering measurements by the so-called cumulant analysis mentioned in the definition of "mean diameter." Under certain prerequisites, it can be used as a measure of the overall size distribution of the nanoparticles.
[0244] The radius of gyration of the particle around the axis of rotation (abbreviated as R in this paper) g ) is the radial distance from the axis of rotation of a point such that, if the entire mass of the particle were assumed to be concentrated at that point, its moment of inertia about a given axis would be the same as its actual mass distribution. Mathematically, R g is the root mean square distance between a particle component and its center of mass or a given axis. For example, for a macromolecule consisting of n mass elements, the mass is m i (i=1,2,3,…,n), located at a fixed distance s from the center of mass i Department, R g is the s of all mass elements i 2 The square root of the mass mean and can be calculated as follows:
[0245]
[0246] The radius of gyration can be determined experimentally or calculated, for example, by using light scattering. In particular, for small scattering vectors The structure function S is defined as follows:
[0247]
[0248] where N is the number of components (Guinier's law).
[0249] The "hydrodynamic radius" of a particle (sometimes called the "Stokes radius" or "Stokes-Einstein radius") is the radius of a hypothetical hard sphere that diffuses at the same speed as the particle. The hydrodynamic radius is related to the mobility of the particle and takes into account not only size but also solvent effects. For example, a smaller charged particle with greater hydration may have a larger hydrodynamic radius than a larger charged particle with lesser hydration. This is because the smaller particle drags more water molecules as it moves through the solution. Because the actual size of the particle in the solvent cannot be directly measured, the hydrodynamic radius can be defined by the Stokes-Einstein equation:
[0250]
[0251] where k B is the Boltzmann constant; T is the temperature; η is the viscosity of the solvent; and D is the diffusion coefficient. The diffusion coefficient can be determined experimentally, for example, by using dynamic light scattering (DLS). Therefore, one method for determining the hydrodynamic radius of a particle or a population of particles (such as the hydrodynamic radius of the particles contained in the sample or control composition disclosed herein, or the hydrodynamic radius of the particle peak obtained by field-flow fractionation of such a sample or control composition) is to measure the DLS signal of the particle or the population of particles (such as the DLS signal of the particles contained in the sample or control composition disclosed herein, or the DLS signal of the particle peak obtained by field-flow fractionation of such a sample or control composition).
[0252] As used herein, the expression "light scattering" refers to the physical process whereby light is forced to deviate from a straight-line trajectory into one or more paths due to local inhomogeneities in a medium through which the light passes.
[0253] The term "UV" stands for ultraviolet light, and designates a band of the electromagnetic spectrum with wavelengths from 10 nm to 400 nm, ie, shorter than visible light but longer than X-rays.
[0254] As used herein, the expression "multi-angle light scattering" or "MALS" relates to a technique for measuring light scattered by a sample into multiple angles. "Multi-angle" in this context means that the scattered light can be detected at different discrete angles during the measurement, for example, by a single detector that is movable within a range that includes a selected specific angle or by an array of detectors that are fixed at specific angular positions. In certain embodiments, the light source used in MALS is a laser source (MALLS: Multi-angle Laser Light Scattering). Based on the MALS signal of a composition comprising particles and by using an appropriate form (e.g., a Zimm plot, a Berry plot, or a Debye plot), the radius of gyration (R g ), and thus determine the size of the particles. Preferably, the Zimm diagram is a graphical representation using the following equation:
[0255]
[0256] Where c is the mass concentration of particles in the solvent (g / mL); A2 is the second virial coefficient (mol·mL / g 2 ); P(θ) is the shape factor related to the angular dependence of the scattered light intensity; R θ is the excess Rayleigh ratio (cm -1 );K * is an optical constant, equal to 4π 2 η o (dn / dc) 2 λ0 -4 N A -1 , where η o is the refractive index of the solvent at the wavelength of the incident radiation (vacuum), λ0 is the wavelength of the incident radiation (vacuum) (nm), N A is Avogadro's number (mol -1 ), dn / dc is the differential refractive index increment (mL / g) (see, for example, Buchholz et al. (Electrophoresis 22 (2001), 4118-4128); BH Zimm (J. Chem. Phys. 13 (1945), 141; P. Debye (J. Appl. Phys. 15 (1944): 338; and W. Burchard (Anal. Chem. 75 (2003), 4279-4291). Preferably, the Berry diagram is calculated using the following terms or their reciprocals:
[0257]
[0258] Where c, R θ and K* are as defined above. Preferably, the Debye graph is calculated using the following terms or their reciprocals:
[0259]
[0260] Where c, R θ and K* are as defined above.
[0261] As used herein, the expression "dynamic light scattering" or "DLS" refers to a technique for determining the size and size distribution profile of particles (particularly with respect to the hydrodynamic radius of the particles). A monochromatic light source, typically a laser, is directed into a sample through a polarizer. The scattered light then passes through a second polarizer, where it is detected, and the resulting image is projected onto a screen. Particles in the solution are struck by the light and diffract it in all directions. The diffracted light from the particles can interfere constructively (bright areas) or destructively (dark areas). This process is repeated at very short time intervals, and the resulting speckle pattern set is analyzed by comparing the light intensity at each point over time using an autocorrelator.
[0262] As used herein, the expression "static light scattering" or "SLS" refers to a technique for determining the size and size distribution spectrum of particles (particularly with respect to the radius of gyration of the particles and / or the molar mass of the particles). High-intensity monochromatic light, typically a laser, is emitted into a solution containing the particles. One or more detectors are used to measure the scattered intensity at one or more angles. Angle dependence is required to obtain accurate measurements of the molar mass and size of macromolecules of all radii. Therefore, simultaneous measurement at several angles relative to the direction of the incident light is called multi-angle light scattering (MALS) or multi-angle laser light scattering (MALLS), which is generally considered to be the standard implementation of static light scattering.
[0263] Docking compounds
[0264] According to the present disclosure, a payload is specifically delivered to a target cell by providing a docking compound having a portion that binds to a target on the target cell, such as an antigen on the target cell, and a portion that binds to a compound (linking compound) that is an integral part of the particle carrying the payload. The target on the target cell is also referred to herein as the "primary target."
[0265] "Docking compounds" are used to form a connection, such as a non-covalent connection, between a primary target (e.g., a target cell or an antigen on a target cell) and a docking compound. The docking compound can form a connection, such as a non-covalent or covalent connection, with a particle containing a payload that is delivered to the target cell via the docking compound. The docking compound comprises a binding moiety for binding to the docking compound, the binding moiety being covalently linked to a hydrophobic moiety (e.g., a lipid). The hydrophobic moiety (e.g., a lipid) forms part of the particle.
[0266] In some embodiments, the docking compound comprises a "primary targeting moiety," e.g., a moiety that targets a cell surface antigen on a target cell that is capable of binding to a primary target of interest, e.g., a cell surface antigen on a target cell. As used herein, a "primary targeting moiety" refers to a moiety that binds to a primary target. Such targeting moieties are typically moieties that have affinity for a cell surface target. These moieties can be any peptide or protein (e.g., an antibody or antibody fragment) that binds to a primary target. Specific embodiments of suitable primary targeting moieties used herein include cell surface antigen binding moieties, such as antibodies, antibody fragments, and DARPins. Other examples of primary targeting moieties are peptides or proteins that bind to a receptor.
[0267] The primary targeting moiety preferably binds with high specificity and / or high affinity, and the binding to the primary target is preferably stable in vivo.
[0268] In order to be able to specifically target the primary target, the primary targeting moiety of the docking compound may comprise compounds including but not limited to antibodies, antibody fragments (eg, Fab2, Fab, scFV, VHH domains) and other proteins or peptides.
[0269] According to some embodiments, the primary target is a cell surface antigen, such as a T cell antigen, e.g., CD3, such as CD3e, CD8 or CD4, and suitable primary targeting moieties include, but are not limited to, peptides and polypeptides that target cell surface antigens, such as antibodies, antibody fragments and DARPins.
[0270] According to some embodiments, the primary target is a receptor, and suitable primary targeting moieties include, but are not limited to, ligands for such receptors or moieties that still bind to a ligand for a receptor, e.g., a receptor binding peptide in the case of a receptor binding protein ligand.
[0271] Other examples of proteinaceous primary targeting moieties include interferons, such as alpha, beta and gamma interferons, interleukins and protein growth factors, such as transforming growth factor (TGF) or platelet-derived growth factor (PDGF).
[0272] According to some embodiments, the primary target and primary targeting moiety are selected to result in specific targeting or increased targeting of certain cells. This can be achieved by selecting a primary target with cell-specific expression. For example, a T cell antigen (such as those described herein) can be expressed in T cells while not expressed or expressed at low levels in other cells.
[0273] The docking compound further comprises a group that can serve as a binding partner for the corresponding binding moiety of the linking compound. The portion of the linking compound comprising a hydrophobic moiety (e.g., a lipid) (having a covalently attached binding moiety for the docking compound) is incorporated into the particle carrying the payload, thereby forming a connection between the particle and the docking compound. The portion of the docking compound that is bound to the linking compound and the primary targeting moiety are connected to each other, preferably by a covalent bond.
[0274] According to some embodiments, the docking compound comprises a bispecific molecule, such as a bispecific polypeptide, for example a bispecific antibody. In some embodiments, the docking compound comprises a binding domain that is bound to the primary target and a binding domain that is bound to the connection compound. In some embodiments, the docking compound comprises an antibody or antibody fragment to the primary target and an antibody or antibody fragment that is bound to the connection compound. In some embodiments, at least one binding domain comprises the heavy chain variable region (VH) and light chain variable region (VL) of an antibody. In some embodiments, each binding domain comprises the heavy chain variable region (VH) and light chain variable region (VL) of an antibody. In some embodiments, at least one binding domain comprises a single domain antibody, such as a VHH. In some embodiments, each binding domain comprises a single domain antibody, such as a VHH. In some embodiments, one binding domain comprises the heavy chain variable region (VH) and light chain variable region (VL) of an antibody, and another binding domain comprises a single domain antibody, such as a VHH. In some embodiments, the binding domain that is bound to the primary target comprises the heavy chain variable region (VH) and light chain variable region (VL) of an antibody. In some embodiments, the binding domain that binds to the primary target comprises a single domain antibody, such as a VHH. In some embodiments, the binding domain that binds to the connecting compound comprises the heavy chain variable region (VH) and light chain variable region (VL) of an antibody. In some embodiments, the binding domain that binds to the connecting compound comprises a single domain antibody, such as a VHH.
[0275] In some embodiments, the docking compound comprises a fusion protein comprising a binding domain that binds to a primary target and a binding domain that binds to a connecting compound.
[0276] In some embodiments, the docking compound comprises a single peptide chain. In some embodiments, the single peptide chain comprises a portion that binds to the primary target (e.g., an antibody, antibody fragment, or DARPin) and a portion that binds to the connecting compound (e.g., an antibody or antibody fragment). In some embodiments, the antibody fragment is a VHH, scFv, or a mixture thereof. In various embodiments, the docking compound comprises one of the following structures (from N-terminus to C-terminus):
[0277] VHH(α linking compound)-optional linker-VHH(α primary target)
[0278] VHH (α primary target) - optional linker - VHH (α linking compound)
[0279] VHH (α linking compound) - optional linker - scFv (α primary target)
[0280] scFv (α primary target) - optional linker - VHH (α linking compound)
[0281] VHH (α primary target) - optional linker - scFv (α linking compound)
[0282] scFv (α linker compound) - optional linker - VHH (α primary target)
[0283] scFv (α linker compound) - optional linker - scFv (α primary target)
[0284] scFv (α primary target) - optional linker - scFv (α linking compound)
[0285] The present disclosure provides, on the one hand, docking compounds as described herein. In some embodiments, the docking compound comprises a bispecific molecule, such as a bispecific polypeptide, such as a bispecific antibody, wherein one specificity binds to an epitope tag, such as an ALFA-tag, and the other specificity binds to a primary target, such as a cell surface antigen on a target cell. In some embodiments, the specificity that binds to the epitope tag is an antibody or antibody fragment, such as NbALFA-nanobody (NbALFA). In some embodiments, the specificity that binds to the primary target is an antibody, antibody fragment, or DARPin. In some embodiments, the portion of the docking compound that targets the primary target is selected from: an anti-primary target DARPin, an anti-primary target VHH, and an anti-primary target scFv and / or the portion of the docking compound that binds to the connecting compound is a NbALFA-nanobody (NbALFA). In some embodiments, the docking compound has a structure selected from the following: NbALFA x anti-primary target DARPin, NbALFA x anti-primary target VHH, and NbALFA x anti-primary target scFv. In some embodiments, the primary target is a T cell antigen, such as CD3, such as CD3e, CD4 or CD8. In some embodiments, the docking compound comprises a bispecific antibody comprising a nanobody and anti-CD3 VHH bound to an epitope tag (e.g., an ALFA-tag). In some embodiments, the docking compound comprises a bispecific antibody comprising a nanobody and anti-CD3 scFv bound to an epitope tag (e.g., an ALFA-tag). In some embodiments, the docking compound comprises a bispecific molecule comprising a nanobody and anti-CD3 DARPin bound to an epitope tag (e.g., an ALFA-tag). In some embodiments, the docking compound comprises a bispecific antibody comprising a nanobody and anti-CD4 VHH bound to an epitope tag (e.g., an ALFA-tag). In some embodiments, the docking compound comprises a bispecific antibody comprising a nanobody and anti-CD4 scFv bound to an epitope tag (e.g., an ALFA-tag). In some embodiments, the docking compound comprises a bispecific molecule comprising a Nanobody bound to an epitope tag (e.g., an ALFA-tag) and an anti-CD4 DARPin. In some embodiments, the docking compound comprises a bispecific antibody comprising a Nanobody bound to an epitope tag (e.g., an ALFA-tag) and an anti-CD8 VHH. In some embodiments, the docking compound comprises a bispecific antibody comprising a Nanobody bound to an epitope tag (e.g., an ALFA-tag) and an anti-CD8 scFv.In some embodiments, the docking compound comprises a bispecific molecule comprising a Nanobody bound to an epitope tag (eg, an ALFA-tag) and an anti-CD8 DARPin.
[0286] Connecting compounds
[0287] The particle of the payload to be delivered described herein comprises a hydrophobic portion, and the hydrophobic portion (e.g., lipid) has a binding portion covalently attached thereto. In this article, the hydrophobic portion with a binding portion covalently attached thereto is also referred to as a "connection compound." The hydrophobic portion of the connection compound relates to a portion that is integrated into the particle comprising the payload in the connection compound. The binding portion of the connection compound relates to a portion that forms a binding partner of a docking compound in the connection compound. Typically, the connection compound is non-covalently incorporated into the particle comprising the payload, that is, it forms an integral part of the particle, and the binding portion of the connection compound is covalently attached to the hydrophobic portion in such a way that it can be attached to the docking compound.
[0288] In some embodiments, the binding moiety of the linking compound comprises a peptide or protein (eg, an antibody or antibody fragment or a peptide tag).
[0289] In some embodiments, the binding moiety of the linking compound comprises a peptide or protein (eg, an antibody or antibody fragment or a peptide tag) and is chemically linked (eg, through a linker) to a hydrophobic moiety (eg, a lipid).
[0290] The linking compound used herein comprises a hydrophobic component (e.g., a lipid component) that allows it to be anchored in the particle. In some embodiments, the hydrophobic component comprises a moiety selected from vitamin E, a dialkylamine, e.g., dimyristamine (DMA), a diacylglyceride, e.g., 1,2-dimyristoyl-sn-glycerol (DMG), and a ceramide. In some embodiments, the hydrophobic moiety comprises two C8-C24 hydrocarbon chains. In some embodiments, the hydrophobic moiety comprises two C10-C18 hydrocarbon chains.
[0291] In some embodiments, the linking compounds used herein have a phospholipid as a hydrophobic group (e.g., a lipid), for example, a biodegradable phospholipid (such as phosphatidylethanolamine). In some embodiments, the linking compounds used herein have a glycerophospholipid as a hydrophobic group (e.g., a lipid). In some embodiments, the phospholipid is selected from DSPE (distearoylphosphatidylethanolamine), DPPE (dipalmitoylphosphatidylethanolamine), DOPE (dioleoylphosphatidylethanolamine), and POPE (palmitoyloleoylphosphatidylethanolamine), and mixtures thereof. In some embodiments, DSPE is used as a phospholipid due to its stability in the particles described herein. In addition, a compound having at least one alkyl chain can be used as a hydrophobic group (e.g., a lipid) that provides a hydrophobic anchor to the particle as described herein.
[0292] In some embodiments, the linking compound comprises a polymer.In some embodiments, the hydrophobic portion (eg, lipid) of the linking compound and the binding portion of the linking compound are linked by a polymer.
[0293] In some embodiments, the polymer is a hydrophilic polymer, and the connecting compound comprises an amphiphilic derivative of the polymer. In some embodiments, the amphiphilic derivative of the polymer comprises a hydrophobic component (e.g., a lipid component) that allows it to be anchored in the particle, and a hydrophilic component of the polymer, the hydrophilic component facing the outside of the particle, thereby giving it surface hydrophilicity. In some embodiments, the amphiphilic derivative of the polymer is inserted into the particle through its hydrophobic end. Therefore, the polymer component faces the outside of the particle and forms a protective hydrophilic shell around the particle. In some embodiments, the polymer portion of the amphiphilic derivative helps to give the particle stealth properties. In some embodiments, the plasma half-life of the particle described herein is greater than 2 hours, for example, between 3-10 hours. This characteristic advantageously allows the particle to accumulate at the target cell and release the contents (payload) therein within a reasonable time. Therefore, the effectiveness of targeted delivery described herein is improved therewith.
[0294] The term "stealth" is used herein to describe the ability of the particles described herein to be undetected and then sequestered and / or degraded, or barely detected and then sequestered and / or degraded, and / or detected and then sequestered and / or degraded relatively late by the immune system of a host to which they are administered.
[0295] Macrophages constitute one of the most important components of the immune system and play a major role in clearing foreign particles, including liposomes and other colloidal particles, from the blood circulation. At the molecular level, particle clearance occurs in two steps: opsonization, through the deposition of serum proteins (or "opsonins") on the particle surface, followed by recognition and capture of the opsonized particles by macrophages.
[0296] Modification of the particle surface with hydrophilic and flexible polymer chains, such as poly(ethylene glycol) type polymers, confers steric protection to the particles by preventing opsonins from reaching the particle surface.
[0297] In some embodiments, the amphiphilic derivatives of the polymers used herein have a hydrophobic group (e.g., a lipid) as specified herein. In some embodiments, the amphiphilic derivatives of the polymers used herein have a phospholipid as the hydrophobic group (e.g., a lipid), such as a biodegradable phospholipid (e.g., phosphatidylethanolamine). In some embodiments, the phospholipid is selected from DSPE (distearoylphosphatidylethanolamine), DPPE (dipalmitoylphosphatidylethanolamine), DOPE (dioleoylphosphatidylethanolamine), and POPE (palmitoyloleoylphosphatidylethanolamine), and mixtures thereof. In some embodiments, DSPE is used as the phospholipid due to its stability in the particles described herein. In addition, a compound having at least one alkyl chain can be used as the hydrophobic group (e.g., a lipid), which provides a hydrophobic anchor to the particle as described herein.
[0298] In some embodiments, the polymer used herein is selected from poly(ethylene glycol) (PEG), polysarcosine (pSar) (poly(N-methylglycine), polyoxazoline (POX), polyoxazine (POZ), and poly-2-(2-(2-aminoethoxy)ethoxy)acetic acid (pAEEA) (including derivatives thereof).
[0299] In some embodiments, the polymer is designed to sterically stabilize the particles by forming a protective hydrophilic layer. In some embodiments, when such particles are administered in vivo, the polymer can reduce the association of the particles with serum proteins and / or the resulting uptake by the reticuloendothelial system.
[0300] In some embodiments, PEG is a linear or branched polymer of optionally substituted ethylene glycol or ethylene oxide. In some embodiments, PEG is unsubstituted. In some embodiments, PEG is substituted, for example, by one or more alkyl, alkoxy, acyl, hydroxyl, or aryl groups. In some embodiments, the molecular weight of PEG is from about 130 to about 50,000, in another embodiment from about 150 to about 30,000, in another embodiment from about 150 to about 20,000, in another embodiment from about 150 to about 15,000, in another embodiment from about 150 to about 10,000, in another embodiment from about 150 to about 6000, in another embodiment from about 150 to about 5000, in another embodiment from about 150 to about 4000, in another embodiment from about 150 to about 3000, in another embodiment from about 300 to about 3000, in another embodiment from about 1000 to about 3000, and in yet another embodiment from about 1500 to about 2500.
[0301] In some embodiments, the molecular weight of the PEG portion of the amphiphilic derivative of the polymer is 1000 or greater. In some embodiments, the PEG portion of the amphiphilic derivative of the polymer comprises 10 or more units of the formula (O-CH2-CH2)n. In some embodiments, the PEG comprises 20-200 ethylene oxide units, such as about 45 ethylene oxide units.
[0302] In some embodiments, the PEG comprises "PEG2k," also known as "PEG 2000," which has an average molecular weight of about 2000 Daltons.
[0303] In some embodiments, DSPE-PEG 2000 , DSPE-PEG 3000 and DSPE-PEG 5000 Used as amphiphilic derivatives of polymers.
[0304] In some embodiments, pSar comprises 2-200 sarcosine units, such as 5-100 sarcosine units, 10-50 sarcosine units, 15-40 sarcosine units, for example about 23 sarcosine units.
[0305] In some embodiments, pSar comprises a structure of the following general formula:
[0306]
[0307] where s is the number of sarcosine units.
[0308] In some embodiments, the POX and / or POZ polymer comprises 2-200, 2-190, 2-180, 2-170, 2-160, 2-150, 2-140, 2-130, 2-120, 2-110, 2-100, 2-90, 2-80, 2-70, 5-200, 5-190, 5-180, 5-170, 5-160, 5-150, 5-140, 5 or 10-70 POX and / or POZ repeating units.
[0309] In some embodiments, the POX and / or POZ polymer comprises the following formula:
[0310]
[0311] Where a is an integer between 1 and 2; R 11 is an alkyl group, especially C 1-3 Alkyl, such as methyl, ethyl, isopropyl or n-propyl, is independently selected for each repeat unit; and m refers to the number of POX and / or POZ repeat units.
[0312] In some embodiments, the POX and / or POZ polymer is a polymer of POX and comprises repeating units of the following formula:
[0313]
[0314] In some embodiments, the POX and / or POZ polymer is a polymer of POZ and comprises repeating units of the following formula:
[0315]
[0316] In any embodiment of the above formula, m (i.e., the number of repeating units in the polymer) is preferably 2-190, such as 2-180, 2-170, 2-160, 2-150, 2-140, 2-130, 2-120, 2-110, 2-100, 2-90, 2-80, 2-70, 5-200, 5-190, 5-180, 5-170, 5-160, 5-15 In some embodiments, m is 2-180, such as 4-160, 6-140, 8-120 or 10-100, for example 20-80, 30-70 or 40-50.
[0317] In some embodiments, the POX and / or POZ polymer is a copolymer comprising repeating units of the following general formula:
[0318]
[0319] The number of repeating units shown on the left side of the copolymer is 1-199; the number of repeating units of the formula on the right side of the copolymer is 1-199; and the sum of the number of repeating units of the formula on the left side and the number of repeating units of the formula on the right side of the copolymer is 2-200.
[0320] In some embodiments of the oxazolinylated and / or oxazinylated hydrophobic portion (e.g., lipid), the number of repeating units of the formula on the left side of the copolymer is 1-179, such as 1-159, 1-139, 1-119, or 1-99; the number of repeating units of the formula on the right side of the copolymer is 1-179, such as 1-159, 1-139, 1-119, or 1-99; and the sum of the number of repeating units of the formula on the left side and the number of repeating units of the formula on the right side of the copolymer is 2-180, such as 4-160, 6-140, 8-120, or 10-100, for example, 20-80, 30-70, or 40-50.
[0321] In some of the above embodiments, at each occurrence (ie, in each repeat unit), R 11 can be the same alkyl group (for example, R 11 In some optional embodiments, R in at least one repeating unit is 11 With another repeating unit R 11 different (e.g., for at least one repeating unit, R11 is a specific alkyl group (such as ethyl), and for at least one different repeating unit, R 11 are different specific alkyl groups (such as methyl). For example, each R 11 Can be selected from two different alkyl groups (such as methyl and ethyl), and not all R 11 All are the same alkyl group.
[0322] In any of the above embodiments, R 11 Preferably, it is methyl or ethyl, more preferably methyl. Therefore, in some embodiments, each R 11 is methyl or each R 11 In some optional embodiments, for each repeating unit, R 11 Independently selected from methyl and ethyl, wherein in at least one repeating unit R 11 is methyl, and in at least one repeating unit R 11 For ethyl.
[0323] In some embodiments, the polymer comprises poly-2-(2-(2-aminoethoxy)ethoxy)acetic acid (pAEEA) or poly-2-(2-(2-methylaminoethoxy)ethoxy)acetic acid (pMAEEA), or a derivative thereof.
[0324] In some embodiments, the polymer comprises the following formula:
[0325]
[0326] in
[0327] X2 and X1 together are optionally substituted amide, optionally substituted thioamide or ester;
[0328] Y is -CH2-, -(CH2)2-, or -(CH2)3-;
[0329] Z is 2-24; and
[0330] n is 1-100.
[0331] In some embodiments,
[0332] (i) When X 1 When it is -C(O)-, X 2 -NR 1 -;
[0333] (ii) When X 1 -NR 1 -When, X 2 is -C(O)-;
[0334] (iii) When X1 When -C(S)-, X 2 -NR 1 -;
[0335] (iv) When X 1 -NR 1 -When, X 2 is -C(S)-;
[0336] (v) When X 1 When it is -C(O)-, X 2 is -O-; or
[0337] (vi) When X 1 When it is -O-, X 2 is -C(O)-;
[0338] where R 1 is hydrogen or C 1-8 alkyl.
[0339] In some embodiments, X 1 is -C(O)- and X 2 -NR 1 -, where R 1 In some embodiments, X 1 is -C(O)- and X 2 -NR 1 -, where R 1 In some embodiments, X 1 is -C(O)- and X 2 -NR 1 -, where R 1 For hydrogen.
[0340] In some embodiments, Y is -CH2- or -(CH2)2-. In some embodiments, Y is -CH2-.
[0341] In some embodiments, the polymer comprises the following formula:
[0342]
[0343] in
[0344] R 1 is hydrogen or C 1-8 alkyl;
[0345] z is 2-24; and
[0346] n is 1-100.
[0347] In some embodiments of the above formula, z is 2-10. In some embodiments, z is 2-7. In some embodiments, z is 2-5. In some embodiments, z is 2 or 3. In some embodiments, z is 2.
[0348] In some embodiments, the polymer comprises the following formula:
[0349]
[0350] in
[0351] R 1 is hydrogen or C 1-8 alkyl; and
[0352] n is 1-100.
[0353] In some embodiments of the above formula, R 1 In some embodiments, R 1 For hydrogen.
[0354] In some embodiments, the polymer comprises the following formula:
[0355]
[0356] in
[0357] n is 1-100.
[0358] In some embodiments of the above formula, n is 5-50. In some embodiments, n is 5-25. In some embodiments, n is 7-14. In some embodiments, n is 10-25. In some embodiments, n is 14-17. In some embodiments, n is 8 or 14.
[0359] In some embodiments, the molar ratio of the amphiphilic derivative of the polymer incorporated into the particle is 0.5-20 mol%, preferably 1-10 mol%, of the lipid molecules constituting the particle.
[0360] In some embodiments, the linker compound comprises the following formula:
[0361] L-X1-P-X2-B
[0362] in
[0363] P contains polymers;
[0364] L comprises a hydrophobic moiety (e.g., a lipid) attached to a first terminus of the polymer;
[0365] B comprises a binding moiety attached to the second terminus of the polymer;
[0366] X1 is absent or is the first linking moiety; and
[0367] X2 does not exist or is a second connecting portion.
[0368] In some embodiments, X1 comprises a carbonyl group. In some embodiments, L comprises a phosphatidylethanolamine that can be linked to P via an amide group.
[0369] In some embodiments, X2 comprises the reaction product of a sulfhydryl or cysteine reactive group (eg, a maleimide group) and a sulfhydryl or cysteine group of a compound comprising a binding moiety.
[0370] In some embodiments, L comprises a lipid as described above. In some embodiments, L comprises DSPE (distearoylphosphatidylethanolamine), DPPE (dipalmitoylphosphatidylethanolamine), DOPE (dioleoylphosphatidylethanolamine), and POPE (palmitoyloleoylphosphatidylethanolamine), which may be linked to P via an amide group.
[0371] In some embodiments, P comprises a polymer as described above. In some embodiments, P comprises a polymer that provides stealth properties, extends circulation half-life, and / or reduces nonspecific protein binding or cell adhesion. In some embodiments, P comprises a polymer selected from the group consisting of poly(ethylene glycol) (PEG), polysarcosine (pSar) (poly(N-methylglycine), polyoxazoline (POX), polyoxazine (POZ), and poly-2-(2-(2-aminoethoxy)ethoxy)acetic acid (pAEEA) (including derivatives thereof). In some embodiments, P comprises polyethylene glycol (PEG); for example, PEG as described above.
[0372] In some embodiments, L-X1-P comprises an amphiphilic derivative of a polymer as described above. In some embodiments, the amphiphilic derivative of a polymer comprises a conjugate of distearoyl-glycero-phosphoethanolamine (DSPE) and a polymer (e.g., a polymer as described above). In some embodiments, the amphiphilic derivative of a polymer comprises distearoyl-glycero-phosphoethanolamine-polyethylene glycol-conjugate (DSPE-PEG).
[0373] In some embodiments, the linking compound can be obtained by reacting a sulfhydryl or cysteine reactive group of a reagent comprising an amphiphilic derivative of a polymer, such as a PEG reagent comprising a hydrophobic moiety (e.g., a lipid), with a sulfhydryl or cysteine group of a compound comprising a binding moiety.
[0374] In some embodiments, the sulfhydryl or cysteine reactive group comprises a maleimide group.
[0375] In some embodiments, the PEG reagent comprises DSPE-PEG-maleimide. In some embodiments, the compound comprising the binding moiety comprises the formula SH(CH2) n C(O)-B, wherein n ranges from 1-5 and B comprises a binding moiety. In some embodiments, n is 2.
[0376] In some embodiments, the linker compound comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)] and a compound comprising the formula SH(CH2) n The reaction product of a compound of C(O)-B, wherein n ranges from 1 to 5 and B comprises a binding moiety. In some embodiments, n is 2.
[0377] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0378] L-X1-P-X2-B
[0379] wherein L, X1, P and B are as described above, and X2 comprises a sulfosuccinimide moiety.
[0380] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0381]
[0382] Wherein B comprises the binding portion.
[0383] In some embodiments of the above formula, B comprises a moiety comprising the structure -N-peptide-C(O)-NH2.
[0384] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0385]
[0386] Wherein, P, X2 and B are as described above, and R1 and R2 independently comprise alkyl moieties. In some embodiments, at least one (e.g., each) alkyl moiety is straight chain or branched, preferably straight chain. In some embodiments, at least one (e.g., each) alkyl moiety has at least 8 carbon atoms, for example, 8-24 carbon atoms, such as 10-18 carbon atoms. Preferably, at least one (e.g., each) alkyl moiety is an alkyl moiety of a fatty acid alcohol, more preferably at least one (e.g., each) alkyl moiety is an alkyl moiety of a fatty acid alcohol having at least 8 carbon atoms (e.g., 8-24 carbon atoms, such as 10-18 carbon atoms). Examples of alkyl moieties include -(CH2)17 CH3(stearyl), -(CH2) 15 CH3(palmitoyl) and -(CH2) 13 CH3 (myristoyl). In some embodiments, R1R2N- in the above formula is 1,2-dimyristylamine, wherein both alkyl groups are -(CH2) 13 CH3(myristoyl).
[0387] In some embodiments, polymer P comprises poly-2-(2-(2-aminoethoxy)ethoxy)acetic acid (pAEEA) or poly-2-(2-(2-methylaminoethoxy)ethoxy)acetic acid (pMAEEA), or a derivative thereof. In some embodiments, polymer P comprises the following general formula:
[0388]
[0389] wherein n is 5-50, such as 5-25, such as 7-14, such as 10-25, such as 14-17. In some embodiments, n is 8 or 14. In some embodiments, n is 14. In some embodiments, R1 and R2 in the above formula are -(CH2) 13 CH3(myristoyl), and the polymer P comprises the following general formula:
[0390]
[0391] Where n is 14.
[0392] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0393]
[0394] Where P, X2 and B are as described above, and R t1 and R t2 Each of R is independently H or methyl. t1 and R t2 In some embodiments, R t1 is methyl, and R t2 is H. In some embodiments, R t1 is H, and R t2 In some embodiments, R t1 and R t2 Both are H.
[0395] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0396]
[0397] wherein P, X2 and B are as described above.
[0398] In some embodiments, the polymer P in the above formula comprises poly-2-(2-(2-aminoethoxy)ethoxy)acetic acid (pAEEA) or poly-2-(2-(2-methylaminoethoxy)ethoxy)acetic acid (pMAEEA), or a derivative thereof. In some embodiments, the polymer P comprises the following general formula:
[0399]
[0400] wherein n is 5-50, such as 5-25, such as 7-14, such as 10-25, such as 14-17. In some embodiments, n is 8 or 14. In some embodiments, n is 8. In some embodiments, n is 14.
[0401] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0402]
[0403] Wherein X1, P, X2 and B are as described above, and R1 and R2 independently comprise acyl moieties. In some embodiments, at least one (e.g., each) acyl moiety is straight chain or branched, preferably straight chain. In some embodiments, at least one (e.g., each) acyl moiety has at least 8 carbon atoms, for example, 8-24 carbon atoms, such as 10-18 carbon atoms. Preferably, at least one (e.g., each) acyl moiety is the acyl moiety of a fatty acid, more preferably at least one (e.g., each) acyl moiety is the acyl moiety of a fatty acid with at least 8 carbon atoms (e.g., 8-24 carbon atoms, such as 10-18 carbon atoms). Examples of acyl moieties include CH3(CH2) 16 C(O)-(stearyl), CH3(CH2) 14 C(O)-(palmitoyl) and CH3(CH2) 12 C(O)-(myristoyl). In some embodiments, both acyl groups are CH3(CH2) 16 C(O)-(stearoyl). In some embodiments, both acyl groups are CH3(CH2) 12 C(O)-(myristoyl). In some embodiments, X1 is absent or comprises -HPO3-(CH2) n NH-, wherein n is 1-5, for example, 2.
[0404] In some embodiments, polymer P comprises poly-2-(2-(2-aminoethoxy)ethoxy)acetic acid (pAEEA) or poly-2-(2-(2-methylaminoethoxy)ethoxy)acetic acid (pMAEEA), or a derivative thereof. In some embodiments, polymer P comprises the following general formula:
[0405]
[0406] wherein n is 5-50, such as 5-25, such as 7-14, such as 10-25, such as 14-17. In some embodiments, n is 8 or 14. In some embodiments, n is 8. In some embodiments, n is 14.
[0407] In some embodiments, polymer P comprises pSar. In some embodiments, polymer P comprises the following general formula:
[0408]
[0409] wherein s is 2-200, such as 5-100, such as 10-50, such as 15-40. In some embodiments, s is 20 or 23.
[0410] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0411]
[0412] Wherein P, X2 and B are as described above, and R1 and R2 independently comprise acyl moieties. In some embodiments, at least one (e.g., each) acyl moiety is straight chain or branched, preferably straight chain. In some embodiments, at least one (e.g., each) acyl moiety has at least 8 carbon atoms, for example 8-24 carbon atoms, such as 10-18 carbon atoms. Preferably, at least one (e.g., each) acyl moiety is the acyl moiety of a fatty acid, more preferably at least one (e.g., each) acyl moiety is the acyl moiety of a fatty acid with at least 8 carbon atoms (e.g., 8-24 carbon atoms, such as 10-18 carbon atoms). Examples of acyl moieties include CH3(CH2) 16 C(O)-(stearyl), CH3(CH2) 14 C(O)-(palmitoyl) and CH3(CH2) 12 C(O)-(myristoyl). In some embodiments, both acyl groups are CH3(CH2) 16 C(O)-(stearoyl). In some embodiments, both acyl groups are CH3(CH2) 12 C(O)-(myristoyl).
[0413] In some embodiments, polymer P comprises poly-2-(2-(2-aminoethoxy)ethoxy)acetic acid (pAEEA) or poly-2-(2-(2-methylaminoethoxy)ethoxy)acetic acid (pMAEEA), or a derivative thereof. In some embodiments, polymer P comprises the following general formula:
[0414]
[0415] wherein n is 5-50, such as 5-25, such as 7-14, such as 10-25, such as 14-17. In some embodiments, n is 8 or 14. In some embodiments, n is 8. In some embodiments, n is 14.
[0416] In some embodiments, n is 8 and R1 and R2 are CH3(CH2) 16 C(O)-(stearoyl). In some embodiments, n is 14 and R1 and R2 are CH3(CH2) 16 C(O)-(stearyl).
[0417] In some embodiments, n is 8 and R1 and R2 are CH3(CH2) 12 C(O)-(myristoyl). In some embodiments, n is 14 and R1 and R2 are CH3(CH2) 12 C(O)-(myristoyl).
[0418] In some embodiments, polymer P comprises pSar. In some embodiments, polymer P comprises the following general formula:
[0419]
[0420] wherein s is 2-200, such as 5-100, such as 10-50, such as 15-40. In some embodiments, s is 20 or 23.
[0421] In some embodiments, s is 20 and R1 and R2 are CH3(CH2) 16 C(O)-(stearyl).
[0422] In some embodiments, s is 20 and R1 and R2 are CH3(CH2) 12 C(O)-(myristoyl).
[0423] In some embodiments, X2 in the above formula comprises the reaction product of a sulfhydryl or cysteine reactive group (e.g., a maleimide group) and a compound comprising a sulfhydryl or cysteine group. In some embodiments, the compound comprising a sulfhydryl or cysteine group comprises a compound of the formula SH(CH2) nC(O)-, wherein n ranges from 1 to 5. In some embodiments, n is 2. In some embodiments, X2 comprises a thiosuccinimide moiety.
[0424] In some embodiments, X2 comprises the following formula:
[0425]
[0426] In some embodiments, X2 comprises the following formula:
[0427]
[0428] wherein n1 and n2 are independently 1 to 5. In some embodiments, n1 is 1 and n2 is 2. In some embodiments, n1 is 2 and n2 is 1.
[0429] In one aspect, the present disclosure provides a linking compound as described herein. In some embodiments of the linking compound, the binding moiety comprises an epitope tag, such as an ALFA-tag, such as an ALFA-tag described herein.
[0430] In one aspect, the present disclosure provides compounds having the following general formula:
[0431] L-X1-P-X2-B
[0432] in
[0433] P contains polymers;
[0434] L comprises a hydrophobic moiety (e.g., a lipid) attached to a first terminus of the polymer;
[0435] B comprises an epitope tag, e.g., an ALFA-tag, e.g., an ALFA-tag described herein, attached to the second terminus of the polymer;
[0436] X1 is absent or is the first linking moiety; and
[0437] X2 does not exist or is a second connecting portion.
[0438] In some embodiments, X1 comprises a carbonyl group. In some embodiments, L comprises a phosphatidylethanolamine that can be linked to P via an amide group.
[0439] In some embodiments, X2 comprises the reaction product of a sulfhydryl or cysteine reactive group (eg, a maleimide group) and a sulfhydryl or cysteine group of a compound comprising an epitope tag. In some embodiments, X2 comprises a sulfosuccinimide moiety.
[0440] In some embodiments, L comprises a lipid as described above. In some embodiments, L comprises DSPE (distearoylphosphatidylethanolamine), DPPE (dipalmitoylphosphatidylethanolamine), DOPE (dioleoylphosphatidylethanolamine), and POPE (palmitoyloleoylphosphatidylethanolamine), which can be linked to P via an amide group.
[0441] In some embodiments, P comprises a polymer as described above. In some embodiments, P comprises a polymer that provides stealth properties, extends circulation half-life, and / or reduces nonspecific protein binding or cell adhesion. In some embodiments, P comprises a polymer selected from the group consisting of poly(ethylene glycol) (PEG), polysarcosine (pSar) (poly(N-methylglycine), polyoxazoline (POX), polyoxazine (POZ), and poly-2-(2-(2-aminoethoxy)ethoxy)acetic acid (pAEEA) (including derivatives thereof). In some embodiments, P comprises polyethylene glycol (PEG); e.g., PEG as described above.
[0442] In some embodiments, L-X1-P comprises an amphiphilic derivative of a polymer as described above. In some embodiments, the amphiphilic derivative of a polymer comprises a conjugate of distearoyl-glycero-phosphoethanolamine (DSPE) and a polymer (e.g., a polymer as described above). In some embodiments, the amphiphilic derivative of a polymer comprises distearoyl-glycero-phosphoethanolamine-polyethylene glycol-conjugate (DSPE-PEG).
[0443] In some embodiments, the linking compound can be obtained by reacting a sulfhydryl or cysteine reactive group of a reagent comprising an amphiphilic derivative of a polymer, such as a PEG reagent comprising a hydrophobic moiety (e.g., a lipid), with a sulfhydryl or cysteine group of a compound comprising an epitope tag.
[0444] In some embodiments, the sulfhydryl or cysteine reactive group comprises a maleimide group.
[0445] In some embodiments, the PEG reagent comprises DSPE-PEG-maleimide. In some embodiments, the compound comprising the epitope tag comprises the formula SH(CH2) n C(O)-B, wherein n ranges from 1 to 5 and B comprises an epitope tag. In some embodiments, n is 2.
[0446] In some embodiments, the linker compound comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)] and a compound comprising the formula SH(CH2) nThe reaction product of a compound of C(O)-B, wherein n ranges from 1 to 5 and B comprises an epitope tag. In some embodiments, n is 2.
[0447] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0448]
[0449] wherein B comprises an epitope tag, eg, an ALFA-tag, such as the ALFA-tag described herein.
[0450] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0451]
[0452] Wherein X2 is as described above, R1 and R2 are CH3(CH2) 16 C(O)-(stearyl) or CH3(CH2) 12 C(O)-(myristoyl), polymer P comprises the following general formula:
[0453]
[0454] wherein n is 5-50, such as 5-25, such as 7-14, such as 10-25, such as 14-17, such as 8 or 14,
[0455] And B comprises an epitope tag, eg, an ALFA-tag, such as the ALFA-tag described herein.
[0456] In some embodiments, n is 8 and R1 and R2 are CH3(CH2) 16 C(O)-(stearoyl). In some embodiments, n is 14 and R1 and R2 are CH3(CH2) 16 C(O)-(stearyl).
[0457] In some embodiments, n is 8 and R1 and R2 are CH3(CH2) 12 C(O)-(myristoyl). In some embodiments, n is 14 and R1 and R2 are CH3(CH2) 12 C(O)-(myristoyl).
[0458] In some embodiments, X2 comprises the following formula:
[0459]
[0460] In some embodiments, the linking compound (having the hydrophobic portion covalently linked thereto) comprises the following general formula:
[0461]
[0462] Wherein X2 is as described above, R1 and R2 are CH3(CH2) 16 C(O)-(stearyl) or CH3(CH2) 12 C(O)-(myristoyl), polymer P comprises the following general formula:
[0463]
[0464] wherein s is 2-200, such as 5-100, such as 10-50, such as 15-40, such as 20 or 23,
[0465] And B comprises an epitope tag, eg, an ALFA-tag, such as the ALFA-tag described herein.
[0466] In some embodiments, s is 20 and R1 and R2 are CH3(CH2) 16 C(O)-(stearyl).
[0467] In some embodiments, s is 20 and R1 and R2 are CH3(CH2) 12 C(O)-(myristoyl).
[0468] In some embodiments, X2 comprises the following formula:
[0469]
[0470] In some embodiments, B comprises a moiety comprising the structure -N-peptide-C(O)-NH2, wherein the peptide comprises an epitope tag, eg, an ALFA-tag, such as the ALFA-tag described herein.
[0471] In one aspect, the present disclosure provides a linking compound as described above, which is incorporated into a particle (eg, a particle as described herein) via the hydrophobic component (eg, lipid component) of the linking compound.
[0472] Interacting moieties on the ligation compound and on the docking compound
[0473] In some embodiments, the moiety on the linking compound (the binding moiety that is covalently attached to the hydrophobic moiety) and the moiety on the docking compound (the moiety that binds to the binding moiety that is covalently attached to the hydrophobic moiety) interact and non-covalently bind to each other.
[0474] In some embodiments, the interacting moieties on the linking compound and the docking compound bind to each other under physiological conditions.
[0475] In some embodiments, the interacting moiety on the linking compound and the docking compound is an antibody / antigen system.
[0476] In some embodiments, the portion of the linking compound that binds to the docking compound comprises a peptide or protein, such as a peptide tag, and the portion of the docking compound that binds to the linking compound comprises a binder, such as an antibody or antibody fragment that binds to the peptide or protein.
[0477] In some embodiments, the portion of the docking compound that binds to the linking compound comprises a peptide or protein, such as a peptide tag, and the portion of the linking compound that binds to the docking compound comprises a binder, such as an antibody or antibody fragment that binds to the peptide or protein. In some embodiments, the portion on the linking compound that interacts with the docking compound comprises an epitope tag / binder system.
[0478] As used herein, "epitope tag" refers to a stretch of amino acids to which an antibody or a protein molecule with antibody-like functions can bind.
[0479] In some embodiments, the epitope tag comprises an ALFA-tag.In some embodiments, the epitope tag / binder system comprises an ALFA-tag and an ALFA-specific single domain antibody (sdAb), NbALFA-Nanobody.
[0480] In some embodiments, the ALFA-tag comprises the amino acid sequence
[0481] -AA0-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-AA10-AA11-AA12-AA13-AA14-,
[0482] The amino acids in AA0, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, AA10, AA11, AA12, AA13 and AA14 are:
[0483] AA0 is Pro or missing;
[0484] AA1 is Ser, Gly, Thr, or Pro;
[0485] AA2 is Arg, Gly, Ala, Glu or Pro;
[0486] AA3 is Leu, Ile, or Val;
[0487] AA4 is Glu or Gln;
[0488] AA5 is Glu or Gln;
[0489] AA6 is Glu or Gln;
[0490] AA7 is Leu, Ile, or Val;
[0491] AA8 is Arg, Ala, Gln or Glu;
[0492] AA9 is Arg, Ala, Gln or Glu;
[0493] AA10 is Arg;
[0494] AA11 is Leu;
[0495] AA12 is Thr, Ser, Asp, Glu, Pro, Ala, or missing;
[0496] AA13 is Glu, Lys, Pro, Ser, Ala, Asp or is missing; and
[0497] AA14 is Pro or missing.
[0498] In some embodiments, the ALFA-tag comprises a sequence selected from the group consisting of: SRLEEELRRRLTE, PSRLEEELRRRLTE, SRLEEELRRRLTEP, and PSRLEEELRRRLTEP.
[0499] In some embodiments, the ALFA-tag comprises a cyclized amino acid sequence
[0500] -AA0-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-AA10-AA11-AA12-AA13-AA14-,
[0501] wherein the side chains of any two amino acids (X1, X2) of AA0, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, AA10, AA11, AA12, AA13 and AA14 are covalently linked; and
[0502] Among AA0, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, AA10, AA11, AA12, AA13 and AA14, the amino acid that is not X1 and X2 is:
[0503] AA0 is Pro or missing;
[0504] AA1 is Ser, Gly, Thr, or Pro;
[0505] AA2 is Arg, Gly, Ala, Glu or Pro;
[0506] AA3 is Leu, Ile, or Val;
[0507] AA4 is Glu or Gln;
[0508] AA5 is Glu or Gln;
[0509] AA6 is Glu or Gln;
[0510] AA7 is Leu, Ile, or Val;
[0511] AA8 is Arg, Ala, Gln or Glu;
[0512] AA9 is Arg, Ala, Gln or Glu;
[0513] AA10 is Arg;
[0514] AA11 is Leu;
[0515] AA12 is Thr, Ser, Asp, Glu, Pro, Ala, or missing;
[0516] AA13 is Glu, Lys, Pro, Ser, Ala, Asp or is missing; and
[0517] AA14 is Pro or missing.
[0518] In some embodiments, X1 and X2 are separated by 2 or 3 amino acids.
[0519] In some embodiments, AA5 is X1 and AA9 is X2, AA5 is X1 and AA8 is X2, AA9 is X1 and AA13 is X2, AA6 is X1 and AA9 is X2, AA9 is X1 and AA12 is X2, AA10 is X1 and AA13 is X2, AA6 is X1 and AA10 is X2, or AA4 is X1 and AA8 is X2.
[0520] In some embodiments, the ALFA-tag comprises a cyclized amino acid sequence selected from the group consisting of:
[0521] a.-AA0-AA1-AA2-AA3-AA4-ring(X1-AA6-AA7-AA8-X2)-Arg-Leu-AA12-AA13-AA14-,
[0522] b.-AA0-AA1-AA2-AA3-AA4-ring(X1-AA6-AA7-X2)-AA9-Arg-Leu-AA12-AA13-AA14-,
[0523] c.-AA0-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-ring(X1-Arg-Leu-AA12-X2)-AA14-,
[0524] d.-AA0-AA1-AA2-AA3-AA4-AA5-ring(X1-AA7-AA8-X2)-Arg-Leu-AA12-AA13-AA14-,
[0525] e.-AA0-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-ring(X1-Arg-Leu-X2)-AA13-AA14-,
[0526] f.-AA0-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-ring(X1-Leu-AA12-X2)-AA14-,
[0527] g.-AA0-AA1-AA2-AA3-AA4-AA5-ring(X1-AA7-AA8-AA9-X2)-Leu-AA12-AA13-AA14-, and
[0528] h.-AA0-AA1-AA2-AA3-ring(X1-AA5-AA6-AA7-X2)-AA9-Arg-Leu-AA12-AA13-AA14-,
[0529] wherein the side chains of the amino acid residues X1 and X2 are covalently linked;
[0530] AA0 is Pro or missing;
[0531] AA1 is Ser, Gly, Thr, or Pro;
[0532] AA2 is Arg, Gly, Ala, Glu or Pro;
[0533] AA3 is Leu, Ile, or Val;
[0534] AA4 is Glu or Gln;
[0535] AA5 is Glu or Gln;
[0536] AA6 is Glu or Gln;
[0537] AA7 is Leu, Ile, or Val;
[0538] AA8 is Arg, Ala, Gln or Glu;
[0539] AA9 is Arg, Ala, Gln or Glu;
[0540] AA12 is Thr, Ser, Asp, Glu, Pro, Ala, or missing;
[0541] AA13 is Glu, Lys, Pro, Ser, Ala, Asp or is missing; and
[0542] AA14 is Pro or missing.
[0543] In some embodiments, X1 and X2 in the peptides disclosed herein are covalently linked through an amide, a disulfide, a thioether, an ether, an ester, a thioester, a thioamide, an alkylene, an alkenylene, an alkynylene, and / or a 1,2,3-triazole.
[0544] In some embodiments, a cyclized amino acid sequence described herein is generated by linking an amino group of the side chain of one of X1 and X2 to a carboxyl group of the side chain of the other of X1 and X2 via an amide bond. The amino group of the side chain of an amino acid having a pendant amine group (e.g., lysine or a lysine derivative) and the carboxyl group of the side chain of an acidic amino acid (e.g., aspartic acid, glutamic acid, or a derivative thereof) can be used to generate a cyclized amino acid sequence via an amide bond.
[0545] In some embodiments, the cyclized amino acid sequences described herein are generated by disulfide bonding the sulfhydryl group of one of the side chains of X1 and X2 to the sulfhydryl group of the side chains of the other of X1 and X2. Sulfhydryl-containing amino acids include cysteine and other sulfhydryl-containing amino acids such as Pen.
[0546] In some embodiments, X1 and X2 are independently selected from Glu, DGlu, Asp, DAsp, Lys, DLys, hLys, DhLys, Orn, DOrn, Dab, DDab, Dap, DDap, Cys, DCys, hCys, DhCys, Pen, and DPen, provided that when X1 is Glu, DGlu, Asp, or DAsp, X2 is Lys, DLys, hLys, DhLys, Orn, , DOrn, Dab, DDab, Dap or DDap; when X1 is Lys, DLys, hLys, DhLys, Orn, DOrn, Dab, DDab, Dap or DDap, X2 is Glu, DGlu, Asp or DAsp; and when X1 is Cys, DCys, hCys, DhCys, Pen or DPen, X2 is Cys, DCys, hCys, DhCys, Pen or DPen.
[0547] In some embodiments, X1 is Glu and X2 is Lys. In some embodiments, -ring(Glu--------Lys)-, -c(Glu-------Lys)-, -ring(E-------K)-, -c(E--------K)-, -E------K-ring or -ringE----ringK- comprises the following structure:
[0548]
[0549] In some embodiments, X1 is Lys and X2 is Glu. In some embodiments, -ring (Lys------Glu)-, -c(Lys------Glu)-, -ring (K------E)-, -c(K------E)-, -K-----E-ring or ring K------ring E- comprises the following structure:
[0550]
[0551] In some embodiments, X1 is Cys and X2 is Cys. In some embodiments, -cyclo(Cys------Cys)-, c(Cys------Cys)-, -cyclo(C------C)-, -c(C--------C)-, -C----C-cyclo or -cycloC-----cycloC- comprises the following structure:
[0552]
[0553] Specific cyclized amino acid sequences of the above formula include, for example,
[0554] -Ser-Arg-Leu-Glu-loop(Glu-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0555] -Ser-Arg-Leu-Glu-loop(Asp-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0556] -Ser-Arg-Leu-Glu-loop(Glu-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-,
[0557] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-loop(Lys-Arg-Leu-Thr-Glu)-,
[0558] -Ser-Arg-Leu-Glu-loop(Cys-Glu-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-,
[0559] -Ser-Arg-Leu-Glu-loop(Asp-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-,
[0560] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-loop(Lys-Arg-Leu-Thr-Asp)-,
[0561] -Ser-Arg-Leu-Glu-loop(Glu-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-,
[0562] -Pro-Ser-Arg-Leu-Glu-loop(Glu-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0563] -Pro-Ser-Arg-Leu-Glu-loop(DGlu-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0564] -Pro-Ser-Arg-Leu-Glu-loop(Glu-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-,
[0565] -Pro-Ser-Arg-Leu-Glu-loop(Lys-Glu-Leu-Arg-Glu)-Arg-Leu-Thr-Glu-,
[0566] -Pro-Ser-Arg-Leu-ring(Glu-Glu-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-,
[0567] -Pro-Ser-Arg-Leu-Glu-ring(Cys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-,
[0568] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-ring(Cys-Arg-Leu-Thr-Cys)-,
[0569] -Pro-Ser-Arg-Leu-Glu-ring(Cys-Glu-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-,
[0570] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-ring(Cys-Leu-Thr-Cys)-,
[0571] -Pro-Ser-Arg-Leu-Glu-Glu-ring(Cys-Leu-Arg-Arg-Cys)-Leu-Thr-Glu-,
[0572] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-ring(Cys-Arg-Leu-Thr-Cys)-,
[0573] -Ser-Arg-Leu-Glu-ring(Cys-Glu-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-,
[0574] -Ser-Arg-Leu-Glu-ring(Cys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-,
[0575] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-ring(Cys-Leu-Thr-Cys)-,
[0576] -Ser-Arg-Leu-Glu-Glu-ring(Cys-Leu-Arg-Arg-Cys)-Leu-Thr-Glu-,
[0577] -Ser-Arg-Leu-Glu-cyclo(DGlu-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu,
[0578] -Ser-Arg-Leu-Glu-cyclo(DLys-Glu-Leu-Arg-Glu)-Arg-Leu-Thr-Glu,
[0579] -Ser-Arg-Leu-Glu-cyclo(Lys-Glu-Leu-Arg-DGlu)-Arg-Leu-Thr-Glu,
[0580] -Ser-Arg-Leu-Glu-cyclo(DLys-Glu-Leu-Arg-DGlu)-Arg-Leu-Thr-Glu,
[0581] -Pro-Ser-Arg-Leu-Glu-cyclo(DGlu-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu,
[0582] -Pro-Ser-Arg-Leu-Glu-cyclo(DLys-Glu-Leu-Arg-Glu)-Arg-Leu-Thr-Glu,
[0583] -Pro-Ser-Arg-Leu-Glu-cyclo(Lys-Glu-Leu-Arg-DGlu)-Arg-Leu-Thr-Glu,
[0584] -Pro-Ser-Arg-Leu-Glu-cyclo(DLys-Glu-Leu-Arg-DGlu)-Arg-Leu-Thr-Glu,
[0585] -Ser-Arg-Leu-Glu-cyclo(DLys-Glu-Leu-Arg-Asp)-Arg-Leu-Thr-Glu,
[0586] -Ser-Arg-Leu-Glu-cyclo(DAsp-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu,
[0587] -Ser-Arg-Leu-Glu-cyclo(DAsp-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu,
[0588] -Ser-Arg-Leu-Glu-Cyclo(Asp-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu,
[0589] -Ser-Arg-Leu-Glu-Cyclo(Lys-Glu-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu,
[0590] -Ser-Arg-Leu-Glu-Cyclo(DLys-Glu-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu,
[0591] -Pro-Ser-Arg-Leu-Glu-Cyclo(DLys-Glu-Leu-Arg-Asp)-Arg-Leu-Thr-Glu,
[0592] -Pro-Ser-Arg-Leu-Glu-Cyclo(DAsp-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu,
[0593] -Pro-Ser-Arg-Leu-Glu-Cyclo(DAsp-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu,
[0594] -Pro-Ser-Arg-Leu-Glu-Cyclo(Asp-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu,
[0595] -Pro-Ser-Arg-Leu-Glu-Cyclo(Lys-Glu-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu,
[0596] -Pro-Ser-Arg-Leu-Glu-Cyclo(DLys-Glu-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu,
[0597] -Ser-Arg-Leu-Glu-Cyclo(DGlu-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu,
[0598] -Ser-Arg-Leu-Glu-Cyclo(Glu-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu,
[0599] -Ser-Arg-Leu-Glu-cyclo(DGlu-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu,
[0600] -Ser-Arg-Leu-Glu-cyclo(Lys-Glu-Leu-Glu)-Arg-Arg-Leu-Thr-Glu,
[0601] -Ser-Arg-Leu-Glu-cyclo(Lys-Glu-Leu-DGlu)-Arg-Arg-Leu-Thr-Glu,
[0602] -Ser-Arg-Leu-Glu-cyclo(DLys-Glu-Leu-DGlu)-Arg-Arg-Leu-Thr-Glu,
[0603] -Ser-Arg-Leu-Glu-cyclo(Asp-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu,
[0604] -Ser-Arg-Leu-Glu-cyclo(Asp-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu,
[0605] -Ser-Arg-Leu-Glu-cyclo(Lys-Glu-Leu-Asp)-Arg-Arg-Leu-Thr-Glu,<000
[0611] -Pro-Ser-Arg-Leu-Glu-loop(Glu-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu,
[0612] -Pro-Ser-Arg-Leu-Glu-loop(DGlu-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu
[0613] -Pro-Ser-Arg-Leu-Glu-loop(Lys-Glu-Leu-Glu)-Arg-Arg-Leu-Thr-Glu,
[0614] -Pro-Ser-Arg-Leu-Glu-loop(Lys-Glu-Leu-DGlu)-Arg-Arg-Leu-Thr-Glu,
[0615] -Pro-Ser-Arg-Leu-Glu-loop(DLys-Glu-Leu-DGlu)-Arg-Arg-Leu-Thr-Glu,
[0616] -Pro-Ser-Arg-Leu-Glu-loop(Asp-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu,
[0617] -Pro-Ser-Arg-Leu-Glu-loop(Asp-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu,
[0618] -Pro-Ser-Arg-Leu-Glu-loop(Lys-Glu-Leu-Asp)-Arg-Arg-Leu-Thr-Glu,
[0619] -Pro-Ser-Arg-Leu-Glu-loop(Lys-Glu-Leu-DAsp)-Arg-Arg-Leu-Thr-Glu,
[0620] -Pro-Ser-Arg-Leu-Glu-loop(DAsp-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu,
[0621] -Pro-Ser-Arg-Leu-Glu-loop(DAsp-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu,
[0622] -Pro-Ser-Arg-Leu-Glu-ring(DLys-Glu-Leu-DAsp)-Arg-Arg-Leu-Thr-Glu-,
[0623] -Pro-Ser-Arg-Leu-Glu-ring(DLys-Glu-Leu-Asp)-Arg-Arg-Leu-Thr-Glu-,
[0624] -Ser-Arg-Leu-Glu-Glu-ring(Asp-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0625] -Ser-Arg-Leu-Glu-Glu-ring(Lys-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-,
[0626] -Ser-Arg-Leu-Glu-Glu-ring(DAsp-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0627] -Ser-Arg-Leu-Glu-Glu-ring(Lys-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-,
[0628] -Ser-Arg-Leu-Glu-Glu-ring(Asp-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-,
[0629] -Ser-Arg-Leu-Glu-Glu-ring(DLys-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-,
[0630] -Ser-Arg-Leu-Glu-Glu-ring(DLys-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-,
[0631] -Ser-Arg-Leu-Glu-Glu-ring(DAsp-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-,
[0632] -Pro-Ser-Arg-Leu-Glu-Glu-ring(Asp-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0633] -Pro-Ser-Arg-Leu-Glu-Glu-ring(Lys-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-,
[0634] -Pro-Ser-Arg-Leu-Glu-Glu-loop(DAsp-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-
[0635] -Pro-Ser-Arg-Leu-Glu-Glu-loop(Lys-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-
[0636] -Pro-Ser-Arg-Leu-Glu-Glu-loop(Asp-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-
[0637] -Pro-Ser-Arg-Leu-Glu-Glu-loop(DLys-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-
[0638] -Pro-Ser-Arg-Leu-Glu-Glu-loop(DLys-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-
[0639] -Pro-Ser-Arg-Leu-Glu-Glu-loop(DAsp-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-
[0640] -Ser-Arg-Leu-Glu-loop(Cys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-
[0641] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-loop(Cys-Leu-Thr-Cys)-
[0642] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-loop(Cys-Arg-Leu-Cys)-Glu-
[0643] -Ser-Arg-Leu-Glu-Glu-loop(Cys-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-
[0644] -Pro-Ser-Arg-Leu-Glu-loop(Cys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-
[0645] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Cys-Leu-Thr-Cys)-,
[0646] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclic (Cys-Arg-Leu-Cys)-Glu-,
[0647] -Pro-Ser-Arg-Leu-Glu-Glu-Cyclic (Cys-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-,
[0648] -Ser-Arg-Leu-Glu-Cyclic (DCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-,
[0649] -Ser-Arg-Leu-Glu-Cyclic (DCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-,
[0650] -Ser-Arg-Leu-Glu-Cyclic (hCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-,
[0651] -Ser-Arg-Leu-Glu-Cyclic (hCys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-,
[0652] -Ser-Arg-Leu-Glu-Cyclic (Cys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-,
[0653] -Ser-Arg-Leu-Glu-Cyclic (hCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-,
[0654] -Ser-Arg-Leu-Glu-Cyclic (DCys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-,
[0655] -Ser-Arg-Leu-Glu-Cyclic (hCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-,
[0656] -Ser-Arg-Leu-Glu-Cyclic (DhCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-,
[0657] -Ser-Arg-Leu-Glu-loop(Cys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-
[0658] -Ser-Arg-Leu-Glu-loop(DCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-
[0659] -Ser-Arg-Leu-Glu-loop(DhCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-
[0660] -Ser-Arg-Leu-Glu-loop(DhCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu- [[ID=十三]]
[0661] -Pro-Ser-Arg-Leu-Glu-loop(DCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-
[0662] -Pro-Ser-Arg-Leu-Glu-loop(DCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-
[0663] -Pro-Ser-Arg-Leu-Glu-loop(hCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-
[0664] -Pro-Ser-Arg-Leu-Glu-loop(hCys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-
[0665] -Pro-Ser-Arg-Leu-Glu-loop(Cys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-
[0666] -Pro-Ser-Arg-Leu-Glu-loop(hCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-
[0667] -Pro-Ser-Arg-Leu-Glu-loop(DCys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-
[0668] -Pro-Ser-Arg-Leu-Glu-ring(hCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-,
[0669] -Pro-Ser-Arg-Leu-Glu-ring(DhCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-,
[0670] -Pro-Ser-Arg-Leu-Glu-ring(Cys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-,
[0671] -Pro-Ser-Arg-Leu-Glu-ring(DCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-,
[0672] -Pro-Ser-Arg-Leu-Glu-ring(DhCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-,
[0673] -Pro-Ser-Arg-Leu-Glu-ring(DhCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-,
[0674] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-ring(Cys-Leu-Thr-DCys)-,
[0675] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-ring(DCys-Leu-Thr-Cys)-,
[0676] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-ring(DCys-Leu-Thr-DCys)-,
[0677] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-ring(hCys-Leu-Thr-Cys)-,
[0678] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-ring(hCys-Leu-Thr-DCys)-,
[0679] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (hCys-Leu-Thr-hCys)-,
[0680] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Cys-Leu-Thr-hCys)-,
[0681] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DCys-Leu-Thr-hCys)-,
[0682] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Cys-Leu-Thr-hCys)-,
[0683] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DhCys-Leu-Thr-Cys)-,
[0684] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DhCys-Leu-Thr-DCys)-,
[0685] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DhCys-Leu-Thr-hCys)-,
[0686] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Cys-Leu-Thr-DhCys)-,
[0687] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DCys-Leu-Thr-DhCys)-, (此处原内容有误,推测是想表达 ,按照要求保留)
[0688] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Cys-Leu-Thr-DhCys)-,
[0689] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Pen-Leu-Thr-Pen)-,
[0690] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Pen-Leu-Thr-DPen)-,
[0691] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DPen-Leu-Thr-Pen)-,
[0692] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DPen-Leu-Thr-DPen)-,
[0693] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(DCys-Arg-Leu-Cys)-Glu-,
[0694] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(DCys-Arg-Leu-DCys)-Glu-,
[0695] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Cys-Arg-Leu-DCys)-Glu-,
[0696] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-Cys)-Glu-,
[0697] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-DCys)-Glu-,
[0698] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Cys-Arg-Leu-hCys)-Glu-,
[0699] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-hCys)-Glu-,
[0700] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-DhCys)-Glu-,
[0701] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(DhCys-Arg-Leu-hCys)-Glu-,
[0702] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(Cys-Leu-Thr-DCys)-,
[0703] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DCys-Leu-Thr-Cys)-,
[0704] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DCys-Leu-Thr-DCys)-,
[0705] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(hCys-Leu-Thr-Cys)-,
[0706] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(hCys-Leu-Thr-DCys)-,
[0707] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(hCys-Leu-Thr-hCys)-,
[0708] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(Cys-Leu-Thr-hCys)-,
[0709] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DCys-Leu-Thr-hCys)-,
[0710] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(Cys-Leu-Thr-hCys)-,
[0711] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DhCys-Leu-Thr-Cys)-,
[0712] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DhCys-Leu-Thr-DCys)-,
[0713] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DhCys-Leu-Thr-hCys)-,
[0714] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(Cys-Leu-Thr-DhCys)-,
[0715] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DCys-Leu-Thr-DhCys)-,
[0716] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(Cys-Leu-Thr-DhCys)-,
[0717] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(Pen-Leu-Thr-Pen)-,
[0718] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(Pen-Leu-Thr-DPen)-,
[0719] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DPen-Leu-Thr-Pen)-,
[0720] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DPen-Leu-Thr-DPen)-,
[0721] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(DCys-Arg-Leu-Cys)-Glu-,
[0722] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(DCys-Arg-Leu-DCys)-Glu-,
[0723] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(Cys-Arg-Leu-DCys)-Glu-, [[ID=3~2]]
[0724] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-Cys)-Glu-,
[0725] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-DCys)-Glu-,
[0726] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Cys-Arg-Leu-hCys)-Glu-,
[0727] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-hCys)-Glu-,
[0728] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-DhCys)-Glu-,
[0729] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(DhCys-Arg-Leu-hCys)-Glu-,
[0730] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Lys-Arg-Leu-Asp)-Glu-,
[0731] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Asp-Arg-Leu-Lys)-Glu-,
[0732] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Lys-Arg-Leu-Glu)-Glu-,
[0733] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Glu-Arg-Leu-Lys)-Glu-, <000!896>-Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Lys-Arg-Leu-Asp)-Glu-,
[0735] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclic(Asp-Arg-Leu-Lys)-Glu-
[0736] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclic(Lys-Arg-Leu-Glu)-Glu-
[0737] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclic(Glu-Arg-Leu-Lys)-Glu-
[0738] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclic(Cys-Arg-Leu-Thr-Cys)-
[0739] -Pro-Ser-Arg-Leu-Glu-cyclic(Cys-Glu-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-
[0740] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclic(Cys-Leu-Thr-Cys)-
[0741] -Pro-Ser-Arg-Leu-Glu-Glu-cyclic(Cys-Leu-Arg-Arg-Cys)-Leu-Thr-Glu-
[0742] -Ser-Arg-Leu-Glu-cyclic(DGlu-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro-
[0743] -Ser-Arg-Leu-Glu-cyclic(DLys-Glu-Leu-Arg-Glu)-Arg-Leu-Thr-Glu-Pro-
[0744] -Ser-Arg-Leu-Glu-cyclic(Lys-Glu-Leu-Arg-DGlu)-Arg-Leu-Thr-Glu-Pro-
[0745] -Ser-Arg-Leu-Glu-cyclic(DLys-Glu-Leu-Arg-DGlu)-Arg-Leu-Thr-Glu-Pro-
[0746] -Pro-Ser-Arg-Leu-Glu-ring (DGlu-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro-,
[0747] -Pro-Ser-Arg-Leu-Glu-ring(DLys-Glu-Leu-Arg-Glu)-Arg-Leu-Thr-Glu-Pro-,
[0748] -Pro-Ser-Arg-Leu-Glu-ring(Lys-Glu-Leu-Arg-DGlu)-Arg-Leu-Thr-Glu-Pro-,
[0749] -Pro-Ser-Arg-Leu-Glu-ring (DLys-Glu-Leu-Arg-DGlu)-Arg-Leu-Thr-Glu-Pro-,
[0750] -Ser-Arg-Leu-Glu-ring(DLys-Glu-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-Pro-,
[0751] -Ser-Arg-Leu-Glu-ring (DAsp-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro-,
[0752] -Ser-Arg-Leu-Glu-ring(DAsp-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-Pro-,
[0753] -Ser-Arg-Leu-Glu-ring(Asp-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro-,
[0754] -Ser-Arg-Leu-Glu-ring(Lys-Glu-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-Pro-,
[0755] -Ser-Arg-Leu-Glu-ring(DLys-Glu-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-Pro-,
[0756] -Pro-Ser-Arg-Leu-Glu-ring(DLys-Glu-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-Pro-,
[0757] -Pro-Ser-Arg-Leu-Glu-loop(DAsp-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro,
[0758] -Pro-Ser-Arg-Leu-Glu-loop(DAsp-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-Pro,
[0759] -Pro-Ser-Arg-Leu-Glu-loop(Asp-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro,
[0760] -Pro-Ser-Arg-Leu-Glu-loop(Lys-Glu-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-Pro,
[0761] -Pro-Ser-Arg-Leu-Glu-loop(DLys-Glu-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-Pro,
[0762] -Ser-Arg-Leu-Glu-loop(DGlu-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0763] -Ser-Arg-Leu-Glu-loop(Glu-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0764] -Ser-Arg-Leu-Glu-loop(DGlu-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0765] -Ser-Arg-Leu-Glu-loop(Lys-Glu-Leu-Glu)-Arg-Arg-Leu-Thr-Glu-Pro,
[0766] -Ser-Arg-Leu-Glu-loop(Lys-Glu-Leu-DGlu)-Arg-Arg-Leu-Thr-Glu-Pro,
[0767] -Ser-Arg-Leu-Glu-loop(DLys-Glu-Leu-DGlu)-Arg-Arg-Leu-Thr-Glu-Pro,
[0768] -Ser-Arg-Leu-Glu-Cyclo(Asp-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0769] -Ser-Arg-Leu-Glu-Cyclo(Asp-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0770] -Ser-Arg-Leu-Glu-Cyclo(Lys-Glu-Leu-Asp)-Arg-Arg-Leu-Thr-Glu-Pro,
[0771] -Ser-Arg-Leu-Glu-Cyclo(Lys-Glu-Leu-DAsp)-Arg-Arg-Leu-Thr-Glu-Pro,
[0772] -Ser-Arg-Leu-Glu-Cyclo(DAsp-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0773] -Ser-Arg-Leu-Glu-Cyclo(DAsp-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0774] -Ser-Arg-Leu-Glu-Cyclo(DLys-Glu-Leu-DAsp)-Arg-Arg-Leu-Thr-Glu-Pro,
[0775] -Ser-Arg-Leu-Glu-Cyclo(DLys-Glu-Leu-Asp)-Arg-Arg-Leu-Thr-Glu-Pro,
[0776] -Pro-Ser-Arg-Leu-Glu-Cyclo(Glu-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0777] -Pro-Ser-Arg-Leu-Glu-Cyclo(DGlu-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0778] -Pro-Ser-Arg-Leu-Glu-Cyclo(Lys-Glu-Leu-Glu)-Arg-Arg-Leu-Thr-Glu-Pro,
[0779] -Pro-Ser-Arg-Leu-Glu-ring(Lys-Glu-Leu-DGlu)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0780] -Pro-Ser-Arg-Leu-Glu-ring(DLys-Glu-Leu-DGlu)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0781] -Pro-Ser-Arg-Leu-Glu-ring(Asp-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0782] -Pro-Ser-Arg-Leu-Glu-ring(Asp-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0783] -Pro-Ser-Arg-Leu-Glu-ring(Lys-Glu-Leu-Asp)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0784] -Pro-Ser-Arg-Leu-Glu-ring(Lys-Glu-Leu-DAsp)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0785] -Pro-Ser-Arg-Leu-Glu-ring(DAsp-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0786] -Pro-Ser-Arg-Leu-Glu-ring (DAsp-Glu-Leu-DLys)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0787] -Pro-Ser-Arg-Leu-Glu-ring (DLys-Glu-Leu-DAsp)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0788] -Pro-Ser-Arg-Leu-Glu-ring(DLys-Glu-Leu-Asp)-Arg-Arg-Leu-Thr-Glu-Pro-,
[0789] -Ser-Arg-Leu-Glu-Glu-ring(Asp-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-Pro-,
[0790] -Ser-Arg-Leu-Glu-Glu-ring(Lys-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-Pro-,
[0791] -Ser-Arg-Leu-Glu-Glu-ring(DAsp-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-Pro-,
[0792] -Ser-Arg-Leu-Glu-Glu-ring(Lys-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-Pro-,
[0793] -Ser-Arg-Leu-Glu-Glu-ring(Asp-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro-,
[0794] -Ser-Arg-Leu-Glu-Glu-ring(DLys-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-Pro-,
[0795] -Ser-Arg-Leu-Glu-Glu-ring(DLys-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-Pro-,
[0796] -Ser-Arg-Leu-Glu-Glu-ring(DAsp-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro-,
[0797] -Pro-Ser-Arg-Leu-Glu-Glu-ring(Asp-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-Pro-,
[0798] -Pro-Ser-Arg-Leu-Glu-Glu-ring(Lys-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-Pro-,
[0799] -Pro-Ser-Arg-Leu-Glu-Glu-ring(DAsp-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-Pro-,
[0800] -Pro-Ser-Arg-Leu-Glu-Glu-ring(Lys-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-Pro-,
[0801] -Pro-Ser-Arg-Leu-Glu-Glu-Cyclo(Asp-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro,
[0802] -Pro-Ser-Arg-Leu-Glu-Glu-Cyclo(DLys-Leu-Arg-Asp)-Arg-Leu-Thr-Glu-Pro,
[0803] -Pro-Ser-Arg-Leu-Glu-Glu-Cyclo(DLys-Leu-Arg-DAsp)-Arg-Leu-Thr-Glu-Pro,
[0804] -Pro-Ser-Arg-Leu-Glu-Glu-Cyclo(DAsp-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-Pro,
[0805] -Ser-Arg-Leu-Glu-Cyclo(Cys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0806] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(Cys-Leu-Thr-Cys)-Pro,
[0807] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Cys-Arg-Leu-Cys)-Glu-Pro,
[0808] -Ser-Arg-Leu-Glu-Glu-Cyclo(Cys-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-Pro,
[0809] -Pro-Ser-Arg-Leu-Glu-Cyclo(Cys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0810] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(Cys-Leu-Thr-Cys)-Pro,
[0811] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Cys-Arg-Leu-Cys)-Glu-Pro,
[0812] -Pro-Ser-Arg-Leu-Glu-Glu-cyclo(Cys-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-Pro,
[0813] -Ser-Arg-Leu-Glu-cyclo(DCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0814] -Ser-Arg-Leu-Glu-cyclo(DCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0815] -Ser-Arg-Leu-Glu-cyclo(hCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0816] -Ser-Arg-Leu-Glu-cyclo(hCys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0817] -Ser-Arg-Leu-Glu-cyclo(Cys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0818] -Ser-Arg-Leu-Glu-cyclo(hCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0819] -Ser-Arg-Leu-Glu-cyclo(DCys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0820] -Ser-Arg-Leu-Glu-cyclo(hCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0821] -Ser-Arg-Leu-Glu-cyclo(DhCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0822] -Ser-Arg-Leu-Glu-cyclo(Cys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0823] -Ser-Arg-Leu-Glu-loop(DCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0824] -Ser-Arg-Leu-Glu-loop(DhCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0825] -Ser-Arg-Leu-Glu-loop(DhCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0826] -Pro-Ser-Arg-Leu-Glu-loop(DCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0827] -Pro-Ser-Arg-Leu-Glu-loop(DCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0828] -Pro-Ser-Arg-Leu-Glu-loop(hCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0829] -Pro-Ser-Arg-Leu-Glu-loop(hCys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0830] -Pro-Ser-Arg-Leu-Glu-loop(Cys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0831] -Pro-Ser-Arg-Leu-Glu-loop(hCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0832] -Pro-Ser-Arg-Leu-Glu-loop(DCys-Glu-Leu-hCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0833] -Pro-Ser-Arg-Leu-Glu-loop(hCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0834] -Pro-Ser-Arg-Leu-Glu-cyclo(DhCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0835] -Pro-Ser-Arg-Leu-Glu-cyclo(Cys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0836] -Pro-Ser-Arg-Leu-Glu-cyclo(DCys-Glu-Leu-DhCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0837] -Pro-Ser-Arg-Leu-Glu-cyclo(DhCys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0838] -Pro-Ser-Arg-Leu-Glu-cyclo(DhCys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-Pro,
[0839] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(Cys-Leu-Thr-DCys)-Pro,
[0840] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DCys-Leu-Thr-Cys)-Pro,
[0841] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(DCys-Leu-Thr-DCys)-Pro,
[0842] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(hCys-Leu-Thr-Cys)-Pro,
[0843] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(hCys-Leu-Thr-DCys)-Pro,
[0844] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-cyclo(hCys-Leu-Thr-hCys)-Pro,
[0845] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Cys-Leu-Thr-hCys)-Pro-
[0846] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DCys-Leu-Thr-hCys)-Pro-
[0847] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Cys-Leu-Thr-hCys)-Pro-
[0848] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DhCys-Leu-Thr-Cys)-Pro-
[0849] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DhCys-Leu-Thr-DCys)-Pro-
[0850] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DhCys-Leu-Thr-hCys)-Pro-
[0851] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Cys-Leu-Thr-DhCys)-Pro-
[0852] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (DCys-Leu-Thr-DhCys)-Pro-
[0853] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Cys-Leu-Thr-DhCys)-Pro-
[0854] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Pen-Leu-Thr-Pen)-Pro-
[0855] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclic (Pen-Leu-Thr-DPen)-Pro-
[0856] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DPen-Leu-Thr-Pen)-Pro-,
[0857] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DPen-Leu-Thr-DPen)-Pro-,
[0858] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(DCys-Arg-Leu-Cys)-Glu-Pro-,
[0859] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(DCys-Arg-Leu-DCys)-Glu-Pro-,
[0860] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Cys-Arg-Leu-DCys)-Glu-Pro-,
[0861] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-Cys)-Glu-Pro-,
[0862] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-DCys)-Glu-Pro-,
[0863] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(Cys-Arg-Leu-hCys)-Glu-Pro-,
[0864] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-hCys)-Glu-Pro-,
[0865] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(hCys-Arg-Leu-DhCys)-Glu-Pro-,
[0866] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(DhCys-Arg-Leu-hCys)-Glu-Pro-,
[0867] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(Cys-Leu-Thr-DCys)-Pro-
[0868] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DCys-Leu-Thr-Cys)-Pro-
[0869] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DCys-Leu-Thr-DCys)-Pro-
[0870] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(hCys-Leu-Thr-Cys)-Pro-
[0871] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(hCys-Leu-Thr-DCys)-Pro-
[0872] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(hCys-Leu-Thr-hCys)-Pro-
[0873] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(Cys-Leu-Thr-hCys)-Pro-
[0874] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DCys-Leu-Thr-hCys)-Pro-
[0875] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(Cys-Leu-Thr-hCys)-Pro-
[0876] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DhCys-Leu-Thr-Cys)-Pro-
[0877] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DhCys-Leu-Thr-DCys)-Pro-
[0878] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DhCys-Leu-Thr-hCys)-Pro-
[0879] [[ID=�]]-Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(Cys-Leu-Thr-DhCys)-Pro-
[0880] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DCys-Leu-Thr-DhCys)-Pro-
[0881] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(Cys-Leu-Thr-DhCys)-Pro-
[0882] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(Pen-Leu-Thr-Pen)-Pro-
[0883] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(Pen-Leu-Thr-DPen)-Pro-
[0884] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DPen-Leu-Thr-Pen)-Pro-
[0885] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cyclo(DPen-Leu-Thr-DPen)-Pro-
[0886] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(DCys-Arg-Leu-Cys)-Glu-Pro-
[0887] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclo(DCys-Arg-Leu-DCys)-Glu-Pro-
[0888] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(Cys-Arg-Leu-DCys)-Glu-Pro,
[0889] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(hCys-Arg-Leu-Cys)-Glu-Pro,
[0890] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(hCys-Arg-Leu-DCys)-Glu-Pro,
[0891] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(Cys-Arg-Leu-hCys)-Glu-Pro,
[0892] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(hCys-Arg-Leu-hCys)-Glu-Pro,
[0893] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(hCys-Arg-Leu-DhCys)-Glu-Pro,
[0894] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(DhCys-Arg-Leu-hCys)-Glu-Pro,
[0895] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(Lys-Arg-Leu-Asp)-Glu-Pro,
[0896] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(Asp-Arg-Leu-Lys)-Glu-Pro,
[0897] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(Lys-Arg-Leu-Glu)-Glu-Pro,
[0898] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-cyclo(Glu-Arg-Leu-Lys)-Glu-Pro,
[0899] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cycle(Lys-Arg-Leu-Asp)-Glu-Pro-,
[0900] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cycle(Asp-Arg-Leu-Lys)-Glu-Pro-,
[0901] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cycle(Lys-Arg-Leu-Glu)-Glu-Pro-,
[0902] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cycle(Glu-Arg-Leu-Lys)-Glu-Pro-,
[0903] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cycle(Cys-Arg-Leu-Thr-Cys)-Pro-,
[0904] -Pro-Ser-Arg-Leu-Glu-Cycle(Cys-Glu-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-Pro-,
[0905] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-Cycle(Cys-Leu-Thr-Cys)-Pro-,
[0906] -Pro-Ser-Arg-Leu-Glu-Glu-Cycle(Cys-Leu-Arg-Arg-Cys)-Leu-Thr-Glu-Pro-,
[0907] -Ser-Arg-Leu-Glu-Cycle(Lys-Glu-Leu-Arg-Glu)-Arg-Leu-Thr-Glu-, and
[0908] -Ser-Arg-Leu-ring (Glu-Glu-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-.
[0909] In some embodiments, the cyclic peptide is linked to the 3-mercaptopropionyl moiety via the α-amine moiety of the leftmost amino acid in the cyclic peptide.In some embodiments, the rightmost amino acid in the cyclic peptide comprises an amide.
[0910] In some embodiments, the cyclized amino acid sequence is a cyclized amino acid sequence selected from the group consisting of
[0911] -Ser-Arg-Leu-Glu-ring(Glu-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0912] -Ser-Arg-Leu-Glu-ring(Asp-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0913] -Ser-Arg-Leu-Glu-ring(Glu-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-,
[0914] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-ring(Lys-Arg-Leu-Thr-Glu)-,
[0915] -Ser-Arg-Leu-Glu-Cycle(Cys-Glu-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-,
[0916] -Ser-Arg-Leu-Glu-ring(Asp-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-,
[0917] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-ring(Lys-Arg-Leu-Thr-Asp)-,
[0918] -Ser-Arg-Leu-Glu-ring(Glu-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-,
[0919] -Pro-Ser-Arg-Leu-Glu-ring(Glu-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0920] -Pro-Ser-Arg-Leu-Glu-ring (DGlu-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-,
[0921] -Pro-Ser-Arg-Leu-Glu-ring(Glu-Glu-Leu-Arg-DLys)-Arg-Leu-Thr-Glu-,
[0922] -Pro-Ser-Arg-Leu-Glu-ring(Lys-Glu-Leu-Arg-Glu)-Arg-Leu-Thr-Glu-,
[0923] -Pro-Ser-Arg-Leu-ring(Glu-Glu-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-,
[0924] -Pro-Ser-Arg-Leu-Glu-ring(Cys-Glu-Leu-DCys)-Arg-Arg-Leu-Thr-Glu-,
[0925] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-ring(Cys-Arg-Leu-Thr-Cys)-,
[0926] -Pro-Ser-Arg-Leu-Glu-ring(Cys-Glu-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-,
[0927] -Pro-Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-ring(Cys-Leu-Thr-Cys)-,
[0928] -Pro-Ser-Arg-Leu-Glu-Glu-ring(Cys-Leu-Arg-Arg-Cys)-Leu-Thr-Glu-,
[0929] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-ring(Cys-Arg-Leu-Thr-Cys)-,
[0930] -Ser-Arg-Leu-Glu-ring(Cys-Glu-Leu-Arg-Cys)-Arg-Leu-Thr-Glu-,
[0931] -Ser-Arg-Leu-Glu-ring(Cys-Glu-Leu-Cys)-Arg-Arg-Leu-Thr-Glu-,
[0932] -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Arg-ring(Cys-Leu-Thr-Cys)-,
[0933] -Ser-Arg-Leu-Glu-Glu-ring(Cys-Leu-Arg-Arg-Cys)-Leu-Thr-Glu-,
[0934] -Ser-Arg-Leu-Glu-Cycle(Lys-Glu-Leu-Arg-Glu)-Arg-Leu-Thr-Glu-, and
[0935] -Ser-Arg-Leu-ring (Glu-Glu-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-.
[0936] In some embodiments, the cyclized amino acid sequence is -Ser-Arg-Leu-Glu-Cyclic(Glu-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu. In some other embodiments, the cyclized amino acid sequence is -Ser-Arg-Leu-Glu-Cyclic(Asp-Glu-Leu-Arg-Lys)-Arg-Leu-Thr-Glu-. In other embodiments, the cyclized amino acid sequence is -Ser-Arg-Leu-Glu-Cyclic(Glu-Glu-Leu-Lys)-Arg-Arg-Leu-Thr-Glu-. In still other embodiments, the cyclized amino acid sequence is -Ser-Arg-Leu-Glu-Glu-Glu-Leu-Arg-Cyclic(Lys-Arg-Leu-Thr-Glu)-.
[0937] Cyclic peptides can have different cyclic bridging moieties that form the ring structure. Preferably, the ring structure includes a chemically stable bridging moiety, such as an amide group, a lactone group, an ether group, a thioether group, a disulfide group, an alkylene group, an alkenyl group, or a 1,2,3-triazole group. The following are examples illustrating the variability of the bridging moiety in peptides:
[0938]
[0939] In some embodiments, the ALFA-tag binding moiety comprises an antibody or antibody fragment, such as a camel VHH domain. In some embodiments, the ALFA-tag binding moiety comprises a single domain antibody (sdAb), NbALFA-nanobody.
[0940] In some embodiments, the ALFA-tag binding portion comprises a single domain antibody, such as a camel VHH domain, comprising the CDR1 sequence VTX1SALNAMAMG, wherein X1 is I or V, the CDR2 sequence AVSX2RGNAM, wherein X2 is E, H, N, D, or S, and the CDR3 sequence LEDRVDSFHDY.
[0941] In some embodiments, the ALFA-tag binding portion comprises a single domain antibody, such as a camel VHH domain, comprising the CDR1 sequence GVTX1SALNAMAMG, wherein X1 is I or V, the CDR2 sequence AVSX2RGNAM, wherein X2 is E, H, N, D, or S, and the CDR3 sequence LEDRVDSFHDY.
[0942] In some embodiments, the ALFA-tag binding moiety comprises a single domain antibody, such as a camel VHH domain comprising the CDR1 sequence VTISALNAMAMG, the CDR2 sequence AVSERGNAM, and the CDR3 sequence LEDRVDSFHDY.
[0943] In some embodiments, the ALFA-tag binding moiety comprises a single domain antibody, such as a camel VHH domain, comprising the CDR1 sequence GVTISALNAMAMG, the CDR2 sequence AVSERGNAM, and the CDR3 sequence LEDRVDSFHDY.
[0944] In some embodiments, the ALFA-tag binding portion comprises a single domain antibody, such as a camelid VHH domain, comprising the amino acid sequence EVQLQESGGGLVQPGGSLRLSCTASGVTISALNAMAMGWYRQAPGERRVMVAAVSERGNAMYRESVQGRFTVTRDFTNKMVSLQMDNLKPEDTAVYYC HVLEDRVDSFHDYWGQGTQVTVSS, an amino acid sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity thereto, or a fragment thereof, or a fragment thereof having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity thereto. In some embodiments, the amino acid sequence comprises CDR1, CDR2, and CDR3 sequences as described above.
[0945] In some embodiments, the epitope tag / binder system comprises an epitope tag comprising the sequence PDRVRAVSHWSS (Spot-tag) and the binder comprises a single domain antibody (sdAb or Nanobody) that specifically binds to the Spot-tag (Spot-Nanobody (14.7 kD)).
[0946] In some embodiments, the interacting moieties on the linking compound and the docking compound are combined to form a covalent bond. In these embodiments, the system used herein can include a tag / catcher system that forms a covalent bond, for example, a SpyTag / SpyCatcher that forms an isopeptide bond.
[0947] The SpyTag / SpyCatcher system is an irreversible conjugation technology for recombinant proteins. The peptide SpyTag and the protein SpyCatcher spontaneously react to form an intermolecular isopeptide bond. Using a Tag / Catcher pair, bioconjugation between two recombinant proteins is possible.
[0948] In one aspect, the present disclosure provides a complex in which a particle comprising a linking compound (a hydrophobic portion having a binding moiety covalently linked thereto) is bound to a docking compound (a compound comprising (i) a moiety that binds to a binding moiety covalently linked to the hydrophobic portion, and (ii) a moiety that targets a cell surface antigen). Thus, the linking compound and the docking compound comprise interacting moieties.
[0949] Thus, in one aspect, the present disclosure provides a composite comprising:
[0950] (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and
[0951] (b) A compound comprising (i) a moiety that binds to a binding moiety that is covalently linked to a hydrophobic moiety and (ii) a moiety that targets a cell surface antigen.
[0952] Various embodiments of composite ligating compounds and docking compounds are described herein.
[0953] In some embodiments, the linking compound comprises an ALFA-tag. In these embodiments, the portion of the docking compound that binds to the linking compound can be a NbALFA-nanobody (NbALFA). In some embodiments, the docking compound can have a structure selected from the group consisting of: NbALFA x anti-primary target DARPin, NbALFA x anti-primary target VHH, and NbALFA x anti-primary target scFv.
[0954] Particles containing payload
[0955] The particles described herein comprise one or more particle-forming agents, a payload to be delivered to a target cell, and a hydrophobic portion having a binding moiety covalently attached thereto for binding to a docking compound.
[0956] Payload
[0957] In some embodiments, the payload comprises a therapeutic or diagnostic moiety. In some embodiments, the payload comprises a nucleic acid, for example, a nucleic acid to be delivered to a target cell to genetically modify the target cell and enable the target cell to express a biomolecule (e.g., a peptide or protein) encoded by the nucleic acid. In some embodiments, the nucleic acid is a nucleic acid encoding an antigen receptor. In these embodiments, the target cell can be an immune cell or an immune effector cell.
[0958] For example, the payload can be a detectable label. As used herein, a "detectable label" refers to a compound that allows detection, for example, when present in a cell, tissue, or organism. In the context of the present disclosure, one type of detectable label contemplated is a contrast agent. In the context of the present disclosure, different types of detectable labels are contemplated and described below.
[0959] Therefore, according to some embodiments of the present disclosure, the agents and methods of the present disclosure are used for imaging, especially medical imaging. In order to identify the primary target, an imaging probe comprising one or more detectable labels can be used as a payload. Specific examples of detectable labels of imaging probes are the parts of the contrast used in traditional imaging systems, such as MRI imageable constructs, spin labels, optical labels, ultrasound response constructs, X-ray response parts, radionuclides, (bio)luminescence and FRET type dyes. Exemplary detectable labels contemplated in the context of the present disclosure include, but are not limited to, fluorescent molecules, such as autofluorescent molecules, molecules that fluoresce when in contact with reagents, etc., radioactive labels; biotin, for example, can be detected by binding of biotin to avidin; fluorescent tags, MRI imaging structures comprising paramagnetic metals, imaging agents, and the like. The radionuclide used for imaging can be, for example, an isotope selected from the following: 3 H. 11 C. 13 N. 15 O. 18 F. 19 F. 51 Cr, 52 Fe, 52 Mn, 55 Co、 60 Cu, 61 Cu, 62 Zn, 62 Cu, 63 Zn, 64 Cu, 66 Ga, 67 Ga, 68 Ga, 70 As、 71 As、 72 As、 74 As、75 Se, 75 Br, 76 Br, 77 Br, 80 Br, 82 Br, 82 Rb, 86 Y. 88 Y. 89 Sr. 89 Zr, 97 Such as 99 Tc, 110 In, 111 In, 113 In, 114 In, 117 Sn, 120 I. 122 Xe, 123 I. 124 I. 125 I. 166 Ho, 167 Tm, 169 Yb, 193 Pt, 195 Pt, 201 Tl, and 203 Other elements and isotopes, such as those used in therapy, may also be used for imaging in certain applications.
[0960] The MRI imageable portion can be a paramagnetic ion or a superparamagnetic particle. The paramagnetic ion can be an element selected from the group consisting of Gd, Fe, Mn, Cr, Co, Ni, Cu, Pr, Nd, Yb, Tb, Dy, Ho, Er, Sm, Eu, Ti, Pa, La, Sc, V, Mo, Ru, Ce, Dy, and Tl.
[0961] X-ray responsive moieties include, but are not limited to, iodine, barium, and barium sulfate.
[0962] Furthermore, detectable labels contemplated in the context of the present disclosure also include peptides or polypeptides detectable by antibody binding, for example, by binding of a detectably labeled antibody. In some embodiments, the detectable labels are small organic PET and SPECT labels, such as 18 F. 11 C or 123 I.
[0963] The payload can also be a therapeutic agent, such as a pharmaceutically active agent. Examples of pharmaceutically active agents are known to those skilled in the art and are provided herein. The therapeutic agent can also optionally contain a detectable label.
[0964] Thus, according to some embodiments, the agents and methods described herein are used for targeted therapy. This is achieved by using a payload comprising one or more pharmaceutically active agents (e.g., drugs or radioisotopes for radiation therapy).
[0965] The term "pharmaceutically active agent" relates to any agent, such as a compound or cell, that has a therapeutic effect when administered to an individual. The term "pharmaceutically active agent" also relates to any agent that, in a therapeutic intervention comprising the administration of said agent, alters, preferably cures, alleviates or partially arrests the clinical manifestations of a given disease and its complications.
[0966] In some embodiments, the pharmaceutically active agent comprises a pharmaceutically active RNA or a pharmaceutically active peptide or protein.
[0967] "Pharmaceutically active RNA" is an RNA that encodes a pharmaceutically active peptide or protein or is itself pharmaceutically active, for example, it has one or more pharmaceutical activities, such as the activities described for pharmaceutically active proteins. For example, the RNA can be one or more RNA interference (RNAi) chains. Such agents include short interfering RNA (siRNA) or short hairpin RNA (shRNA) targeted to a target transcript (e.g., a transcript of an endogenous disease-associated transcript of a subject), or a precursor of a siRNA or microRNA-like RNA.
[0968] A "pharmaceutically active peptide or protein" has a positive or beneficial effect on the condition or disease state of the subject when administered in a therapeutically effective amount. Preferably, the pharmaceutically active peptide or protein has curative or palliative properties and can be administered to improve, alleviate, mitigate, reverse one or more symptoms of a disease or condition, delay the onset of one or more symptoms of a disease or condition, or reduce the severity of one or more symptoms of a disease or condition. Pharmaceutically active peptides or proteins can have prophylactic properties and can be used to delay the onset of a disease or reduce the severity of such a disease or pathological condition. The term "pharmaceutically active peptide or protein" includes the entire protein or polypeptide and can also refer to pharmaceutically active fragments thereof. It can also include pharmaceutically active analogs of the peptide or protein. The term "pharmaceutically active peptide or protein" includes peptides and proteins that are antigens, that is, administration of the peptide or protein to a subject will elicit an immune response in the subject that can be therapeutic or partially or fully protective.
[0969] Examples of pharmaceutically active proteins include, but are not limited to, cytokines and immune system proteins, such as immunologically active compounds (e.g., interleukins, colony stimulating factor (CSF), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), erythropoietin, tumor necrosis factor (TNF), interferons, integrins, addressins, selectins, homing receptors, T cell receptors, immunoglobulins, soluble major histocompatibility complex antigens, immunologically active antigens such as bacterial, parasitic or viral antigens, allergens, autoantigens, antibodies), hormones (insulin, thyroid hormones, catecholamines, gonadotropins, trophic hormones), hormones), prolactin, oxytocin, dopamine, bovine growth hormone, leptin, etc.), growth hormone (e.g., human growth hormone), growth factors (e.g., epidermal growth factor, nerve growth factor, insulin-like growth factor, etc.), growth factor receptors, enzymes (tissue plasminogen activator, streptokinase, cholesterol biosynthesis or degradation enzymes, steroidogenic enzymes, kinases, phosphodiesterases, methylases, demethylases, dehydrogenases, cellulases, proteases, lipases, phospholipases, aromatase, cytochromes, adenylate or guanylate cyclases, ceramidase etc.), receptors (steroid hormone receptors, peptide receptors), binding proteins (growth hormone or growth factor binding protein, etc.), transcription and translation factors, tumor growth inhibitory proteins (for example, proteins that inhibit angiogenesis), structural proteins (such as collagen, fibroin, fibrinogen, elastin, tubulin, actin and myosin), blood proteins (thrombin, serum albumin, factor VII, factor VIII, insulin, factor IX, factor X, tissue plasminogen activator, protein C, von Wilebrand factor, antithrombin III, glucocerebrosidase, erythropoietin granulocyte colony stimulating factor (GCSF) or modified factor VIII, anticoagulants, etc.
[0970] In some embodiments, the pharmaceutically active protein is a cytokine that participates in regulating lymphoid homeostasis, preferably a cytokine that participates in and preferably induces or enhances the development, priming, expansion, differentiation and / or survival of T cells. In some embodiments, the cytokine is an interleukin. In some embodiments, the pharmaceutically active protein according to the present disclosure is an interleukin selected from IL-2, IL-7, IL-12, IL-15 and IL-21.
[0971] In some embodiments, the payload comprises a compound useful for radiation therapy and / or chemotherapy. In some embodiments, the payload comprises a chemotherapeutic compound.
[0972] Chemotherapy is a cancer treatment method that uses one or more anticancer drugs (chemotherapeutic agents), usually as part of a standardized chemotherapy regimen. The term chemotherapy has come to imply the nonspecific use of intracellular toxins to inhibit mitosis. This implicit meaning does not include more selective agents that block extracellular signals (signal transduction). The development of therapies with specific molecular or genetic targets that inhibit growth-promoting signals from classical endocrine hormones (primarily estrogens for breast cancer and androgens for prostate cancer) is now known as hormone therapy. In contrast, the inhibition of other growth signals (such as those associated with receptor tyrosine kinases) is known as targeted therapy.
[0973] Traditional chemotherapeutic agents are cytotoxic by interfering with cell division (mitosis), but cancer cells vary widely in their sensitivity to these agents. Chemotherapy can largely be considered a form of cell damage or stress, which can subsequently lead to cell death if apoptosis is triggered.
[0974] Chemotherapeutic agents include alkylating agents, antimetabolites, antimicrotubule agents, topoisomerase inhibitors, and cytotoxic antibiotics.
[0975] Alkylating agents can alkylate many molecules, including proteins, RNA, and DNA. Subtypes of alkylating agents include nitrogen mustards, nitrosoureas, tetrazines, aziridines, cisplatin and its derivatives, and nonclassical alkylating agents. Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide, and busulfan. Nitrosoureas include N-nitroso-N-methylurea (MNU), carmustine (BCNU), lomustine (CCNU), semustine (MeCCNU), fotemustine, and streptozotocin. Tetrazines include dacarbazine, mitozolomide, and temozolomide. Aziridines include thiotepa, mytomycin, and diaziquone (AZQ). Cisplatin and its derivatives include cisplatin, carboplatin, and oxaliplatin. They impair cellular function by forming covalent bonds with amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. Nonclassical alkylating agents include procarbazine and hexamethylmelamine. In a particularly preferred embodiment, the alkylating agent is cyclophosphamide.
[0976] Antimetabolites are a group of molecules that block DNA and RNA synthesis. Many of them have similar structures to the building blocks of DNA and RNA. Antimetabolites resemble nucleobases, or nucleosides, but have altered chemical groups. These drugs work by blocking enzymes required for DNA synthesis or by incorporating into DNA or RNA. Subtypes of antimetabolites include antifolates, fluoropyrimidines, deoxynucleoside analogs, and thiopurines. Antifolates include methotrexate and pemetrexed. Fluoropyrimidines include fluorouracil and capecitabine. Deoxynucleoside analogs include cytarabine, gemcitabine, decitabine, azacitidine, fludarabine, nelarabine, cladribine, clofarabine, and pentostatin. Thiopurines include thioguanine and mercaptopurine.
[0977] Antimicrotubule agents block cell division by preventing the function of microtubules. Vinca alkaloids prevent the formation of microtubules, while taxanes prevent the depolymerization of microtubules. Vinca alkaloids include vinorelbine, vindesine, and vinflunine. Taxanes include docetaxel (Taxotere) and paclitaxel (Taxol).
[0978] Topoisomerase inhibitors are drugs that affect the activity of two enzymes (topoisomerase I and topoisomerase II). They include irinotecan, topotecan, camptothecin, etoposide, doxorubicin, mitoxantrone, teniposide, novobiocin, merbarone, and aclarubicin.
[0979] Cytotoxic antibiotics are a group of different drugs with various mechanisms of action. Their common theme in terms of their chemotherapeutic hallmark is that they interrupt cell division. The most important subgroups are the anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, pirarubicin, and aclarubicin) and the bleomycins; other prominent examples include mitomycin C, mitoxantrone, and dactinomycin.
[0980] particles
[0981] Payloads such as nucleic acids can be administered with one or more delivery vehicles that protect the payload from degradation, maximize delivery to target cells, and minimize exposure to non-target cells. Such delivery vehicles can compound or encapsulate the payload and include a range of substances, including polymers, lipids, and mixtures thereof. In some embodiments, such delivery vehicles can form particles with the payload.
[0982] In the context of the present disclosure, the term "particle" refers to a structured entity formed by molecules or molecular complexes (particularly particle-forming compounds). In some embodiments, the particle is a particle containing nucleic acid, such as a particle comprising DNA, RNA or a mixture thereof. In some embodiments, the particle contains an envelope (e.g., one or more layers or lamellae) made of one or more types of amphiphilic substances (e.g., amphiphilic lipids). In this context, the expression "amphiphilic substance" means that the substance has both hydrophilic and lipophilic properties. The envelope may also include additional substances (e.g., additional lipids) that are not necessarily amphiphilic. Therefore, the particle can be a monolayer or multilayer structure, in which the substance constituting the one or more layers or lamellae includes one or more types of amphiphilic substances (particularly selected from amphiphilic lipids), optionally in combination with additional compounds (e.g., additional lipids) that are not necessarily amphiphilic. In some embodiments, the term "particle" refers to a micron or nanometer-sized structure, such as a micron or nanometer-sized dense structure. According to the present disclosure, the term "particle" includes nanoparticles.
[0983] The term "nanoparticle" refers to a nanosized particle comprising at least one particle forming agent (e.g., at least one cationic or cationically ionizable lipid), wherein all three external dimensions of the particle are nanometer-sized, i.e., at least about 1 nm and less than about 1000 nm. Preferably, the dimension of the particle is its diameter.
[0984] In some embodiments, the size (e.g., diameter) of the particles described herein is in the range of about 10 to about 2000 nm, such as at least about 15 nm (e.g., at least about 20 nm, at least about 25 nm, at least about 30 nm, at least about 35 nm, at least about 40 nm, at least about 45 nm, at least about 50 nm, at least about 55 nm, at least about 60 nm, at least about 65 nm, at least about 70 nm, at least about 75 nm, at least about 80 nm, at least about 85 nm, at least about 90 nm, at least about 95 nm, or at least about 100 nm) and / or at most about 1900 nm (e.g., at most about 1800 nm, at most about 1700 nm, at most about 1600 nm, at most about 1500 nm, at most about 1400 nm, at most about 1300 nm, at most about 1200 nm, at most about 1100 nm, at most about 1000 nm, at most about 950 nm, or at least about 100 nm). m, at most about 900 nm, at most about 850 nm, at most about 800 nm, at most about 750 nm, at most about 700 nm, at most about 650 nm, at most about 600 nm, at most about 550 nm or at most about 500 nm), such as in the range of about 20 to about 1500 nm, such as about 30 to about 1200 nm, about 40 to about 1100 nm, about 50 to about 1000 nm, about 60 to about 900 nm, about 7 In some embodiments, the particles described herein have a size (e.g., diameter) in the range of about 40 nm to about 200 nm, such as about 50 nm to about 180 nm, about 60 nm to about 160 nm, about 80 nm to about 150 nm, or about 80 nm to about 120 nm.
[0985] In some embodiments, the average diameter of the particles described herein is, in some embodiments, in the range of about 50 nm to about 1000 nm, about 50 nm to about 800 nm, about 50 nm to about 700 nm, about 50 nm to about 600 nm, about 50 nm to about 500 nm, about 50 nm to about 450 nm, about 50 nm to about 400 nm, about 50 nm to about 350 nm, about 50 nm to about 300 nm, about 50 nm to about 500 nm, about 50 nm to about 600 nm, about 50 nm to about 700 nm, about 50 nm to about 800 nm, about 50 nm to about 900 nm, about 50 nm to about 1000 nm, about 50 nm to about 15 ... about 250 nm, about 50 nm to about 200 nm, about 100 nm to about 1000 nm, about 100 nm to about 800 nm, about 100 nm to about 700 nm, about 100 nm to about 600 nm, about 100 nm to about 500 nm, about 100 nm to about 450 nm, about 100 nm to about 400 nm, about 100 nm to about 350 nm, about 100 nm to about 300 nm, about 100 nm to about 250 nm, about 100 nm to about 200 nm, about 150 nm to about 1000 nm, about 150 nm to about 800 nm, about 150 nm to about 700 nm, about 150 nm to about 600 nm, about 150 nm to about 500 nm, about 150 nm to about 450 nm, about 150 nm to about 400 nm, about 150 nm to about 350 nm, about 150 nm to about 300 nm, about 150 nm to about 250 nm, about 150 nm In some embodiments, the particles described herein have an average diameter in the range of about 40 nm to about 200 nm, such as about 50 nm to about 180 nm, about 60 nm to about 160 nm, about 80 nm to about 150 nm, or about 80 nm to about 120 nm.
[0986] The particles described herein can exhibit a polydispersity index (PDI) of less than about 0.5, less than about 0.4, less than about 0.3, less than about 0.2, less than about 0.1, or less than about 0.05. For example, the particles can exhibit a polydispersity index in the range of about 0.01 to about 0.4 or about 0.1 to about 0.3.
[0987] "Nucleic acid particles" can be used to deliver nucleic acids to a target site of interest (e.g., a cell, tissue, organ, etc.). Nucleic acid particles can be formed from at least one cationic compound or cationically ionizable compound (e.g., a polymer or lipid complexed with the nucleic acid). Without being bound by any theory, it is believed that the cationic compound or cationically ionizable compound binds to the nucleic acid to form aggregates, and this aggregation produces colloidally stable particles.
[0988] In some embodiments, the nucleic acid can be non-covalently associated with the particle.In some embodiments, the nucleic acid can be adhered to the outer surface of the particle (surface nucleic acid) and / or can be contained within the particle (encapsulated nucleic acid).
[0989] The N / P ratio provides the ratio of the nitrogen groups in lipids to the number of phosphate groups in nucleic acids. It is relevant with charge ratio, because nitrogen atoms (depending on pH) are usually positively charged, and phosphate groups are negatively charged. When there is charge balance, the N / P ratio depends on pH. Lipid formulations are usually formed with N / P ratios greater than 4 to 12, because it is believed that positively charged nanoparticles are conducive to transfection. In this case, it is believed that nucleic acid is fully attached to nanoparticles.
[0990] A wide range of methods can be used to prepare the particles described herein. For example, a method for preparing nucleic acid particles can include obtaining a colloid from at least one cationic or cationically ionizable lipid and mixing the colloid with a nucleic acid to obtain the nucleic acid particle.
[0991] As used herein, the term "colloid" refers to a type of homogeneous mixture in which the dispersed particles do not settle. The insoluble particles in the mixture are microscopic, with particle sizes ranging from 1 to 1000 nanometers. This mixture can be referred to as a colloid or a colloidal suspension. Sometimes the term "colloid" refers only to the particles in the mixture, rather than the entire suspension.
[0992] For the preparation of colloids comprising at least one cationic or cationically ionizable lipid, conventional methods for preparing liposome vesicles and appropriately modified can be applied herein. The most common methods for preparing liposome vesicles share the following basic steps: (i) dissolving the lipid in an organic solvent, (ii) drying the resulting solution, and (iii) hydrating the dried lipid (using various aqueous media).
[0993] In the film hydration method, lipids are first dissolved in a suitable organic solvent and then dried to produce a thin film at the bottom of a flask. The lipid film obtained is hydrated using a suitable aqueous medium to produce a liposomal dispersion. In addition, an additional downsizing step may be included.
[0994] Reverse phase evaporation is an alternative method of membrane hydration for the preparation of liposome vesicles. It involves forming a water-in-oil emulsion between an aqueous phase and an organic phase containing lipids. This mixture is briefly sonicated to homogenize the system. Removal of the organic phase under reduced pressure produces a milky gel, which subsequently becomes a liposome suspension.
[0995] The term "ethanol injection technique" refers to a process in which an ethanol solution containing lipids is rapidly injected through a needle into an aqueous solution. This action disperses the lipids throughout the solution and promotes lipid structure formation, such as lipid vesicle formation such as liposome formation. Typically, lipoplex particles can be obtained by adding nucleic acids to a colloidal liposomal dispersion. In some embodiments, the ethanol injection technique is used to form such a colloidal liposomal dispersion by injecting an ethanol solution containing lipids (such as cationic or cationically ionizable lipids) and additional lipids into an aqueous solution under stirring.
[0996] The term "particle-forming component" or "particle-forming agent" refers to any component that forms a particle (e.g., by associating with a payload). Delivery vehicles (e.g., particle-forming agents) useful herein include polymers, polymer derivatives, lipids, e.g., as described herein, and mixtures thereof. Such components include any component that can become part of a nucleic acid particle, such as a cationic or cationically ionizable lipid.
[0997] polymer
[0998] In view of their high chemical flexibility, polymer is the common material for the delivery based on nanoparticle.Usually, cationic polymer is used for the electrostatic coagulation of negatively charged nucleic acid into nanoparticle.These positively charged groups are usually composed of amine, and described amine changes their protonation state within the pH range of 5.5-7.5, and it is believed that this causes ion imbalance, causes endosome rupture.Polymer such as poly-L-lysine, polyamidoamine (polyamidoamine), protamine and polyethyleneimine and naturally occurring polymer (such as chitosan) have all been applied to nucleic acid delivery, and are suitable as cationic polymers herein.In addition, some researchers have synthesized the polymer that is specifically designed for nucleic acid delivery.Especially, poly-(β-amino ester) has obtained widespread use in nucleic acid delivery due to its easy synthesis and biodegradability.This type of synthetic polymer is also suitable as cationic polymers herein.
[0999] As used herein, "polymer" has its usual meaning, i.e., a molecular structure comprising one or more repeating units (monomers) linked by covalent bonds. The repeating units may all be identical, or in some cases, more than one type of repeating unit may be present in a polymer. In some cases, the polymer is biologically derived, i.e., a biopolymer such as a protein. In some cases, additional moieties, such as targeting moieties, may also be present in the polymer.
[1000] If there are more than one type of repeating unit in a polymer, the polymer is referred to as a "copolymer". It should be understood that the polymers used herein can be copolymers. The repeating units that form the copolymer can be arranged in any manner. For example, the repeating units can be arranged in a random order, an alternating order, or as a "block" copolymer, that is, comprising one or more regions, each comprising a first repeating unit (e.g., a first block), and one or more regions, each comprising a second repeating unit (e.g., a second block), and so on. Block copolymers can have two (diblock copolymers), three (triblock copolymers), or more different blocks.
[1001] In certain embodiments, the polymer is biocompatible. A biocompatible polymer is one that generally does not cause significant cell death at moderate concentrations. In certain embodiments, the biocompatible polymer is biodegradable, that is, the polymer is capable of chemically and / or biologically degrading in a physiological environment, such as in vivo.
[1002] In certain embodiments, the polymer may be protamine or a polyalkyleneimine.
[1003] The term "protamine" refers to any of various relatively low molecular weight, strongly basic proteins that are rich in arginine and found in the sperm cells of various animals (such as fish) in association with DNA in place of somatic histones. In particular, the term "protamine" refers to proteins found in fish sperm that are strongly basic, soluble in water, do not coagulate upon heating, and yield primarily arginine upon hydrolysis. In purified form, they are used in long-acting formulations of insulin and to neutralize the anticoagulant effect of heparin.
[1004] According to the present disclosure, the term "protamine" as used herein is intended to encompass any protamine amino acid sequence obtained or derived from a natural or biological source, including fragments thereof and multimeric forms of said amino acid sequence or fragments thereof as well as (synthetic) polypeptides that are artificial, specifically designed for a specific purpose and cannot be isolated from a natural or biological source.
[1005] In some embodiments, the polyalkyleneimine comprises polyethyleneimine and / or polypropyleneimine, preferably polyethyleneimine. The preferred polyalkyleneimine is polyethyleneimine (PEI). The average molecular weight of PEI is preferably 0.75·10 2 -10 7 Da, preferably 1000-10 5 Da, more preferably 10000-40000 Da, more preferably 15000-30000 Da, even more preferably 20000-25000 Da.
[1006] Linear polyalkyleneimines such as linear polyethyleneimine (PEI) are preferred according to the present disclosure.
[1007] Cationic polymers (including polycationic polymers) contemplated for use herein include any cationic polymer capable of electrostatically binding to nucleic acids. In some embodiments, cationic polymers contemplated for use herein include any cationic polymer with which nucleic acids can associate, for example, by forming a complex with the nucleic acid or forming a vesicle that surrounds or encapsulates the nucleic acid.
[1008] The particles described herein may also comprise polymers other than cationic polymers, ie, non-cationic polymers and / or anionic polymers. Anionic polymers and neutral polymers are collectively referred to herein as non-cationic polymers.
[1009] Particles comprising nucleic acids are also referred to herein as "polyplexes (PLX)". Such PLXs may comprise a lipid component, e.g., a lipid component to which a compound is attached. Such particles containing polymers and lipids (e.g., functionalized lipids) are also referred to as lipidated polyplexes (LPLX).
[1010] Polyamine derivatives (Viromer)
[1011] In some embodiments, the delivery vehicle comprises a polyamine derivative, such as a carboxylated polyamine derivative. Polyamines form polycations in solution, which facilitate the formation of complexes with polyanions (such as nucleic acids).
[1012] In some embodiments, polyamine derivatives useful herein as delivery vehicles for polyanions include:
[1013] a polyamine moiety comprising a plurality of amino groups;
[1014] a plurality of carboxylated substituents comprising a carboxyl group bound to the amino group of the polyamine moiety via a hydrophobic linker; and
[1015] A plurality of hydrophobic substituents are bonded to the amino groups of the polyamine moiety.
[1016] In some embodiments, polyamine derivatives useful herein as delivery vehicles for polyanions include:
[1017] a polyamine moiety comprising a plurality of amino groups;
[1018] a plurality of carboxylated substituents comprising a carboxyl group bound to the amino group of the polyamine moiety via a hydrophobic linker, wherein each of the carboxylated substituents comprises 6 to 40 carbon atoms, preferably 6 to 20 carbon atoms, and more preferably 8 to 16 carbon atoms, and each of the hydrophobic linkers may comprise 1 to 3 heteroatoms selected from O, N, and S; and
[1019] A plurality of hydrophobic substituents bonded to the amino groups of the polyamine moieties, wherein each of the hydrophobic substituents comprises at least 2 carbon atoms, preferably 6 to 40 carbon atoms, and may comprise 1 to 3 heteroatoms selected from O, N, and S, provided that the hydrophobic substituents have at least 6 carbon atoms.
[1020] In some embodiments, each of the carboxylated substituents of the polyamine derivative comprises as the hydrophobic linker any one or more of the following moieties: alkylene, alkenylene, alkynylene, cycloalkylene, cycloalkenylene, arylene, and combinations thereof; and / or
[1021] Each of the hydrophobic substituents of the polyamine derivative comprises any one or more of the following moieties: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and combinations thereof.
[1022] In some embodiments, the polyamine derivatives useful herein as delivery vehicles for polyanions are polyalkyleneimine derivatives having one or more carboxyalkyl substituents containing 6-40 carbon atoms and one or more hydrophobic substituents selected from hydrocarbon substituents having at least 2 carbon atoms, preferably 6-40 carbon atoms, wherein each of the hydrophobic substituents can be or can contain an alkyl group and / or each of the hydrophobic substituents can be or can contain an aryl group.
[1023] In some embodiments, the polyalkylenimine is selected from polyethyleneimine, polypropyleneimine, and polybutyleneimine.
[1024] In some embodiments, the polyamine portion of the polyamine derivative may contain 4 to 20,000 nitrogen atoms, more preferably 6 to 10,000 nitrogen atoms, such as 6 to 1,000 nitrogen atoms, or 6 to 100 nitrogen atoms per polyamine molecule.
[1025] In some embodiments, the polyamine portion of the polyamine derivative may be a branched polyamine, preferably a branched polyalkyleneimine.
[1026] In some embodiments, the carboxylated substituent comprises one or two carboxyl groups, preferably one carboxyl group. In some embodiments, each carboxylated substituent comprises 6-40 carbon atoms, preferably 6-20 carbon atoms, and more preferably 8-16 carbon atoms. The hydrophobic linker of the carboxylated substituent may comprise 1-3, preferably 1 or 2 heteroatoms, and the heteroatoms are selected from O, N and S. Preferably, the heteroatoms are selected from O and S. In one embodiment, the hydrophobic linker may contain 1 or 2 heteroatoms, and the heteroatoms are selected from O, N and S, preferably O and S. Therefore, the carboxylated substituent may be a carboxylic alkyl, or may be a carboxylic heteroalkyl comprising 1-3 heteroatoms, the heteroatoms being selected from O, N and S, preferably selected from O and S.
[1027] The multiple carboxylated substituents of the polyamine derivative molecule may all be carboxyalkyl groups, all be carboxyheteroalkyl groups, or may be carboxyalkyl groups and carboxyheteroalkyl groups. In some embodiments, the multiple carboxylated substituents are all carboxyalkyl groups. In some embodiments, the multiple carboxylated substituents are all carboxyheteroalkyl groups.
[1028] When the carboxylated substituent is a carboxyalkyl, the hydrocarbyl portion of the carboxyalkyl can be a saturated aliphatic hydrocarbyl moiety, an unsaturated aliphatic hydrocarbyl moiety, an alicyclic hydrocarbyl moiety, an aromatic hydrocarbyl moiety, or a moiety comprising two or more moieties from the foregoing list.
[1029] Examples of carboxyalkyl groups are carboxyalkyl, carboxyalkenyl, carboxyalkynyl, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylcycloalkyl, carboxycycloalkylalkyl, carboxyalkylcycloalkylalkyl, carboxyaryl, carboxyalkylaryl, carboxyarylalkyl, and carboxyalkylarylalkyl. One, two, or three, preferably one or two, carbon atoms of the carboxylated substituent's hydrocarbyl portion may be replaced with oxygen, nitrogen, or sulfur to form a carboxyheterohydrocarbyl moiety. It will be understood that any such formal replacement by a heteroatom will include adjustment of the bound hydrogen atoms to accommodate the valence of the replaced heteroatom. In preferred embodiments, such carboxyheteroalkyl moieties comprise one or more functional groups in a hydrophobic linker selected from: -O-, -S-, -N(H)C(O)-, -C(O)O-, -OC(O)N(H)-, -C(O)-, -C(O)-N(H)-, -N(H)-C(O)-O-, -OC(O)-, or -SS-.
[1030] In some embodiments, the hydrophobic joint is or comprises an alkylene group, such as a linear or branched alkylene group, or the joint is or comprises a cycloalkylene group. The alkylene group can be a normal alkylene group or an isoalkylene group. Examples of alkylene groups are propylene, butylene, pentylene, hexylene, heptylene, octylene, nonylene, decylene, undecylene, dodecylene, tetradecylene or hexadecylene. Examples of cycloalkylene groups are cyclopentylene, cyclohexylene and cycloheptylene. Examples of alkylcycloalkyl groups are methylcyclopentylene, ethylcyclopentylene, propylcyclopentylene, butylcyclopentylene, pentylcyclopentylene, hexylcyclopentylene, methylcyclohexylene, ethylcyclohexylene, propylcyclohexylene, butylcyclohexylene, pentylcyclohexylene and hexylcyclohexylene. One or more of these can be combined in the hydrophobic joint.
[1031] In some embodiments, the carboxylated substituent is or comprises carboxyalkyl or carboxycycloalkyl, and described carboxyalkyl or carboxycycloalkyl comprise 6-20 carbon atom.This type of carboxylated substituent can be selected from carboxyl-n-alkyl, branched carboxyalkyl or cyclic carboxyalkyl and structural isomer or conformational isomer thereof.In preferred embodiments, carboxyalkyl is an acid radical, and described acid is selected from hexanoic acid, enanthic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tetradecanoic acid, hexadecanoic acid, 2-cyclohexyl acetic acid, 4-cyclohexylbutyric acid, 6-cyclohexyl hexanoic acid, 2-(2 ', 3 ' or 4 ' ethylcyclohexyl)-acetic acid or 4-(2 ', 3 ' or 4 ' ethylcyclohexyl)-butyric acid or 6-(2 ', 3 ' or 4 ' ethylcyclohexyl)-hexanoic acid.
[1032] In some embodiments, the hydrophobic linker is or comprises an arylene group, and has 6-20 carbon atoms. The aryl forming the arylene group includes aromatic hydrocarbon groups (only carboaryl) and aromatic heteroalkyl groups (heteroaryl). The former example is phenyl, naphthyl, anthracenyl and phenanthrenyl. In some embodiments, the pK value of nitrogen-containing heteroaryl is less than 5, to avoid extra cationic charge at neutral pH. The example of such nitrogen-containing heteroaryl is indole, pyrazinyl, pyridazinyl, pyrimidinyl, cinnolinyl (cinnolinyl), phthalazinyl and purinyl. In some embodiments, the pK value of the oxygen-containing heteroalkyl forming hydroxyl group is greater than 12, to avoid the negative charge at neutral pH.
[1033] Examples of alkylaryl groups are methylphenyl (tolyl), ethylphenyl, 4-isopropylphenyl and xylyl. Examples of arylalkyl (aralkyl) groups are benzyl, phenylethyl and trityl. Examples of alkylarylalkyl groups are methylbenzyl and 4-isopropylbenzyl. The carboxyarylalkyl moiety can, for example, be a group derived from o-, m- or p-toluic acid or o-, m- or p-ethylbenzoic acid. The carboxyalkylarylalkyl moiety can, for example, be o-, m- or p-tolueneacetic acid. The carboxyalkenylarylalkyl moiety can, for example, be or be derived from o-, m- or p-methylcinnamic acid.
[1034] Multiple carboxylated substituents present on a polyamine derivative (e.g., those that are or contain carboxyalkyl groups) may be the same or different. For simplicity, they may be the same. The carboxyl group of the carboxylated substituent may be bound to any carbon atom of the hydrophobic linker. Preferably, the carboxyl group is bound to a carbon atom as follows: if z is the number of carbon atoms in the longest carbon chain of the carboxylated substituent (e.g., carboxyalkyl group) bound to a carbon atom of a polyamine nitrogen atom, then, if the carbon atom bound to the polyamine nitrogen is designated as position 1, the carboxyl group is bound to a carbon atom that is more than z / 2 atoms away from the polyamine nitrogen. If the value of z / 2 is not an integer, the above definition is applied to the position defined by the next integer greater than z / 2. In one embodiment, the carboxyl group is bound to a carbon atom of the hydrophobic linker that is furthest (in terms of carbon number) from the polyamine nitrogen atom to which the hydrophobic linker (in the case of a carboxyalkyl group, an alkylene chain) is attached. The carboxyl group may be bonded to the carbon atom within the carboxylated substituent (or carboxyalkyl group) furthest from the polyamine nitrogen, such as, in the case of a linear carboxylated substituent, to the terminal (ω position) carbon atom of the carboxylated substituent (or carboxyalkyl group).
[1035] In some embodiments, the hydrophobic substituent comprises 2-40 carbon atoms, in some embodiments 3-40 carbon atoms, in some embodiments 6-40 carbon atoms, and in some embodiments 6-20 carbon atoms. The hydrophobic substituent may comprise 1-3, preferably 1 or 2 heteroatoms, the heteroatoms being selected from O, N and S, provided that the hydrophobic substituent comprises 6 or more carbon atoms. Preferably, the heteroatoms are selected from O and S. Therefore, the hydrophobic substituent can be a hydrocarbon group or a heteroalkyl group, the latter comprising 1-3 heteroatoms as described above. Among the multiple hydrophobic substituents of the polyamine derivative molecule, all can be hydrocarbon groups, all can be heteroalkyl groups, or can be hydrocarbon groups and heteroalkyl groups. In some embodiments, all of the multiple hydrophobic substituents are hydrocarbon groups. In some embodiments, all of the multiple hydrophobic substituents are heteroalkyl groups.
[1036] When the hydrophobic substituent is a hydrocarbyl, they can be selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkylalkyl, aryl, alkylaryl, arylalkyl, alkylarylalkyl and a group comprising two or more groups from the above list. 1, 2 or 3 of the carbon atoms of the hydrocarbyl can be replaced with oxygen, nitrogen or sulphur (preferably oxygen or sulphur) to form a heteroalkyl substituent, provided that the hydrophobic substituent comprises 6 or more carbon atoms. Such heteroalkyl substituents can comprise a functional group selected from -O-, -S-, -N(H)C(O)-, -C(O)O-, -OC(O)N(H)-, -C(O)-, -C(O)-N(H)-, -N(H)-C(O)-O-, -OC(O)- or -SS-.
[1037] In some embodiments, the hydrophobic substituent is or comprises an alkyl group, such as a straight or branched chain alkyl group, or a cycloalkyl group. The alkyl group can be a normal alkyl group or an isoalkyl group. Examples of alkyl groups are propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, or hexadecyl. Examples of cycloalkyl groups are cyclopentyl, cyclohexyl, and cycloheptyl.
[1038] Examples of alkenyl groups are propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tetradecenyl and hexadecenyl. Examples of alkynyl groups are propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, undecynyl, dodecynyl, tetradecynyl and hexadecynyl.
[1039] Examples of cycloalkenyl groups are cyclopentenyl, cyclohexenyl, and cycloheptenyl. Cycloalkylalkyl groups are groups in which a cycloalkyl group is attached to an alkylene group corresponding to an alkyl group. Examples are cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, and the like.
[1040] Alkylcycloalkyl is a group in which an alkyl group is attached to the corresponding cycloalkylene group of the cycloalkyl group. Examples of alkylcycloalkyl are methylcyclopentyl, ethylcyclopentyl, propylcyclopentyl, butylcyclopentyl, pentylcyclopentyl, hexylcyclopentyl, methylcyclohexyl, ethylcyclohexyl, propylcyclohexyl, butylcyclohexyl, pentylcyclohexyl and hexylcyclohexyl.
[1041] Alkylcycloalkylalkyl is a group in which an alkyl group is attached to a cycloalkylalkylene group.
[1042] In some embodiments, the hydrophobic substituent comprises an aryl group and has 6-20, preferably 7-15 carbon atoms. Aryl includes aromatic hydrocarbon groups (aryl groups of only carbon) and aromatic heteroalkyl groups (heteroaryl groups). Examples of the former are phenyl, naphthyl and phenanthrenyl. In some embodiments, the pK value of nitrogen-containing heteroaryl groups is less than 5, to avoid extra cationic charge at neutral pH. Examples of such nitrogen-containing heteroaryl groups are indole, pyrazinyl, pyridazinyl, pyrimidinyl, cinnozinyl, phthalazinyl and purinyl. In some embodiments, the pK value of the oxygen-containing heteroalkyl groups forming hydroxyl groups is greater than 12, to avoid negative charge at neutral pH.
[1043] Examples of alkylaryl groups are methylphenyl (tolyl), ethylphenyl, 4-isopropylphenyl, methylindolyl, and xylyl. Examples of arylalkyl (aralkyl) groups are benzyl, phenethyl, indolemethyl, and trityl. Examples of alkylarylalkyl groups are methylbenzyl and 4-isopropylbenzyl.
[1044] The different hydrophobic substituents on the polyamine derivative molecule may be the same or different. For simplicity, they may be the same.
[1045] In some embodiments, the polyamine derivative has a linear polyethyleneimine portion of 2-500 kDa (in terms of number average molecular weight), the carboxylated substituent has 10-16 carbon atoms and is an n-alkyl carboxylic acid, and the hydrophobic substituent has 1-12 carbon atoms and is an alkyl group, preferably an n-alkyl group, and / or an alkylarylalkyl group.
[1046] In some embodiments, the polyamine derivative has a branched polyethyleneimine portion of 0.5-200 kDa (in terms of number average molecular weight), the carboxylated substituent has 10-16 carbon atoms and is an n-alkyl carboxylic acid, and the hydrophobic substituent has 1-12 carbon atoms and is an alkyl group, preferably an n-alkyl group, and / or an alkylarylalkyl group.
[1047] lipids
[1048] As used herein, the terms "lipid" and "lipid-like substance" are broadly defined as molecules comprising one or more hydrophobic moieties or groups and optionally one or more hydrophilic moieties or groups. Molecules comprising a hydrophobic moiety and a hydrophilic moiety are also often referred to as amphiphilic molecules. Lipids are generally insoluble or poorly soluble in water, but are soluble in many organic solvents. In aqueous environments, the amphiphilic nature allows the molecules to self-assemble into organized structures and different phases. One of these phases consists of a lipid bilayer, as they are present in vesicles, multilamellar / unilamellar liposomes, or membranes in an aqueous environment. Hydrophobicity can be imparted by including non-polar groups, including but not limited to long-chain saturated and unsaturated aliphatic hydrocarbon groups, and such groups substituted with one or more aromatic, alicyclic, or heterocyclic groups. The hydrophilic group can contain polar and / or charged groups, and includes carbohydrates, phosphates, carboxyls, sulfates, amino groups, sulfhydryls, nitro groups, hydroxyl groups, and other similar groups.
[1049] As used herein, the term "hydrophobic" refers to any molecule, moiety, or group that is substantially immiscible or insoluble in aqueous solution. The term hydrophobic group includes hydrocarbons having at least 6 carbon atoms. A monovalent group of a hydrocarbon is referred to herein as a hydrocarbyl. A hydrophobic group may have functional groups (e.g., ethers, esters, halides, etc.) and atoms other than carbon and hydrogen, as long as the group satisfies the condition of being substantially immiscible or insoluble in aqueous solution.
[1050] The term "hydrocarbon" includes non-cyclic, for example, linear (straight chain) or branched hydrocarbon groups, such as alkyl, alkenyl or alkynyl groups as defined herein. It should be understood that one or more of the hydrogen atoms in an alkyl, alkenyl or alkynyl group may be replaced by other atoms (e.g., halogen, oxygen or sulfur). Unless otherwise indicated, hydrocarbon groups may also include cyclic (alkyl, alkenyl or alkynyl) groups or aryl groups, provided that the overall polarity of the hydrocarbon remains relatively non-polar.
[1051] The term "alkyl" refers to a saturated, linear or branched, monovalent hydrocarbon moiety having 1 to 30, typically 1 to 20, and often 6 to 18 carbon atoms. Exemplary non-polar alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, hexyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, and the like.
[1052] The term "alkenyl" refers to a linear or branched monovalent hydrocarbon moiety having at least one carbon-carbon double bond, wherein the total carbon atoms can be 2-30, typically 6-20, and often 6-18. Typically, the maximum number of carbon-carbon double bonds in an alkenyl group can be equal to the integer calculated by dividing the number of carbon atoms in the alkenyl group by 2, and if the number of carbon atoms in the alkenyl group is an odd number, the division result is rounded down to the nearest integer. For example, for an alkenyl group having 9 carbon atoms, the maximum number of carbon-carbon double bonds is 4. Preferably, the alkenyl group has 1-6 (e.g., 1-4), i.e., 1, 2, 3, 4, 5, or 6 carbon-carbon double bonds.
[1053] The term "alkynyl" refers to a linear or branched monovalent hydrocarbon moiety having at least one carbon-carbon triple bond, wherein the total carbon atoms can be 2-30, typically 6-20, often 6-18. An alkynyl group may optionally have one or more carbon-carbon double bonds. Typically, the maximum number of carbon-carbon triple bonds in an alkynyl group can be equal to the integer calculated by dividing the number of carbon atoms in the alkynyl group by 2, and if the number of carbon atoms in the alkynyl group is an odd number, the division result is rounded down to the nearest integer. For example, for an alkynyl group with 9 carbon atoms, the maximum number of carbon-carbon triple bonds is 4. Preferably, an alkynyl group has 1-6 (e.g., 1-4), i.e., 1, 2, 3, 4, 5 or 6, more preferably 1 or 2 carbon-carbon triple bonds.
[1054] The term "alkylene" refers to a saturated linear or branched divalent hydrocarbon moiety having 1 to 30, typically 2 to 20, and often 4 to 12 carbon atoms. Exemplary non-polar alkylene groups include, but are not limited to, methylene, ethylene, trimethylene, hexamethylene, decamethylene, dodecamethylene, tetradecamethylene, hexadecamethylene, octadecamethylene, and the like.
[1055] The term "alkenylene" refers to a linear or branched divalent hydrocarbon moiety having at least one carbon-carbon double bond, wherein the total carbon atoms may be 2-30, typically 2-20, and often 4-12. Typically, the maximum number of carbon-carbon double bonds in an alkenylene group can be equal to the integer calculated by dividing the number of carbon atoms in the alkenylene group by 2, and if the number of carbon atoms in the alkenylene group is an odd number, the result of the division is rounded down to the nearest integer. For example, for an alkenylene group having 9 carbon atoms, the maximum number of carbon-carbon double bonds is 4. Preferably, the alkenylene group has 1-6 (e.g., 1-4), i.e., 1, 2, 3, 4, 5, or 6 carbon-carbon double bonds.
[1056] The term "alkynylene" refers to a linear or branched divalent hydrocarbon moiety having at least one carbon-carbon triple bond, wherein the total carbon atoms may be 2 to 30, typically 2 to 20, and often 4 to 12. Alkynyl groups may optionally have one or more carbon-carbon double bonds.
[1057] The term "cycloalkyl" represents the cyclic non-aromatic forms of "alkyl" and "alkenyl", preferably having 3-14 carbon atoms, such as 3-12 or 3-10 carbon atoms, that is, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms (such as 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms), more preferably 3-7 carbon atoms. Exemplary cycloalkyls include cyclopropyl, cyclopropenyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, cyclononyl, cyclononenyl, cyclododecyl, cyclododecenyl and adamantyl. Cycloalkyl can be composed of one ring (monocycle), two rings (bicycle) or more than two rings (polycycle).
[1058] The term "aryl" refers to a monovalent group of an aromatic cyclic hydrocarbon. Preferably, the aryl group contains 3-14 (e.g., 5, 6, 7, 8, 9 or 10, such as 5, 6 or 10) carbon atoms, which can be arranged into a ring (e.g., phenyl) or two or more condensed rings (e.g., naphthyl). Exemplary aryl groups include cyclopropenyl, cyclopentadienyl, phenyl, indenyl, naphthyl, azulenyl, fluorenyl, anthracenyl and phenanthrenyl. Preferably, "aryl" refers to a monocycle containing 6 carbon atoms or an aromatic bicyclic system containing 10 carbon atoms. Preferred examples are phenyl and naphthyl. Fullerenes are not encompassed by aryl groups.
[1059] The term "aromatic" as used in the context of hydrocarbons means that the entire molecule must be aromatic. For example, if a monocyclic aromatic group is hydrogenated (partially or completely), the resulting hydrogenated cyclic structure is classified as a cycloalkyl for the purposes of this disclosure. Similarly, if a bicyclic or polycyclic aromatic group (such as naphthyl) is hydrogenated, the resulting hydrogenated bicyclic or polycyclic structure (such as 1,2-dihydronaphthyl) is classified as a cycloalkyl for the purposes of this disclosure (even though one ring (such as in 1,2-dihydronaphthyl) is still aromatic).
[1060] As used herein, the term "amphiphilic" refers to a molecule having a polar portion and a non-polar portion. Typically, an amphiphilic compound has a polar head attached to a long hydrophobic tail. In some embodiments, the polar portion is soluble in water, while the non-polar portion is insoluble in water. In addition, the polar portion can have a formal positive charge or a formal negative charge. Alternatively, the polar portion can have a formal positive charge and a formal negative charge and be a zwitterion or an inner salt. For the purposes of this disclosure, the amphiphilic compound can be, but is not limited to, one or more natural or non-natural lipids and lipid-like compounds.
[1061] The term "lipid-like substance", "lipid-like compound" or "lipid-like molecule" refers to substances that are structurally and / or functionally related to lipids but that may not be considered lipids in the strict sense, in particular amphiphilic substances. For example, the term includes compounds that are capable of forming an amphiphilic layer when present in a vesicle, multilamellar / unilamellar liposome or membrane in an aqueous environment, and includes surfactants or synthetic compounds having hydrophilic and hydrophobic parts. In general, the term includes molecules that contain hydrophilic and hydrophobic parts with different structural organizations, which may be similar or dissimilar to the lipid structural organization. Examples of lipid-like compounds that can spontaneously integrate into cell membranes include functional lipid constructs such as synthetic function-spacer-lipid constructs (FSLs), synthetic function-spacer-sterol constructs (FSSs) and artificial amphiphilic molecules. Lipids containing two long alkyl chains and a polar head group are generally cylindrical. The area occupied by the two alkyl chains is similar to the area occupied by the polar head group. Such lipids have low solubility as monomers and tend to aggregate into planar bilayers that are insoluble in water. Conventional surfactant monomers containing only one linear alkyl chain and one hydrophilic head group are generally tapered. The hydrophilic head group tends to take up more molecular space than the linear alkyl chain. In some embodiments, surfactants tend to aggregate into water-soluble spherical or elliptoid micelles. Although lipids also have the same general structure as surfactants - a polar hydrophilic head group and a non-polar hydrophobic tail - lipids differ from surfactants in the shape of the monomer, the type of aggregates formed in solution, and the concentration range required for aggregation. As used herein, the term "lipid" is interpreted to encompass lipids and lipid-like substances, unless otherwise specified herein or clearly contradicted by the context.
[1062] In general, lipids can be divided into 8 categories: fatty acids, glycerolipids, glycerophospholipids, sphingolipids, glycolipids, polyketides (derived from the condensation of ketoacyl subunits), sterol lipids and prenol lipids (derived from the condensation of isoprene subunits). Although the term "lipid" is sometimes used as a synonym for fat, fat is a subclass of lipids, known as triglycerides. Lipids also encompass molecules such as fatty acids and derivatives thereof (including triglycerides, diglycerides, monoglycerides and phospholipids), and steroids, i.e., sterol-containing metabolites, such as cholesterol or its derivatives. Examples of cholesterol derivatives include, but are not limited to, cholestanol, cholestanone, cholesterenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-4'-hydroxybutyl ether, tocopherol and derivatives thereof, and mixtures thereof.
[1063] Fatty acids, or fatty acid residues, are a group of different molecules formed by a hydrocarbon chain terminating in a carboxylic acid group; this arrangement gives the molecule a polar, hydrophilic end, and a nonpolar, hydrophobic end that is insoluble in water. The carbon chain, typically 4-24 carbons in length, can be saturated or unsaturated and can be attached to functional groups containing oxygen, halogens, nitrogen, and sulfur. If a fatty acid contains a double bond, it can have cis or trans geometric isomers, which significantly affect the configuration of the molecule. Cis double bonds cause the fatty acid chain to bend, an effect exacerbated by more cis double bonds in the chain. The other major lipid classes within the fatty acid class are fatty esters and fatty amides.
[1064] Glycerolipids are composed of mono-, di- and tri-substituted glycerols, the most famous being the fatty acid triesters of glycerol, known as triglycerides. The term "triacylglycerol" is sometimes used synonymously with "triglyceride." In these compounds, the three hydroxyl groups of glycerol are typically esterified with different fatty acids. Another subclass of glycerolipids is represented by glycerol glucosides, which are characterized by the presence of one or more sugar residues attached to the glycerol via a glycosidic bond.
[1065] Glycerophospholipids are amphipathic molecules (containing hydrophobic and hydrophilic regions) that contain a glycerol core linked by ester bonds to two fatty acid-derived "tails" and by a phosphate bond to a "head" group. Examples of glycerophospholipids, commonly referred to as phospholipids (although sphingomyelin is also classified as a phospholipid), are phosphatidylcholine (also known as PC, GPCho, or phosphatidylcholine), phosphatidylethanolamine (PE or GPEtn), and phosphatidylserine (PS or GPSer).
[1066] Sphingolipids are a complex family of compounds that share a common structural feature, the sphingoid base backbone. The major sphingoid base in mammals is commonly referred to as sphingosine. Ceramides (N-acyl-sphingoid bases) are the major subclass of sphingoid base derivatives, which have amide-linked fatty acids. Fatty acids are typically saturated or monounsaturated, with chain lengths of 16-26 carbon atoms. The major phospho-sphingolipid in mammals is sphingomyelin (ceramide phosphocholine), while insects primarily contain ceramide phosphoethanolamine, and fungi have phytoceramide phosphoinositol and a mannose-containing head group. Glycosphingolipids are a diverse family of molecules composed of one or more sugar residues attached to a sphingoid base via a glycosidic bond. Examples of these include simple and complex glycosphingolipids such as cerebrosides and gangliosides.
[1067] Sterol lipids, such as cholesterol and its derivatives, or tocopherol and its derivatives, together with glycerophospholipids and sphingomyelin, are important components of membrane lipids.
[1068] Glycolipids describe compounds in which fatty acids are directly attached to a sugar backbone, forming a structure compatible with the membrane bilayer. In glycolipids, monosaccharides replace the glycerol backbone present in glycerolipids and glycerophospholipids. The most familiar glycolipids are the acylated glucosamine precursors of the lipid A component of lipopolysaccharides in Gram-negative bacteria. The typical lipid A molecule is a disaccharide of glucosamine, which is derived from up to seven fatty-acyl chains. The minimal lipopolysaccharide required for growth in Escherichia coli (E. coli) is Kdo2-lipid A, a hexaacylated disaccharide of glucosamine glycosylated with two 3-deoxy-D-manno-octulosonic acid (Kdo) residues.
[1069] Polyketides are synthesized by polymerization of acetyl and propionyl subunits via classical enzymes as well as iterative and multimodular enzymes that share mechanistic features with fatty acid synthases. They comprise a vast array of secondary metabolites and natural products from animal, plant, bacterial, fungal, and marine sources and exhibit considerable structural diversity. Many polyketides are cyclic molecules whose backbones are often further modified by glycosylation, methylation, hydroxylation, oxidation, or other processes.
[1070] According to the present disclosure, lipids and lipid-like substances can be cationic, anionic or neutral. Neutral lipids or lipid-like substances exist as uncharged or neutral zwitterionic forms at a selected pH.
[1071] Cationic / cation-ionizable lipids
[1072] In some embodiments, particles described herein, e.g., nucleic acid particles, comprise at least one cationic or cationically ionizable lipid as a particle-forming agent.
[1073] Cationic or cationically ionizable lipids contemplated for use herein include any cationic or cationically ionizable lipid (including lipid-like substances) that can electrostatically bind to nucleic acids. In some embodiments, cationic or cationically ionizable lipids contemplated for use herein can associate with nucleic acids, for example, by forming a complex with the nucleic acid or forming a vesicle that surrounds or encapsulates the nucleic acid therein.
[1074] As used herein, "cationic lipid" refers to a lipid or lipid-like substance having a net positive charge. Typically, a cationic lipid has a lipophilic portion, such as a sterol, an acyl chain, a diacyl chain, or a chain of more acyl groups, and the head group of the lipid typically carries a positive charge.
[1075] In some embodiments, the cationic lipid has a net positive charge only at certain pH, particularly at acidic pH, whereas at a different, preferably higher pH, such as physiological pH, it preferably has no net positive charge, preferably no charge, i.e., it is neutral. Compared to particles that remain cationic at physiological pH, it is believed that this ionizable property enhances efficacy by facilitating endosomal escape and reducing toxicity.
[1076] As used herein, "cationically ionizable lipid" refers to a lipid or lipid-like substance that has a net positive charge or is neutral, i.e., it is not permanently cationic. Thus, depending on the pH of the composition in which the cationically ionizable lipid is dissolved, the cationically ionizable lipid is either positively charged or neutral. For the purposes of this disclosure, unless inconsistent with the context, the term "cationic lipid" encompasses cationically ionizable lipids.
[1077] In some embodiments, the cationic or cationically ionizable lipid comprises a head group that includes at least one nitrogen atom (N) that is positively charged or capable of protonation, eg, under physiological conditions.
[1078] Examples of cationic or cationically ionizable lipids include, but are not limited to, N,N-dimethyl-2,3-dioleyloxypropylamine (DODMA), 1,2-dioleoyl-3-trimethylammonium propane (DOTAP); 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTAP); propane (DOTMA), 3-(N—(N′,N′-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), dimethyldioctadecylammonium (DDAB); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-diacyloxy-3-dimethylammonium propane; 1,2-dialkyloxy-3-dimethylammonium propane; dioctadecyldimethyl ammonium chloride chloride (DODAC), 1,2-distearyloxy-N,N-dimethyl-3-aminopropane (DSDMA), 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium (DMRIE), 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC), l,2-dimyristoyl-3-trimethylammonium propane (DMTAP), 1,2-dioleyloxypropyl-3-dimethyl-hydroxyethylammonium bromide (1,2-dimethylaminopropyl-3-hydroxyethylammonium bromide).2-dioleyloxypropyl-3-dimethyl-hydroxyethylammonium bromide (DORIE), 2,3-dioleoyloxy-N-[2(spermine carboxamide)ethyl]-N,N-dimethyl-l-propanamium trifluoroacetate (DOSPA), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), dioctadecylamidoglycyl spermine spermine (DOGS), 3-dimethylamino-2-(cholest-5-en-3-beta-oxybutan-4-oxy)-1-(cis,cis-9,12-octadecadienoxy)propane (CLinDMA), 2-[5′-(cholest-5-en-3-beta-oxy)-3′-oxapentoxy)-3-dimethyl-1-(cis,cis-9′,12′-octadecadienoxy)propane (2-[5′-(cholest-5-en-3-beta-oxy)-3′-oxapentoxy)-3- dimethyl-1-(cis,cis-9′,12′-octadecadienoxy)propane, CpLinDMA), N,N-dimethyl-3,4-dioleyloxybenzylamine (DMOBA), 1,2-N,N′-dioleylcarbamyl-3-dimethylaminopropane (DOcarbDAP), 2,3-Dilinoleoyloxy-N,N-dimethylpropylamine (DLinDAP), 1,2-N,N′-dioleylcarbamyl-3-dimethylaminopropane (DOcarbDAP), 2,3-Dilinoleoyloxy-N,N-dimethylpropylamine (DLinDAP), 1,2-N,1,2-N,N'-Dilinoleylcarbamyl-3-dimethylaminopropane (DLincarbDAP), 1,2-Dilinoleoylcarbamyl-3-dimethylaminopropane (DLinCDAP), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-K-DMA), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-K-DMA), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane n-K-XTC2-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate (DLin-MC3-DMA), N-(2-Hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide bromide, DMRIE), (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyloxy)-1-propanaminium bromide (GAP-DMORIE), (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyloxy)-1-propanaminium bromide (GAP-DMORIE), (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide (GAP-DMORIE), (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide3-bis(dodecyloxy)-1-propanaminium bromide, GAP-DLRIE), (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide, GAP-DMRIE), N-(2-Aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bromide, bromide, βAE-DMRIE), N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propan-1-aminium (DOBAQ), 2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl- 3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine, Octyl-CLinDMA), 1,2-dimyristoyl-3 1,2-dimyristoyl-3-dimethylammonium-propane (DMDAP), 1,2-dipalmitoyl-3-dimethylammonium-propane (DPDAP), N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide (MVL5), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 2,3-bis(dodecyloxy)-N-(2-hydroxyethyl)-N,N-dimethylpropan-1-amonium bromide (DLRIE), N-(2-aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)propan-1-aminium bromide (DLRIE), bromide, DMORIE), di((Z)-non-2-en-1-yl)8,8'-((((2(dimethylamino)ethyl)thio)carbonyl)azanediyl)dioctanoate (ATX), N,N-dimethyl-2,3-bis(dodecyloxy)propan-1-amine (DLDMA), N,N-dimethyl-2,3-bis(dodecyloxy)propan-1-amine (DLDMA), N,N-dimethyl-2,3-bis(tetra ...3-bis(tetradecyloxy)propan-1-amine, DMDMA), Di((Z)-non-2-en-1-yl)-9-((4-(dimethylaminobutanoyl)oxy)heptadecanedioate (L319), N-dodecyl-3-((2-dodecylcarbamoyl-ethyl)-{2-[(2-dodecylcarbamoyl-ethyl)-2-{(2-dodecylcarbamoyl- N-Dodecyl-3-((2-dodecylcarbamoyl-ethyl)-{2-[(2-dodecylcarbamoyl-ethyl)-2-{(2-dodecylcarbamoyl-ethyl)-[2-(2-dodecylcarbamoyl-ethylamino)-ethyl]-amino}-ethylamino)propionamide, lipidoid 98N, 12 -5), 1-[2-[bis(2-hydroxydodecyl)amino]ethyl-[2-[4-[2-[bis(2hydroxydodecyl)amino]ethyl]piperazin-1-yl]ethyl]amino]dodecan-2-ol (1-[2-[bis(2-hydroxydodecyl)amino]ethyl-[2-[4-[2-[bis(2hydroxydodecyl)amino]ethyl]piperazin-1-yl]ethyl]amino]dodecan-2-ol, lipidoid C12-200).
[1079] In some embodiments, the cationic or cationically ionizable lipid is DOTMA. In some embodiments, the cationic or cationically ionizable lipid is DODMA.
[1080] DOTMA is a cationic lipid with a quaternary amine head group. The structure of DOTMA can be shown as follows:
[1081]
[1082] DODMA is an ionizable cationic lipid with a tertiary amine head group. The structure of DODMA can be shown as follows:
[1083]
[1084] In some embodiments, the cationic or cationically ionizable lipids may comprise about 10 mol% to about 95 mol%, about 20 mol% to about 95 mol%, about 20 mol% to about 90 mol%, about 30 mol% to about 90 mol%, about 40 mol% to about 90 mol%, or about 40 mol% to about 80 mol% of the total lipids present in the particle.
[1085] Additional lipids
[1086] Particles described herein, for example nucleic acid particles, can also include lipids (including lipid-like substances) other than cations or ionizable lipids (also referred to herein as cationic lipids), that is, non-cationic lipids (including non-cationic lipids or non-cationic lipids or lipid-like substances). Anions and neutral lipids or lipid-like substances are collectively referred to herein as non-cationic lipids. By adding other hydrophobic moieties such as cholesterol and lipids other than cations or ionizable lipids, the preparation of nucleic acid particles can be optimized to enhance particle stability and the effectiveness of nucleic acid delivery.
[1087] One or more additional lipids may or may not affect the overall charge of the nucleic acid particle. In some embodiments, one or more additional lipids are non-cationic lipids or lipid-like substances. The non-cationic lipids may comprise, for example, one or more anionic lipids and / or neutral lipids. As used herein, "anionic lipids" refers to any lipid with a negative charge at a selected pH. As used herein, "neutral lipids" refers to any of a variety of lipid species that exist in an uncharged or neutral zwitterionic form at a selected pH.
[1088] In some embodiments, the nucleic acid particles described herein comprise a cationic or cationically ionizable lipid and one or more additional lipids.
[1089] Without wishing to be bound by theory, the amount of the cation or cation-ionizable lipid compared to the amount of one or more additional lipids may affect important characteristics of the nucleic acid particle, such as charge, particle size, stability, tissue selectivity, and biological activity of the nucleic acid. Thus, in some embodiments, the molar ratio of the cation or cation-ionizable lipid to the one or more additional lipids is from about 10:0 to about 1:9, from about 4:1 to about 1:2, from about 4:1 to about 1:1, from about 3:1 to about 1:1, or from about 3:1 to about 2:1.
[1090] In some embodiments, the one or more additional lipids included in the nucleic acid particles described herein comprise one or more of the following: a neutral lipid, a steroid, and combinations thereof.
[1091] In some embodiments, one or more additional lipids include neutral lipids, which are phospholipids. In some embodiments, phospholipids are selected from phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, and sphingomyelin. Specific phospholipids that can be used include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, and sphingomyelin. Such phospholipids include in particular diacylphosphatidylcholine, such as distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipentadecanoylphosphatidylcholine, dilauroylphosphatidylcholine, dipalmitoylphosphatidylcholine, atidylcholine, DPPC), diarachidoylphosphatidylcholine (DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), dilignoceroylphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine, 18:0Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16Lyso PC) and phosphatidylethanolamine, especially diacylphosphatidylethanolamine, such as dioleoylphosphatidylethanolamine (DOPE), distearoyl-phosphatidylethanolamine (DSPE), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoy-phosphatidylethanolamine (DPEE), and diacylphosphatidylethanolamine (DPEE). l-phosphatidylethanolamine, DMPE), dilauroyl-phosphatidylethanolamine (DLPE), diphytanoyl-phosphatidylethanolamine (DPyPE), 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine (DOPG), 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol, DPPG), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, POPE), N-palmitoyl-D-erythro-sphingosylphosphorylcholine (N-palmitoyl-D-erythro-sphingosylphosphorylcholine, SM), and other phosphatidylethanolamine lipids with different hydrophobic chains. In some embodiments, the neutral lipid is selected from DSPC, DOPC, DMPC, DPPC, POPC, DOPE, DOPG, DPPG, POPE, DPPE, DMPE, DSPE and SM. In some embodiments, the neutral lipid is selected from DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM. In some embodiments, the neutral lipid is DSPC. In some embodiments, the neutral lipid is DOPE.
[1092] In some embodiments, the additional lipid comprises one of the following: (1) a phospholipid, (2) cholesterol or a derivative thereof; or (3) a mixture of a phospholipid and cholesterol or a derivative thereof. Examples of cholesterol derivatives include, but are not limited to, cholestanol, cholestanone, cholestenone, coprostanol, cholesteryl-2'-hydroxyethyl ether, cholesteryl-4'-hydroxybutyl ether, tocopherol and derivatives thereof, and mixtures thereof.
[1093] Thus, in some embodiments, the nucleic acid particles described herein comprise (1) a cationic or cationically ionizable lipid, and a phospholipid (such as DSPC or DOPE) or (2) a cationic or cationically ionizable lipid and a phospholipid (such as DSPC or DOPE) and cholesterol.
[1094] In some embodiments, the nucleic acid particles described herein comprise (1) DOTMA and DOPE, (2) DOTMA, DOPE, and cholesterol (3) DODMA and DOPE, or (4) DODMA, DOPE, and cholesterol.
[1095] DSPC is a neutral phospholipid. The structure of DSPC can be shown as follows:
[1096]
[1097] DOPE is a neutral phospholipid. The structure of DOPE can be shown as follows:
[1098]
[1099] The structure of cholesterol can be seen as follows:
[1100]
[1101] In some embodiments, the nucleic acid particles described herein do not include polymer-conjugated lipids, such as PEGylated lipids.
[1102] In some embodiments, the additional lipids (e.g., one or more phospholipids and / or cholesterol) can comprise about 0 mol% to about 90 mol%, about 0 mol% to about 80 mol%, about 2 mol% to about 80 mol%, about 5 mol% to about 80 mol%, about 5 mol% to about 60 mol%, about 5 mol% to about 50 mol%, about 7.5 mol% to about 50 mol%, or about 10 mol% to about 40 mol% of the total lipids present in the particle. In some embodiments, the additional lipids (e.g., one or more phospholipids and / or cholesterol) comprise about 10 mol%, about 15 mol%, or about 20 mol% of the total lipids present in the particle.
[1103] In some embodiments, the additional lipid comprises a mixture of: (i) a phospholipid, such as DOPE; and (ii) cholesterol or a derivative thereof. In some embodiments, the molar ratio of the phospholipid (such as DOPE) to the cholesterol or a derivative thereof is from about 9:0 to about 1:10, from about 2:1 to about 1:4, from about 1:1 to about 1:4, or from about 1:1 to about 1:3.
[1104] polymer-conjugated lipids
[1105] In some embodiments, the particles described herein, such as nucleic acid particles, may comprise at least one polymer-conjugated lipid. In some embodiments, the polymer-conjugated lipid comprises an amphiphilic derivative of a polymer that is part of a linking compound and / or a polymer-conjugated lipid that is not part of a linking compound. A polymer-conjugated lipid is typically a molecule comprising a lipid portion and a polymer portion conjugated thereto. In some embodiments, the polymer of the polymer-conjugated lipid is a polymer as described herein for the linking compound. In some embodiments, the polymer-conjugated lipid is a PEG-conjugated lipid, also referred to herein as a PEGylated lipid or PEG-lipid. The term "PEGylated lipid" refers to a molecule that comprises both a lipid portion and a polyethylene glycol portion. PEGylated lipids are known in the art. In some embodiments, the polymer-conjugated lipid is a polysarcosine-conjugated lipid, also referred to herein as a sarcosinated lipid or pSar-lipid. The term "sarcosinated lipid" refers to a molecule that comprises both a lipid portion and a polysarcosine portion.
[1106] In some embodiments, the polymer-conjugated lipids are designed to sterically stabilize the lipid particles by forming a protective hydrophilic layer that shields the hydrophobic lipid layer. In some embodiments, when such lipid particles are administered in vivo, the polymer-conjugated lipids can reduce their association with serum proteins and / or the resulting uptake by the reticuloendothelial system.
[1107] Polyethylene glycol (PEG)-conjugated lipids
[1108] In some embodiments, a particle described herein, e.g., a nucleic acid particle, comprises a PEG-conjugated lipid.
[1109] In some embodiments, the PEG-conjugated lipid (PEGylated lipid) is a lipid having the following general structure:
[1110]
[1111] or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
[1112] R 12 and R 13 Each of w is independently a straight or branched, alkyl or alkenyl chain containing 10-30 carbon atoms, wherein the alkyl / alkenyl chain is optionally interrupted by one or more ester bonds; and the average value of w is 30-60.
[1113] In some embodiments of this formula, R 12 and R 13 Each of is independently a straight alkyl chain containing 10 to 18 carbon atoms, preferably 12 to 16 carbon atoms.
[1114] In some embodiments of this formula, R 12 and R 13 In some embodiments, R 12 and R 13 Each of is a straight chain alkyl chain containing 12 carbon atoms. In some embodiments, R 12 and R 13 Each of is a straight chain alkyl chain containing 14 carbon atoms. In some embodiments, R 12 and R 13 Each of is a straight alkyl chain containing 16 carbon atoms.
[1115] In some embodiments of this formula, R 12 and R 13 In some embodiments, R 12 and R 13 One of the is a straight alkyl chain containing 12 carbon atoms, and R 12 and R13 The other is a straight alkyl chain containing 14 carbon atoms.
[1116] In some embodiments of this formula, w has an average value of 40-50, such as an average value of 45.
[1117] In some embodiments of this formula, w is within a range such that the average molecular weight of the PEG portion of the PEGylated lipid is from about 400 to about 6000 g / mol, such as from about 1000 to about 5000 g / mol, from about 1500 to about 4000 g / mol, or from about 2000 to about 3000 g / mol. 12 and R 13 Each of the groups is a linear alkyl chain containing 14 carbon atoms, and the average value of w is 45.
[1118] Various PEG-conjugated lipids are known in the art, including but not limited to pegylated diacylglycerol (PEG-DAG) such as 1-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG), pegylated phosphatidylethanolamine (PEG-PE), PEG succinate diacylglycerol (PEG-DAG), and PEG-DMG. diacylglycerol (PEG-S-DAG) such as 4-O-(2',3'-di(tetradecanoyloxy)propyl-1-O-(w-methoxy(polyethoxy)ethyl)butanedioate (PEG-S-DMG), PEGylated ceramide (PEG-cer), or PEG dialkoxypropyl carbamate (PEG dialkoxypropylcarbamate) such as w-methoxy(polyethoxy)ethyl-N-(2,3-di(tetradecanoxy)propyl)carbamate or 2,3-di(tetradecanoxy)propyl-N-(wmethoxy(polyethoxy)ethyl)carbamate, etc.
[1119] In some embodiments, the PEG conjugated lipid (PEGylated lipid) is or comprises 2-[(polyethylene glycol)-2000]-N,N-ditetradecyl acetamide. In some embodiments, the PEGylated lipid has the following structure:
[1120]
[1121] In some embodiments, the PEG-conjugated lipid (PEGylated lipid) is DMG-PEG 2000, for example, having the following structure:
[1122]
[1123] In some embodiments, the PEG-conjugated lipid (PEGylated lipid) has the following structure:
[1124] The average value of n is 30-60, such as about 50.
[1125]
[1126] In some embodiments, the PEG-conjugated lipid (PEGylated lipid) is PEG 2000 -C-DMA, which preferably refers to 3-N-[(ω-methoxy poly(ethylene glycol)2000)carbamoyl]-1,2-dimyristyloxy-propylamine (MPEG-(2kDa)-C-DMA) or methoxy-polyethylene glycol-2,3-bis(tetradecyloxy)propylcarbamate (2000).
[1127] In some embodiments, the nucleic acid particles described herein may comprise one or more PEG-conjugated lipids or PEGylated lipids as described in WO 2017 / 075531 and WO 2018 / 081480, the entire contents of each of which are incorporated herein by reference for the purposes described herein.
[1128] In some embodiments, the PEGylated lipids comprise from about 1 mol% to about 10 mol%, preferably from about 1 mol% to about 5 mol%, and more preferably from about 1 mol% to about 2.5 mol% of the total lipids present in the nucleic acid compositions / formulations and nucleic acid particles described herein.
[1129] Embodiments of Lipid Complex Particles
[1130] In some embodiments of the present disclosure, the nucleic acids described herein (eg, RNA) can be present in lipoplex particles.
[1131] Lipoplexes (LPXs) are electrostatic complexes that are typically formed by mixing preformed cationic lipid liposomes with anionic nucleic acids. The resulting lipoplexes have a distinct internal molecular arrangement that results from the transition from a liposome structure to a compact nucleic acid-lipid complex.
[1132] In some embodiments, liposomes are self-enclosed unilamellar or multilamellar vesicle particles in which the layers comprise a lipid bilayer and the encapsulated cavity comprises an aqueous phase. A prerequisite for forming nanoparticles using liposomes is that the lipids in the mixture are able to form a lamellar (bilayer) phase in the aqueous environment of application.
[1133] In certain embodiments, the nucleic acid lipid complex particle comprises a cationic lipid and an additional lipid. In an exemplary embodiment, the cationic lipid is DOTMA and the additional lipid is DOPE.
[1134] In some embodiments, the molar ratio of the at least one cationic lipid to the at least one additional lipid is about 10:0 to about 1:9, about 4:1 to about 1:2, or about 3:1 to about 1: 1. In specific embodiments, the molar ratio can be about 3: 1, about 2.75: 1, about 2.5: 1, about 2.25: 1, about 2: 1, about 1.75: 1, about 1.5: 1, about 1.25: 1, or about 1: 1. In exemplary embodiments, the molar ratio of the at least one cationic lipid to the at least one additional lipid is about 2: 1.
[1135] In some embodiments, the nucleic acid lipoplex particles described herein have an average diameter of about 200 nm to about 1000 nm, about 200 nm to about 800 nm, about 250 to about 700 nm, about 400 to about 600 nm, about 300 nm to about 500 nm, or about 350 nm to about 400 nm. In specific embodiments, the RNA lipoplex particles have an average diameter of about 200 nm, about 225 nm, about 250 nm, about 275 nm, about 300 nm, about 325 nm, about 350 nm, about 375 nm, about 400 nm, about 425 nm, about 450 nm, about 475 nm, about 500 nm, about 525 nm, about 550 nm, about 575 nm, about 600 nm, about 625 nm, about 650 nm, about 675 nm, about 700 nm, about 725 nm, about 750 nm, about 775 nm, about 800 nm, about 825 nm, about 850 nm, about 875 nm, about 900 nm, about 925 nm, about 950 nm, about 975 nm, or about 1000 nm. In some embodiments, the nucleic acid lipoplex particles have an average diameter of about 250 nm to about 700 nm. In some embodiments, the RNA lipid complex particles have an average diameter of about 300 nm to about 500 nm. In an exemplary embodiment, the RNA lipid complex particles have an average diameter of about 400 nm.
[1136] In some embodiments, the functionalized particles described herein are lipid particles, particularly lipoplexes comprising an RNA drug substance, 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000-alfa peptide (DSPE-PEG2k-alfa), and tetradecyl-poly(sarcosine) 23-acetate (C14-PSar(23)-Ac). The functionalized lipoplexes are made using a two-step protocol: (1) making alfa-tagged RNA particles and then (2) functionalizing the alfa-tagged lipoplexes with a ligand. Alfa-tagged RNA lipid particles can be prepared using either aqueous / aqueous or aqueous / organic manufacturing protocols.
[1137] Embodiments of lipid nanoparticles (LNPs)
[1138] In some embodiments, the nucleic acids described herein are present in the form of lipid nanoparticles (LNPs). LNPs can comprise any lipid capable of forming particles to which one or more nucleic acid molecules are attached or to which one or more nucleic acid molecules are encapsulated.
[1139] Typically, lipid nanoparticles can be obtained by directly mixing nucleic acids (e.g., RNA) in an aqueous phase with lipids in a phase comprising an organic solvent (e.g., ethanol). In this case, lipids or lipid mixtures that do not form a lamellar (bilayer) phase in water can be used for particle formation.
[1140] LNPs typically contain four components: a cationic ionizable lipid, a neutral lipid (such as a phospholipid), a steroid (such as cholesterol), and a polymer-conjugated lipid (such as a PEG-lipid). LNPs can be prepared by mixing lipids dissolved in ethanol with nucleic acids in an aqueous buffer.
[1141] In some embodiments, the LNP comprises 40-60 mole percent, 40-55 mole percent, 45-55 mole percent, or 45-50 mole percent of cationically ionizable lipids.
[1142] In some embodiments, the neutral lipid is present at a concentration of 5-15 molar percent, 7-13 molar percent, or 9-11 molar percent.
[1143] In some embodiments, the steroid is present at a concentration of 30-50 mole percent, 30-45 mole percent, 35-45 mole percent, or 35-43 mole percent.
[1144] In some embodiments, the LNP comprises 1-10 mole percent, 1-5 mole percent, or 1-2.5 mole percent of the polymer-conjugated lipid.
[1145] In some embodiments, the LNP comprises 45-55 mole percent cationically ionizable lipids; 5-15 mole percent neutral lipids; 30-45 mole percent steroids; 1-5 mole percent polymer-conjugated lipids; and nucleic acids encapsulated within or associated with the lipid nanoparticles.
[1146] In some embodiments, the mole percentage is determined based on the total moles of lipids present in the lipid nanoparticles. In some embodiments, the mole percentage is determined based on the total moles of cationically ionizable lipids, neutral lipids, steroids, and polymer-conjugated lipids present in the lipid nanoparticles.
[1147] In some embodiments, the neutral lipid is selected from DSPC, DPPC, DMPC, DOPC, POPC, DOPE, DOPG, DPPG, POPE, DPPE, DMPE, DSPE and SM. In some embodiments, the neutral lipid is selected from DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM. In some embodiments, the neutral lipid is DSPC.
[1148] In some embodiments, the steroid is cholesterol.
[1149] In some embodiments, the polymer-conjugated lipid is a PEGylated lipid, eg, as described above.
[1150] In some embodiments, the cationically ionizable lipid component of the LNP has the structure of Formula (III):
[1151]
[1152] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:
[1153] L 1 or L 2 One of them is –O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -、NR a C(=O)NR a -、-OC(=O)NR a -or-NR aC(=O)O-, and L 1 or L 2 Another one is -O(C=O)-、-(C=O)O-、-C(=O)-、-O-、-S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -、NR a C(=O)NR a -、-OC(=O)NR a -or-NR a C(=O)O- or direct bond;
[1154] G 1 and G 2 Each independently is an unsubstituted C1-C 12 Alkylene or C1-C 12 alkenylene;
[1155] G 3 It is C1-C 24 Alkylene, C1-C 24 Alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene;
[1156] R a Is H or C1-C 12 alkyl;
[1157] R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 alkenyl;
[1158] R 3 It is H, OR 5 、CN、-C(=O)OR 4 、-OC(=O)R 4 or –NR 5 C(=O)R 4 ;
[1159] R 4 It is C1-C 12 alkyl;
[1160] R 5 is H or C1-C6 alkyl; and
[1161] x is 0, 1, or 2.
[1162] In some of the foregoing embodiments of Formula (III), the lipid has one of the following structures (IIIA) or (IIIB):
[1163]
[1164] in:
[1165] A is a 3-8 membered cycloalkyl or cycloalkylene ring;
[1166] At each occurrence, R 6 are independently H, OH or C1-C 24 alkyl;
[1167] n is an integer from 1 to 15.
[1168] In some of the foregoing embodiments of Formula (III), the lipid has structure (IIIA), and in other embodiments, the lipid has structure (IIIB).
[1169] In other embodiments of Formula (III), the lipid has one of the following structures (IIIC) or (IIID):
[1170]
[1171] wherein y and z are each independently an integer from 1 to 12.
[1172] In any of the preceding embodiments of Formula (III), L 1 or L 2 One of them is -O(C=O)-. For example, in some embodiments, L 1 and L 2 In some embodiments of any of the foregoing, each of L 1 and L 2 Each is independently -(C=O)O- or -O(C=O)-. For example, in some embodiments, L 1 and L 2 Each of is -(C=O)O-.
[1173] In some different embodiments of Formula (III), the lipid has one of the following structures (IIIE) or (IIIF):
[1174]
[1175] In some of the foregoing embodiments of Formula (III), the lipid has one of the following structures (IIIG), (IIIH), (IIII), or (IIIJ):
[1177]
[1178] In some of the foregoing embodiments of Formula (III), n is an integer from 2 to 12, such as an integer from 2 to 8 or from 2 to 4. For example, in some embodiments, n is 3, 4, 5, or 6. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6.
[1179] In some other foregoing embodiments of Formula (III), y and z are each independently an integer from 2 to 10. For example, in some embodiments, y and z are each independently an integer from 4 to 9 or 4 to 6.
[1180] In some of the foregoing embodiments of Formula (III), R 6 is H. In other of the foregoing embodiments, R 6 It is C1-C 24 In other embodiments, R 6 It's OH.
[1181] In some embodiments of Formula (III), G 3 In other embodiments, G3 is substituted. In various embodiments, G 3 It is linear C1-C 24 Alkylene or linear C1-C 24 Alkenylene.
[1182] In some other of the foregoing embodiments of Formula (III), R 1 or R 2 or both are C6-C 24 For example, in some embodiments, R 1 and R 2 Each independently has the following structure:
[1183]
[1184] in:
[1185] At each occurrence, R 7a and R 7b are independently H or C1-C 12 alkyl; and
[1186] a is an integer from 2 to 12,
[1187] Each of them chooses R 7a 、R 7b and a, so that R 1 and R 2 Each independently contains 6-20 carbon atoms. For example, in some embodiments, a is an integer from 5-9 or 8-12.
[1188] In some of the foregoing embodiments of Formula (III), R 7a At least one occurrence of is H. For example, in some embodiments, at each occurrence of R 7a is H. In other various embodiments of the foregoing, R 7b At least one occurrence of is C1-C8 alkyl. For example, in some embodiments, C1-C8 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, or n-octyl.
[1189] In various embodiments of formula (III), R 1 or R 2 or both have one of the following structures:
[1190]
[1191] In some of the foregoing embodiments of Formula (III), R 3 is OH, CN, -C(=O)OR 4 、-OC(=O)R 4 or –NHC(=O)R 4 In some embodiments, R 4 It is a methyl or ethyl group.
[1192] In various embodiments, the cationic lipid of formula (III) has one of the structures listed in the table below.
[1193] Representative compounds of formula (III)
[1194]
[1195]
[1196]
[1197]
[1198]
[1199]
[1200]
[1201]
[1202] Other representative cationically ionizable lipids are as follows:
[1203]
[1204] In some embodiments, a nucleic acid (such as RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid (e.g., a cationically ionizable lipid as set forth above), a neutral lipid, a steroid, and a polymer-conjugated lipid.
[1205] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid of Formula III, a neutral lipid, a steroid, and a polymer-conjugated lipid.
[1206] In some embodiments, the nucleic acids described herein (eg, RNA) are formulated in LNP compositions comprising a cationically ionizable lipid, a neutral lipid, a steroid, and a polymer-conjugated lipid as shown in the table above.
[1207] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising 3D-P-DMA, a neutral lipid, a steroid, and a polymer-conjugated lipid.
[1208] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0366, a neutral lipid, a steroid, and a polymer-conjugated lipid.
[1209] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0315, a neutral lipid, a steroid, and a polymer-conjugated lipid.
[1210] In some embodiments, the neutral lipid is DSPC. In some embodiments, the steroid is cholesterol. In some embodiments, the polymer-conjugated lipid is a pegylated lipid, e.g., DMG-PEG 2000, PEG 2000 -C-DMA or ALC-0159.
[1211] In some embodiments, a nucleic acid (such as RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid (e.g., a cationically ionizable lipid as set forth above), a neutral lipid, a steroid, and a PEGylated lipid.
[1212] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid of Formula III, a neutral lipid, a steroid, and a PEGylated lipid.
[1213] In some embodiments, the nucleic acids described herein (eg, RNA) are formulated in LNP compositions comprising a cationically ionizable lipid, a neutral lipid, a steroid, and a PEGylated lipid as shown in the table above.
[1214] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising 3D-P-DMA, a neutral lipid, a steroid, and a PEGylated lipid.
[1215] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0366, a neutral lipid, a steroid, and a PEGylated lipid.
[1216] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0315, a neutral lipid, a steroid, and a PEGylated lipid.
[1217] In some embodiments, the neutral lipid is DSPC. In some embodiments, the steroid is cholesterol. In some embodiments, the pegylated lipid is DMG-PEG 2000, PEG 2000 -C-DMA or ALC-0159.
[1218] In some embodiments, a nucleic acid (such as RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid (e.g., a cationically ionizable lipid as set forth above), DSPC, cholesterol, and a PEGylated lipid.
[1219] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid of Formula III, DSPC, cholesterol, and a PEGylated lipid.
[1220] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid as shown in the table above, DSPC, cholesterol, and a PEGylated lipid.
[1221] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising 3D-P-DMA, DSPC, cholesterol, and a PEGylated lipid.
[1222] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0366, DSPC, cholesterol, and a PEGylated lipid.
[1223] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0315, DSPC, cholesterol, and a PEGylated lipid.
[1224] In some embodiments, the PEGylated lipid is DMG-PEG 2000, PEG 2000 -C-DMA or ALC-0159.
[1225] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid (eg, a cationically ionizable lipid as set forth above), DSPC, cholesterol, and DMG-PEG 2000.
[1226] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid of Formula III, DSPC, cholesterol, and DMG-PEG 2000.
[1227] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid as shown in the table above, DSPC, cholesterol, and DMG-PEG 2000.
[1228] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising 3D-P-DMA, DSPC, cholesterol, and DMG-PEG 2000.
[1229] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0366, DSPC, cholesterol, and DMG-PEG 2000.
[1230] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0315, DSPC, cholesterol, and DMG-PEG 2000.
[1231] In some embodiments, the nucleic acids described herein (e.g., RNA) are formulated in LNP compositions comprising a cationically ionizable lipid (e.g., a cationically ionizable lipid as described above), DSPC, cholesterol, and PEG. 2000 -C-DMA.
[1232] In some embodiments, the nucleic acids described herein (e.g., RNA) are formulated in LNP compositions comprising a cationic ionizable lipid of Formula III, DSPC, cholesterol, and PEG. 2000 -C-DMA.
[1233] In some embodiments, the nucleic acids described herein (e.g., RNA) are formulated in LNP compositions comprising a cationic ionizable lipid, DSPC, cholesterol, and PEG as shown in the table above. 2000 -C-DMA.
[1234] In some embodiments, the nucleic acids described herein (e.g., RNA) are formulated in LNP compositions comprising 3D-P-DMA, DSPC, cholesterol, and PEG. 2000 -C-DMA.
[1235] In some embodiments, the nucleic acids described herein (e.g., RNA) are formulated in LNP compositions comprising ALC-0366, DSPC, cholesterol, and PEG. 2000 -C-DMA.
[1236] In some embodiments, the nucleic acids described herein (e.g., RNA) are formulated in LNP compositions comprising ALC-0315, DSPC, cholesterol, and PEG. 2000 -C-DMA.
[1237] In some embodiments, a nucleic acid described herein (eg, RNA) is formulated in an LNP composition comprising a cationically ionizable lipid (eg, a cationically ionizable lipid as set forth above), DSPC, cholesterol, and ALC-0159.
[1238] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid of Formula III, DSPC, cholesterol, and ALC-0159.
[1239] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising a cationically ionizable lipid as shown in the table above, DSPC, cholesterol, and ALC-0159.
[1240] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising 3D-P-DMA, DSPC, cholesterol, and ALC-0159.
[1241] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0366, DSPC, cholesterol, and ALC-0159.
[1242] In some embodiments, a nucleic acid (eg, RNA) described herein is formulated in an LNP composition comprising ALC-0315, DSPC, cholesterol, and ALC-0159.
[1243] 3D-P-DMA: (6Z,16Z)-12-((Z)-dec-4-en-1-yl)docosa-6,16-dien-11-yl 5-(dimethylamino)pentanoate
[1244]
[1245] ALC-0366: ((3-Hydroxypropyl)azadiyl)bis(nonane-9,1-diyl)bis(2-butyloctanoate)
[1246]
[1247] ALC-0315: ((4-Hydroxybutyl)azadiyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) / 6-[N-6-(2-hexyldecanoyloxy)hexyl-N-(4-hydroxybutyl)amino]hexyl 2-hexyldecanoate
[1248]
[1249] DMG-PEG 2000:
[1250]
[1251] PEG 2000 -C-DMA: 3-N-[(ω-methoxypoly(ethylene glycol) 2000)carbamoyl]-1,2-dimyristoyloxy-propylamine (MPEG-(2kDa)-C-DMA or methoxy-poly(ethylene glycol)-2,3-bis(tetradecyloxy)propylcarbamate (2000))
[1252]
[1253] The average value of n is in the range of 30-60, such as about 50.
[1254] ALC-0159: 2-[(Polyethylene glycol)-2000]-N,N-ditetradecyl acetamide / 2-[2-(ω-methoxy(polyethylene glycol 2000)ethoxy]-N,N-ditetradecyl acetamide
[1255]
[1256] DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine
[1257]
[1258] cholesterol:
[1259]
[1260] The N / P value is preferably at least about 4. In some embodiments, the N / P value is 4 to 20, 4 to 12, 4 to 10, 4 to 8, or 5 to 7. In some embodiments, the N / P value is about 6.
[1261] Cells for targeted delivery
[1262] According to the present disclosure, a payload is specifically delivered to a target cell by targeting a target on the target cell (eg, an antigen on the target cell, also referred to herein as a "primary target").
[1263] In some embodiments, the primary target is a structure present on the surface of a target cell, such as a protein, eg, a cell surface antigen (including a cell surface receptor).
[1264] Terms such as "expressed on the surface of a cell", "associated with the cell surface" or "cell surface molecule" mean that a molecule, such as a receptor or antigen, is associated with and located on the plasma membrane of a cell, wherein at least a portion of the molecule faces the extracellular space of the cell and is accessible from outside the cell, for example by a binding molecule (such as an antibody) located outside the cell. In this context, a portion is preferably at least 4 amino acids, preferably at least 8 amino acids, preferably at least 12 amino acids, more preferably at least 20 amino acids. The association can be direct or indirect. For example, the association can be through one or more transmembrane domains, one or more lipid anchors, or through interaction with any other protein, lipid, carbohydrate or other structure found on the outer leaflet of the plasma membrane of the cell. For example, a molecule associated with the cell surface can be a transmembrane protein with an extracellular portion, or can be a protein that is associated with the cell surface through interaction with another protein (which is a transmembrane protein).
[1265] "Cell surface" or "surface of a cell" is used in accordance with its normal meaning in the art and thus includes the exterior of a cell that is accessible to proteins and other molecules for binding. An antigen is expressed on the surface of a cell if it is located on the surface of the cell and is accessible to, for example, antigen-specific antibodies added to the cell for binding. In one embodiment, an antigen expressed on the cell surface is an integral membrane protein having an extracellular portion that is recognized by a binding molecule, such as an antibody.
[1266] In the context of the present invention, the term "extracellular part" or "extracellular domain" refers to a part of a molecule (such as a protein) that faces the extracellular space of a cell and is preferably accessible from outside the cell, for example by binding molecules (such as antibodies) located outside the cell.
[1267] During disease, such as infection or cancer, major targets may be upregulated. In diseased tissue, markers may differ from healthy tissue and offer unique possibilities for treatment, especially targeted therapies.
[1268] In some embodiments, the primary target is a disease-associated antigen, such as a tumor antigen, a viral antigen, or a bacterial antigen. This allows for targeting diseased cells by the methods and agents described herein, for example, for the delivery of pharmaceutically active agents.
[1269] The term "disease-associated antigen" is used in its broadest sense to refer to any antigen associated with a disease. A disease-associated antigen may be associated with infection with a microorganism (usually a microbial antigen) or with a cancer (usually a tumor).
[1270] In some embodiments, the primary target is a tumor antigen. In the context of the present disclosure, the term "tumor antigen" or "tumor-associated antigen" refers to a protein that is specifically expressed in a limited number of tissues and / or organs or at a specific developmental stage under normal conditions. For example, a tumor antigen can be specifically expressed in gastric tissue, preferably in gastric mucosa, in reproductive organs, such as the testis, in trophoblastic tissue, such as the placenta, or in germline cells under normal conditions, and is expressed or abnormally expressed in one or more tumors or cancer tissues. In this context, "limited number" preferably means no more than 3, more preferably no more than 2. Tumor antigens in the context of the present disclosure include, for example, differentiation antigens, preferably cell type-specific differentiation antigens, i.e., proteins that are specifically expressed in a specific cell type at a specific differentiation stage under normal conditions, cancer / testicular antigens, i.e., proteins that are specifically expressed in the testis and sometimes specifically expressed in the placenta under normal conditions, and germline-specific antigens. In the context of the present disclosure, tumor antigens are preferably associated with the cell surface of cancer cells and are preferably not or only rarely expressed in normal tissues. Preferably, tumor antigens or abnormal expression of tumor antigens identify cancer cells. In the context of the present disclosure, a tumor antigen expressed in a cancer cell of a subject (e.g., a patient suffering from a cancer disease) is preferably a self-protein in the subject. In a preferred embodiment, the tumor antigen in the context of the present disclosure is specifically expressed under normal conditions in non-essential tissues or organs (i.e., tissues or organs that do not lead to the death of the subject when destroyed by the immune system), or is expressed in body organs or structures that are inaccessible or difficult to access by the immune system. Preferably, the amino acid sequence of the tumor antigen expressed in normal tissue and the tumor antigen expressed in cancer tissue are identical.
[1271] Examples of tumor antigens include p53, ART-4, BAGE, β-catenin / m, Bcr-abL CAMEL, CAP-1, CASP-8, CDC27 / m, CDK4 / m, CEA, cell surface proteins of the tight junction protein family, such as CLAUDIN-6, CLAUDIN-18.2 and CLAUDIN-12, c-MYC, CT, Cyp-B, DAM, ELF2M, ETV6-AML1, G250, GAGE, GnT-V, Gap100, HAGE, HER-2 / neu, HPV-E7, HPV-E6, HAST-2, hTERT (or hTRT), LAGE, LDL R / FUT, MAGE-A, preferably MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A 11 or MAGE-A12, MAGE-B, MAGE-C, MART-1 / Melan-A, MC1R, Myosin / m, MUC1, MUM-1, -2, -3, NA88-A, NF1, NY-ESO-1, NY-BR-1, p190 Minor BCR-abL, Pm1 / RARa, PRAME, proteinase 3, PSA, PSM, RAGE, RU1 or RU2, SAGE, SART-1 or SART-3, SCGB3A2, SCP1, SCP2, SCP3, SSX, SURVIVIN, TEL / AML1, TPI / m, TRP-1, TRP-2, TRP-2 / INT2, TPTE and WT. Particularly preferred tumor antigens include CLAUDIN-18.2 (CLDN18.2) and CLAUDIN-6 (CLDN6).
[1272] In some embodiments, the primary target is a structure present on the surface of the target cell, such as a protein, for example a cell surface antigen or a cell surface receptor, the presence or amount of which is characteristic for certain cell types compared to others. This allows for targeting certain cell types characterized by the presence or increased amount of the methods and agents described herein. In some embodiments, the cells for targeted delivery are immune effector cells, and the primary target is a cell surface antigen that is characteristic for immune effector cells. Targeting immune effector cells by the methods and agents described herein allows for transfection of these cells with nucleic acids encoding antigen receptors and produces immune effector cells genetically modified to express antigen receptors.
[1273] immune effector cells
[1274] The immune effector cells used in connection with the methods and agents described herein, and into which nucleic acids encoding antigen receptors (DNA or RNA) can be introduced, include, in particular, immune effector cells such as cells with lysis potential, in particular lymphoid cells, and preferably T cells, in particular cytotoxic lymphocytes, preferably selected from cytotoxic T cells, natural killer (NK) cells, and lymphokine-activated killer (LAK) cells. After activation, each of these cytotoxic lymphocytes triggers the destruction of target cells. For example, cytotoxic T cells trigger the destruction of target cells in one or both of the following ways. First, after activation, T cells release cytotoxins, such as perforin, granzymes, and granulysin. Perforin and granulysin produce holes in target cells, and granzymes enter the cells and trigger the caspase cascade in the cytoplasm, which induces apoptosis (programmed cell death) of the cells. Second, apoptosis can be induced by the Fas-Fas ligand interaction between the T cells and the target cells. The cells used in connection with the present disclosure are preferably autologous cells, although heterologous cells or allogeneic cells can be used.
[1275] The term "effector function" in the context of the present disclosure includes any function mediated by a component of the immune system that results in, for example, killing of diseased cells (such as tumor cells), or inhibition of tumor growth and / or inhibition of tumor progression, including inhibition of tumor spread and metastasis. Preferably, the effector function in the context of the present disclosure is a T cell mediated effector function. Such functions are found in helper T cells (CD4 + In the case of T cells, it includes the release of cytokines and / or activation of CD8+ lymphocytes (CTLs) and / or B cells, and in the case of CTLs, it includes the elimination of cells (i.e., cells characterized by antigen expression), for example, by apoptosis or perforin-mediated cell lysis, the production of cytokines such as IFN-g and TNF-α, and specific cytolytic killing of target cells expressing the antigen.
[1276] In the context of the present disclosure, the term "immune effector cell" or "immunoreactive cell" refers to a cell that performs effector functions during an immune response. In some embodiments, an "immune effector cell" is capable of binding to an antigen, such as an antigen presented on a cell or expressed on a cell surface in the case of MHC, and mediating an immune response. For example, immune effector cells include T cells (cytotoxic T cells, helper T cells, tumor infiltrating T cells), B cells, natural killer cells, neutrophils, macrophages, and dendritic cells. Preferably, in the context of the present disclosure, an "immune effector cell" is a T cell, preferably a CD4 T cell. + and / or CD8 + T cells, most preferably CD8 +T cells. The term "immune effector cells" also includes cells that can mature into immune cells (such as T cells, especially T helper cells or cytolytic T cells) under appropriate stimulation. Immune effector cells include CD34 + Hematopoietic stem cells, immature and mature T cells, and immature and mature B cells. T cell precursors differentiate into cytolytic T cells when exposed to antigen, similar to clonal selection in the immune system.
[1277] In some embodiments, the genetically modified immune effector cells are immune effector cells expressing CAR. In some embodiments, the genetically modified immune effector cells are immune effector cells expressing TCR.
[1278] Immune effector cells to be used herein may express endogenous antigen receptors, such as T cell receptors or B cell receptors, or may lack expression of endogenous antigen receptors.
[1279] "Lymphoid cells" are cells or precursors of such cells that are capable of producing an immune response (such as a cellular immune response), optionally after appropriate modification (e.g., after transferring an antigen receptor (such as a TCR or CAR)), and include lymphocytes, preferably T lymphocytes, lymphoblasts, and plasma cells. Lymphoid cells can be immune effector cells as described herein. Preferred lymphoid cells are T cells, which can be modified to express antigen receptors on the cell surface. In some embodiments, lymphoid cells lack endogenous expression of T cell receptors.
[1280] The terms "T cells" and "T lymphocytes" are used interchangeably herein and include T helper cells (CD4 + T cells) and cytotoxic T cells (CTL, CD8 + T cells), wherein the cytotoxic T cells include cytolytic T cells.
[1281] T cells belong to a group of white blood cells called lymphocytes and play a central role in cell-mediated immunity. They can be distinguished from other lymphocyte types, such as B cells and natural killer cells, by a specialized receptor on their cell surface called the T cell receptor (TCR). The thymus gland is the primary organ responsible for T cell maturation. Several distinct subsets of T cells have been identified, each with distinct functions.
[1282] T helper cells assist other white blood cells in immune processes, including the maturation of B cells into plasma cells and the activation of cytotoxic T cells and macrophages. These cells are also called CD4 +T cells, because they express the CD4 glycoprotein on their surface. Helper T cells are activated when they are presented with peptide antigens by MHC class II molecules expressed on the surface of antigen-presenting cells (APCs). Once activated, they divide rapidly and secrete small proteins called cytokines that regulate or assist in active immune responses.
[1283] Cytotoxic T cells destroy virus-infected cells and tumor cells and are also involved in transplant rejection. These cells are also called CD8 + T cells, because they express the CD8 glycoprotein on their surface. These cells recognize their targets by binding to antigens associated with MHC class I, which is present on the surface of almost every cell in the body.
[1284] "Regulatory T cells," or "Tregs," are a subset of T cells that regulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune diseases. Tregs are immunosuppressive and typically inhibit or downregulate the induction and proliferation of effector T cells. Tregs express the biomarkers CD4, FoxP3, and CD25.
[1285] As used herein, the term "naive T cells" refers to mature T cells that, unlike activated or memory T cells, have not encountered their cognate antigen in the periphery. Naive T cells are typically characterized by surface expression of L-selectin (CD62L), lack of the activation markers CD25, CD44, or CD69, and lack of the memory CD45RO isoform.
[1286] As used herein, the term "memory T cells" refers to a subset or subpopulation of T cells that have previously encountered and responded to their cognate antigen. Upon encountering the antigen a second time, memory T cells can replicate to produce a faster and stronger immune response than the first time the immune system responded to the antigen. Memory T cells can be CD4 + or CD8 + and usually express CD45RO.
[1287] As used herein, the term "T cell" also includes cells that can mature into T cells under appropriate stimulation.
[1288] Most T cells have a T cell receptor (TCR) that exists as a complex of several proteins. The actual T cell receptor is composed of two separate peptide chains, which are generated from independent T cell receptor α and β (TCRα and TCRβ) genes and are called α- and β-TCR chains. γδ T cells (gamma delta T cells) represent a small subset of T cells that have different T cell receptors (TCRs) on their surface. However, in γδ T cells, the TCR is composed of one γ chain and one δ chain. This group of T cells is much less common than αβ T cells (comprising 2% of total T cells).
[1289] All T cells are derived from hematopoietic stem cells in the bone marrow. Hematopoietic progenitor cells derived from hematopoietic stem cells migrate (populate) into the thymus and amplify by cell division to produce a large number of immature thymocytes. The earliest thymocytes neither express CD4 nor CD8 and are therefore classified as double negative (CD4-CD8-) cells. As they develop, they become double positive thymocytes (CD4 + CD8 + ) and finally mature into single positive (CD4 + CD8- or CD4-CD8 + ) thymocytes, which are then released from the thymus into peripheral tissues.
[1290] T cells can generally be prepared in vitro or ex vivo using standard procedures. For example, T cells can be isolated from the bone marrow, peripheral blood, or a portion of the bone marrow or peripheral blood of a mammal (e.g., a patient) using a commercially available cell separation system. Alternatively, T cells can be derived from related or unrelated humans, non-human animals, cell lines, or cultures. The sample comprising T cells can be, for example, peripheral blood mononuclear cells (PBMCs).
[1291] As used herein, the term "NK cell" or "natural killer cell" refers to a subset of peripheral blood lymphocytes defined as expressing CD56 or CD16 and lacking the T cell receptor. As defined herein, NK cells can also be differentiated from stem cells or progenitor cells.
[1292] Targeted delivery of payloads
[1293] The agents and methods described herein can be used in various applications in which it is desired to introduce a payload (e.g., an exogenous nucleic acid sequence) into a target cell, and of particular interest is when it is desired to express a peptide or polypeptide encoded by the nucleic acid in the target cell into which the nucleic acid has been introduced. The agents described herein can be administered by in vitro or in vivo protocols.
[1294] The methods and reagents described herein for payload delivery, such as nucleic acid transfection, can be used for a variety of target cells, thereby introducing a payload, such as a nucleic acid, into the target cell. The present disclosure can provide for the introduction of a payload into a target cell in vitro or in vivo, depending on the location of the target cell. For example, when the target cell is an isolated cell, the payload can be introduced directly into the cell under cell culture conditions that allow the target cell to survive. Alternatively, when the target cell is part of a multicellular organism, the targeted particles described herein can be administered to the organism or host in a manner that allows the targeted particle to enter the target cell. "In vivo" refers to the administration of the targeted particle to a living animal. "Ex vivo" refers to the modification of cells in vitro. Such cells can be returned to the living organism. The route of administration of the targeted particle to a multicellular organism depends on several parameters, including the properties of the targeted particle. Of particular interest as a systemic route is the vascular route, by which the targeted particle is introduced into the host's vascular system, such as an artery or vein, with intravenous administration being of particular interest in many embodiments. For administration, the targeted particle is typically present in a pharmaceutical preparation, such as one comprising a pharmaceutically acceptable carrier, diluent, and / or adjuvant, and includes an effective amount of the payload. In certain embodiments, the targeted particles are administered in an aqueous delivery vehicle (e.g., saline solution). Thus, in many embodiments, the targeted particles are administered intravascularly (e.g., intraarterially or intravenously) using an aqueous delivery vehicle (e.g., saline solution).
[1295] In many embodiments, targeted particles are administered to a multicellular organism in an in vivo manner so that a payload is introduced into the target cells of the multicellular organism. In the case of a nucleic acid payload, administration is typically performed under conditions sufficient to allow expression of the nucleic acid to occur. In some embodiments, the agents and methods described herein result in sustained expression of the nucleic acid payload, rather than transient expression as described above. Sustained expression means that after administration of the nucleic acid payload, expression of the nucleic acid at a detectable level continues for a long period of time, if not indefinitely. A long period of time refers to at least 1 week, typically at least 2 months, more typically at least 6 months. Detectable levels refer to that the expression of the nucleic acid is at such a level that the encoded protein can be detected in a mammal (e.g., in the serum of a mammal) at a therapeutic concentration.
[1296] In some embodiments, the sustained expression described above is achieved with or without integration of the nucleic acid payload into the host's target cell genome. In some embodiments, the nucleic acid introduced into the target cell integrates into the target cell genome, i.e., into one or more chromosomes of the target cell. In some embodiments, the nucleic acid is maintained in episomal form, e.g., it is an episomal vector that provides sustained expression.
[1297] Therefore, cells described herein, such as immune effector cells, can be genetically modified in vitro / in vitro or in a subject being treated to express peptides or polypeptides, such as antigen receptors, such as chimeric antigen receptors (CAR) or T cell receptors (TCR) or their processed products, particularly when present on or by target cells (such as antigen presenting cells or diseased cells). In some embodiments, modification of expression peptides or polypeptides (such as antigen receptors) occurs in vivo. The cell can be an endogenous cell of the patient or can be administered to the patient. In some embodiments, modification of expression peptides or polypeptides (such as antigen receptors) occurs in vitro / in vitro. Subsequently, the modified cells can be administered to the patient.
[1298] In some embodiments, the methods and agents described herein are used to transfect immune effector cells with a nucleic acid encoding an antigen receptor to generate immune effector cells genetically modified to express the antigen receptor.
[1299] T cell receptor (TCR)
[1300] As used herein, the term "T cell receptor" or "TCR" refers to a protein receptor on T cells that is composed of a heterodimer of alpha (α) and beta (β) chains, although in some cells the TCR is composed of gamma and delta (γδ) chains. In some embodiments, the TCR can be derived from any cell comprising a TCR, including, for example, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, and γδ T cells. Each α, β, γ, and δ chain is composed of two Ig-like domains: a variable domain (V), which confers antigen recognition through a complementary determining region (CDR), followed by a constant domain (C), which is anchored to the cell membrane through a connecting peptide and a transmembrane (TM) region. The TM region is associated with the invariant subunit of the CD3 signaling apparatus. Each of the V domains has three CDRs. These CDRs interact with a complex between antigenic peptides bound to proteins encoded by the major histocompatibility complex (MHC).
[1301] Chimeric Antigen Receptor (CAR)
[1302] Adoptive cell transfer therapy of CAR-engineered T cells expressing chimeric antigen receptors is a promising anti-cancer therapy because CAR-modified T cells can be engineered to target almost any tumor antigen, preferably in an MHC-independent manner. For example, a patient's T cells can be genetically engineered (genetically modified) to express a CAR specifically for an antigen on the patient's tumor cells.
[1303] As used herein, the term "CAR" (or "chimeric antigen receptor") is synonymous with the term "chimeric T cell receptor" and "artificial T cell receptor", and relates to an artificial receptor comprising a single molecule or a molecular complex, which recognizes (i.e., binds to) a target structure (e.g., an antigen) on a target cell (e.g., a cancer cell) (e.g., by the combination of an antigen binding domain to an antigen expressed on the surface of a target cell) and can confer immune effector cells (e.g., T cells ...
Claims
1. A method for preparing a composition for delivering a payload to a cell expressing a cell surface antigen, the method comprising: (a) providing a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and (b) binding the particle from (a) to a compound comprising (i) a moiety that binds to said binding moiety covalently linked to a hydrophobic moiety, and (ii) a moiety that targets said cell surface antigen.
2. The method of claim 1, further comprising: (c) loading the particles with the payload.
3. A method of delivering a payload to a cell expressing a cell surface antigen, comprising adding to the cell a composition comprising: (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto and carrying the payload, and (b) A compound comprising (i) a portion that binds to said binding moiety covalently linked to said hydrophobic moiety, and (ii) a portion that targets said cell surface antigen.
4. The method of any one of claims 1-3, wherein the payload comprises a nucleic acid.
5. The method of any one of claims 1-4, wherein the cells comprise diseased cells.
6. The method of claim 5, wherein the payload comprises a compound effective for treating a disease.
7. The method of any one of claims 1-6, wherein the cell surface antigen comprises a tumor antigen.
8. The method of any one of claims 1-7, wherein the cell comprises a tumor cell or a cancer cell.
9. The method of any one of claims 1-4, wherein the cells comprise immune effector cells.
10. The method of any one of claims 1-4 and 9, wherein the payload comprises a nucleic acid encoding an antigen receptor.
11. The method of any one of claims 1-4, 9 and 10, wherein the cell surface antigen comprises a cell surface antigen on an immune effector cell.
12. A method of preparing an immune effector cell genetically modified to express an antigen receptor, comprising adding to the immune effector cell a composition comprising: (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and carrying a nucleic acid encoding the antigen receptor, and (b) A compound comprising (i) a portion that binds to the binding moiety covalently linked to the hydrophobic moiety, and (ii) a portion that targets a cell surface antigen on the immune effector cell.
13. The method of any one of claims 3-12, wherein the cells are present ex vivo.
14. The method of any one of claims 3-12, wherein the cell is present in a subject, and the method comprises administering the composition to the subject.
15. A method of treating a subject, comprising: (I) preparing ex vivo immune effector cells genetically modified to express an antigen receptor using a method comprising adding to the immune effector cells a composition comprising: (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and carrying a nucleic acid encoding the antigen receptor, and (b) a compound comprising (i) a portion that binds to the binding moiety covalently linked to the hydrophobic moiety, and (ii) a portion that targets a cell surface antigen on the immune effector cell; as well as (II) administering to the subject the immune effector cells genetically modified to express the antigen receptor.
16. A method of treating a subject, comprising administering to the subject: (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto and carrying a nucleic acid encoding an antigen receptor, and (b) A compound comprising (i) a portion that binds to the binding moiety covalently linked to the hydrophobic moiety, and (ii) a portion that targets a cell surface antigen on the immune effector cell.
17. The method of any one of claims 10-16, wherein the nucleic acid encoding the antigen receptor is delivered to the immune effector cell.
18. The method of claim 17, wherein the nucleic acid encoding the antigen receptor is delivered to the immune effector cell to produce an immune effector cell genetically modified to express the antigen receptor.
19. The method of any one of claims 9-18, wherein the cell surface antigen is characteristic of the immune effector cell.
20. The method of any one of claims 9-19, wherein the immune effector cells comprise T cells.
21. The method of any one of claims 9-20, wherein the immune effector cells comprise CD8+ and / or CD4+ T cells.
22. The method of any one of claims 1-4 and 9-21, wherein the cell surface antigen comprises CD4 and / or CD8.
23. The method of any one of claims 1-4 and 9-21, wherein the cell surface antigen comprises CD3.
24. The method of any one of claims 10-23, wherein the antigen receptor targets an antigen associated with a disease, disorder or condition or a cell expressing an antigen associated with a disease, disorder or condition.
25. The method of any one of claims 14-24, wherein the subject suffers from a disease, disorder or condition associated with the antigen.
26. The method of claim 24 or 25, wherein the antigen associated with the disease, disorder or condition comprises a tumor antigen.
27. The method of claims 24-26, wherein the cell expressing an antigen associated with a disease, disorder or condition is a tumor or cancer cell.
28. The method of claims 24-27, wherein the disease, disorder or condition associated with the antigen comprises a tumor or cancer.
29. The method of any one of claims 15-28, which is a method of treating or preventing cancer in a subject.
30. The method of claim 24 or 25, wherein the antigen associated with the disease, disorder or condition comprises an antigen of an infectious agent.
31. The method of claim 30, wherein the infectious agent comprises a virus.
32. The method of claims 24, 25, 30 and 31, wherein the disease, disorder or condition associated with the antigen is an infection.
33. The method of any one of claims 15-25 and 30-32, which is a method of treating or preventing an infection in a subject.
34. The method of any one of claims 15-33, further comprising administering to the subject an antigen targeted by an antigen receptor, a polynucleotide encoding the antigen, or a host cell genetically modified to express the antigen.
35. The method of claim 34, wherein the polynucleotide is RNA.
36. The method of any one of claims 10-35, wherein the antigen receptor comprises a chimeric antigen receptor (CAR) or a T cell receptor (TCR).
37. The method of any one of claims 12-15 and 18-36, wherein the genetic modification is transient or stable.
38. The method of any one of claims 12-15 and 18-37, wherein the genetic modification is performed by a viral-based method, a transposon-based method, or a gene editing-based method.
39. The method of any one of claims 1-38, wherein the particle is a lipid particle, a polymer particle, or a mixture thereof.
40. The method of any one of claims 1-39, wherein the particle is a viromer.
41. The method of any one of claims 1-40, wherein the particle is a non-viral particle.
42. The method of any one of claims 1-41, wherein the particles are nanoparticles.
43. The method of any one of claims 4-42, wherein the nucleic acid comprises DNA and / or RNA.
44. The method of any one of claims 1-43, wherein the hydrophobic moiety having a binding moiety covalently linked thereto and the particle are non-covalently associated with each other.
45. The method of any one of claims 1-44, wherein the hydrophobic moiety having the binding moiety covalently linked thereto is an integral part of the particle.
46. The method of any one of claims 1-45, wherein the hydrophobic moiety having a binding moiety covalently linked thereto comprises a polymer.
47. The method of any one of claims 1-46, wherein the hydrophobic moiety having a binding moiety covalently linked thereto comprises a compound of Formula I: L-X1-P-X2-B(I) in P contains polymers; L comprises a hydrophobic moiety attached to a first terminus of the polymer; B comprises a binding moiety attached to the second terminus of the polymer; X1 is absent or is the first linking moiety; and X2 does not exist or is a second connecting portion.
48. The method of claim 47, wherein X1 comprises a carbonyl group.
49. The method of claim 47 or 48, wherein X2 comprises the reaction product of a maleimide group and a sulfhydryl or cysteine group of a compound comprising the binding moiety.
50. The method of any one of claims 1-49, wherein the hydrophobic portion comprises two C8-C24 hydrocarbon chains.
51. The method of any one of claims 1-50, wherein the hydrophobic moiety comprises two C10-C18 hydrocarbon chains.
52. The method of any one of claims 1-51, wherein the hydrophobic moiety is or is contained in a lipid.
53. The method of claim 52, wherein the lipid comprises a phospholipid, such as a glycerophospholipid.
54. The method of claim 52 or 53, wherein the lipid comprises 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE).
55. The method of any one of claims 46-54, wherein the polymer provides stealth properties, increases circulation half-life, and / or reduces non-specific protein binding or cell adhesion.
56. The method of any one of claims 46-55, wherein the polymer comprises polyethylene glycol (PEG).
57. The method of any one of claims 1-56, wherein the hydrophobic moiety having a binding moiety covalently attached thereto comprises a distearoyl-glycero-phosphoethanolamine-polyethylene glycol conjugate (DSPE-PEG).
58. The method of any one of claims 1 to 57, wherein the hydrophobic moiety having the binding moiety covalently linked thereto is obtainable by reacting a thiol or cysteine reactive group of a heterobifunctional PEGylation reagent comprising the hydrophobic moiety with a thiol or cysteine group of a compound comprising the binding moiety.
59. The method of claim 58, wherein the heterobifunctional PEGylation reagent comprises a linear heterobifunctional PEGylation reagent.
60. The method of claim 58 or 59, wherein the sulfhydryl or cysteine reactive group comprises a maleimide group.
61. The method of any one of claims 58-60, wherein the heterobifunctional PEGylation agent comprises DSPE-PEG-maleimide.
62. The method of any one of claims 1-61, wherein the hydrophobic portion having a binding portion covalently linked thereto comprises the reaction product of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)] and a compound comprising the formula SH(CH2)nC(O)-B, wherein n ranges from 1-5 and B comprises the binding portion.
63. The method of claim 62, wherein n is 2.
64. The method of any one of claims 1-63, wherein the hydrophobic moiety having a binding moiety covalently linked thereto comprises a compound of formula II wherein B comprises the binding portion.
65. The method of any one of claims 62-64, wherein B comprises a moiety comprising the structure -N-peptide-C(O)-NH2.
66. The method of any one of claims 56-64, wherein the polyethylene glycol (PEG) comprises 20-200 ethylene oxide units, such as about 45 ethylene oxide units.
67. The method of any one of claims 56-66, wherein the polyethylene glycol (PEG) comprises polyethylene glycol-2000.
68. The method of any one of claims 1-67, wherein the binding moiety covalently linked to the hydrophobic moiety and the moiety bound to the binding moiety covalently linked to the hydrophobic moiety are non-covalently bound to each other.
69. The method of any one of claims 1-64 and 66-68, wherein the binding moiety covalently linked to the hydrophobic moiety comprises an antibody or an antibody derivative.
70. The method of claim 69, wherein the antibody derivative comprises an antibody fragment.
71. The method of claim 69 or 70, wherein the moiety that binds to the binding moiety that is covalently linked to the hydrophobic moiety comprises a peptide.
72. The method of any one of claims 1-68, wherein the binding moiety covalently linked to the hydrophobic moiety comprises a peptide.
73. The method of claim 72, wherein the moiety that binds to the binding moiety that is covalently linked to the hydrophobic moiety comprises an antibody or an antibody derivative.
74. The method of claim 73, wherein the antibody derivative comprises an antibody fragment.
75. The method of any one of claims 65-68 and 71-74, wherein the peptide comprises an ALFA-tag.
76. The method of any one of claims 69-71 and 73-75, wherein the antibody or antibody derivative comprises a VHH domain comprising the CDR1 sequence VTISALNAMAMG, the CDR2 sequence AVSERGNAM, and the CDR3 sequence LEDRVDSFHDY.
77. The method of any one of claims 1-68 and 72-76, wherein the binding moiety covalently linked to the hydrophobic moiety comprises a peptide comprising an ALFA-tag; and The moiety that binds to the binding moiety covalently linked to the hydrophobic moiety comprises an antibody or antibody derivative comprising a VHH domain comprising the CDR1 sequence VTISALNAMAMG, the CDR2 sequence AVSERGNAM, and the CDR3 sequence LEDRVDSFHDY.
78. The method of any one of claims 1-77, wherein (i) the moiety that binds to the binding moiety that is covalently linked to the hydrophobic moiety and (ii) the moiety that targets a cell surface antigen are linked to each other.
79. The method of any one of claims 1-78, wherein (i) the moiety that binds to a binding moiety that is covalently linked to a hydrophobic moiety and (ii) the moiety that targets a cell surface antigen are covalently linked to each other.
80. The method of any one of claims 1-79, wherein the compound of (b) comprises a peptide or polypeptide.
81. The method of any one of claims 1-80, wherein the moiety that targets a cell surface antigen comprises an antibody or an antibody derivative.
82. The method of claim 81, wherein the antibody derivative comprises an antibody fragment.
83. The method of any one of claims 1-82, wherein the compound of (b) comprises a bispecific antibody.
84. The method of claim 83, wherein the bispecific antibody comprises a bispecific single chain antibody.
85. The method of any one of claims 1-80, wherein the moiety targeting a cell surface antigen comprises an ankyrin repeat protein.
86. The method of any one of claims 1-85, wherein the component of (a) is bound to the compound of (b).
87. A composite comprising: (a) a particle comprising a hydrophobic portion having a binding moiety covalently attached thereto, and (b) A compound comprising (i) a portion that binds to the binding moiety covalently linked to the hydrophobic moiety, and (ii) a portion that targets a cell surface antigen.
88. The complex of claim 87, wherein the particles carry a payload.
89. The complex of claim 87 or 88, wherein the binding moiety covalently linked to the hydrophobic moiety comprises a peptide comprising an ALFA-tag; and The moiety that binds to the binding moiety covalently linked to the hydrophobic moiety comprises an antibody or antibody derivative comprising a VHH domain comprising the CDR1 sequence VTISALNAMAMG, the CDR2 sequence AVSERGNAM, and the CDR3 sequence LEDRVDSFHDY.
90. A particle comprising a hydrophobic portion having a peptide covalently attached thereto, wherein the peptide comprises an ALFA-tag.
91. A compound comprising a hydrophobic portion having a peptide covalently attached thereto, wherein the peptide comprises an ALFA-tag.
92. A bispecific binding molecule comprising: (i) a moiety that binds to a peptide comprising an ALFA-tag, and (ii) A moiety that targets a cell surface antigen.
93. A bispecific binding molecule comprising: (i) an antibody or antibody derivative comprising a VHH domain comprising a CDR1 sequence of VTISALNAMAMG, a CDR2 sequence of AVSERGNAM, and a CDR3 sequence of LEDRVDSFHDY, and (ii) A moiety that targets a cell surface antigen.
Citation Information
Patent Citations
Treatments for neurotoxicity in Alzheimer's disease caused by beta amyloid peptides
US6172043B1
Method for making humanized antibodies
WO1992022653A1
Recombinant monovalent antibodies and methods for production thereof
WO2007059782A1
Stabilization of poly(a) sequence encoding DNA sequences
WO2016005324A1
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017075531A1
